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E-1,2-Dichlorovinyl ethers as irreversible protease inhibitors
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Abstract—The synthesis of a novel motif for threonine protease inhibition is described. The desired E-1,2-dichlorovinyl ethers are
obtained from alcohols and trichloroethylene as single diastereomers. Aqueous treatment at pH11 unmasks the hidden a-chloro-
acetate, which is required for the reaction with the active site of the protease.
 2003 Elsevier Ltd. All rights reserved.
Cellular processes depend on the delicate balance of
protein synthesis and degradation. Therefore cells fea-
ture two major pathways for protein degradation: pro-
teolytic enzymes within the lysosome and the proteolytic
core of the ubiquitin proteasome. The disregulation of
protein half-life via disturbed destruction is common to
many pathological processes. The selective inhibition of
the multi-catalytic proteasome subunits is thus an
attractive target for drug development in oncology and
Alzheimers disease.1 For these therapeutic areas we
investigate novel inhibitors of threonine proteases fea-
turing reactive moieties, which bias their inhibition
toward threonine over serine proteases. Several inhibi-
tors of threonine proteases are known, both selective
and unselective (Fig. 1).2 Currently the most prominent
threonine protease inhibitor: bortezomib 2, is approved
for the treatment of multiple myeloma by the FDA.3
We take the unspeciﬁc serine protease inhibitor 1 and its
mode of action as our lead and intend to improve the
selective inhibition of chymotrypsin-like activity of the
20S proteasome by reducing the inherent overkill. This
over-activation derives from the dichlorovinyl ester,
which reacts readily with all sorts of nucleophiles such as
cysteine, serine and eventually threonine. The removal
of the acyl function will signiﬁcantly reduce the unspe-
ciﬁc hydrolysis by ubiquitous nucleophiles and results in
a reasonably stable dichlorovinyl ether. This ether tol-
erates acidic environment, but hydrolyses readily at
pH 11 to be converted into an a-chloroacetate, which in
turn reacts with nucleophiles. This dual reactivity, which
is delivered in a cascade reaction, fulﬁls the speciﬁc
requirements of an N-terminal threonine protease
inhibitor. The general hydrolysis of an amide bond by a
threonine protease is depicted in Scheme 1. Structural
analysis of the proteasome b-subunits revealed that the
2-hydroxyls of the N-terminal threonines serve as acyl
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Scheme 1. Hydrolysis by threonine proteases.
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Figure. 1. Serine and threonine protease inhibitors.
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carriers. This diﬀerence from cysteine and serine prote-
ases, which utilize less hindered 1 nucleophiles of an
internal amino acid, holds potential for selective,
mechanism-based inhibitors. The importance of the free
amino terminus is apparent in the states I and III, where
the amine directs a deprotonation cascade. These
deprotonations result in hydrolysis of the amide and
ﬁnally regenerate the catalytic site. Inhibitors addressing
the active site may interact with the hydroxyl, the free
amine or both. We have chosen compact, robust 2-
alcohols and aminoalcohols to explore the accessibility
and stability of the required dichlorovinyl ethers. As it
turned out, treatment of the alcohols with sodium
hydride and trichloroethylene4 in dry THF at )50 C and
slow warming to room temperature provided the desired
ethers in moderate to excellent yields (Scheme 2).5
All compounds were obtained as single diastereomers,
which were assigned the E-stereochemistry, based on the
known menthyl ester 8.6 Further derivatization was
accomplished by a palladium-mediated cross-coupling
reaction, which resulted in the selective arylation of the
2-position (11, Scheme 3) by a magnesium acetylide
species. All other methods and conditions for the cross-
coupling (Stephens-Castro, Corey-House, Sonogashira)
provided only trace amounts of the desired product. The
initial work-up procedure involved extraction with
sodium hydrogen carbonate solution and led to signiﬁcant
hydrolysis resulting in an a-chloroacyl ester. This reac-
tivity suggests these derivatives as potential threonine
protease inhibitors.
The introduction of amino acid sequences provides
protease speciﬁcity and is accomplished by standard
peptide synthesis in solution (Scheme 4). Condensation
of the Z-protected Leucine–Leucine sequence is
achieved using EDAC (1-ethyl-3-(30-dimethylamino-
propyl)carbodiimide) and HOBt (N-hydroxybenzo-
triazoleÆH2O) in DMF.
The resulting peptide mimetics are insensitive to air or
moisture at neutral or slightly acid pH. However,
exposure to strong nucleophiles or pH>11 leads to
rapid hydrolysis. The inhibition of the b-subunits of the
proteasome by the compounds 12, 13 and close ana-
logues thereof is subject to ongoing investigations.
Acknowledgements
We thank the Fonds der Chemischen Industrie, the
DFG SPP1085 SCHM1012-3 and A. Hallberg, Uppsala
Universitet for support of this work.
References and notes
1. Myung, J.; Kim, K. B.; Crews, C. M. Med. Res. Rev. 2001,
21, 245–273.
2. Hudig, D.; Allison, N. J.; Kam, C. M.; Powers, J. C. Mol.
Immun. 1989, 26, 793–798.
3. Paramore, A.; Frantz, S. Nat. Rev. Drug. Discov. 2003, 2,
611–612.
4. Klementschitz, W. Monatsh. Chemie 1953, 84, 1201–1205.
5. A suspension of NaH (48mg, 2.0mmol) in dry THF (2mL)
was treated with (S)-())-1-methyl-2-pyrrolidinemethanol
(115mg, 1.0mmol) and stirred at )15 C for 30min. The
mixture was cooled to )50 C prior to the addition of
9
Z-Leu-Leu
EDAC, HOBt
DMF, 77%
O
Cl
Cl
N
H
Z-Leu-Leu
O
Cl
Cl
N
H
Z-Leu-Leu
Z-Leu-Leu
EDAC, HOBt
DMF, 65%
10
12
13
Scheme 4. Synthesis of tripeptide mimetics.
O
Cl
8
Ph MgBr
(PPh3)2PdCl2 5%
Et2O 35 °C 8 h
55%
2 eq
11
Scheme 3. Synthesis of an enyne chlorovinyl ether.
OH
Cl
Cl
Cl
NaH THF
-50 °C
pH 11
H2O
N ON
Cl
Cl
ON
O
Cl
O
Cl
Cl
N
3 4 (39%) 5
6 (81%)
O
Cl Cl
H2N
9 (57%)
O
Cl Cl
8 (85%)
O
Cl
Cl
N
7 (52%)
O
Cl Cl
H2N
10 (25%)
Scheme 2. Synthesis of dichlorovinyl ethers.
1752 B. Schmidt et al. / Tetrahedron Letters 45 (2004) 1751–1753
trichloroethylene (1.23mmol, 110 lL) in THF (2mL). The
mixture was warmed to +8 C within 2 h and quenched with
2mL sat. NH4Cl solution and 6mL Et2O. The organic
phase was washed with 2mL H2O, dried (Na2SO4) and
concentrated. The crude oil was puriﬁed by ﬁltration
through Alox 90-II using CHCl3/EtOH 100:1 Rf : 0.88
(Alox 60-N-E) to give the ether as a colorless oil (82.3mg,
39%).
6. Moyano, A.; Charbonnier, F.; Greene, A. E. J. Org. Chem.
1987, 52, 2919–2922.
B. Schmidt et al. / Tetrahedron Letters 45 (2004) 1751–1753 1753
Tripeptide Mimetics Inhibit the 20 S Proteasome by Covalent
Bonding to the Active Threonines*
Received for publication, March 4, 2005, and in revised form, May 25, 2005
Published, JBC Papers in Press, May 26, 2005, DOI 10.1074/jbc.M502453200
Hannes A. Braun‡, Sumaira Umbreen‡, Michael Groll§, Ulrike Kuckelkorn¶,
Izabela Mlynarczuk¶, Moritz E. Wigand¶, Ilse Drung¶, Peter-Michael Kloetzel¶,
and Boris Schmidt‡**
From the ‡Darmstadt University of Technology, Clemens Scho¨pf-Institute for Organic Chemistry and Biochemistry,
D-64287 Darmstadt, Germany, §Institute for Physiological Chemistry, Ludwig Maximilian University Mu¨nchen, D-81377
Munich, Germany, ¶Charite´-Universita¨tsmedizin Berlin, Institute for Biochemistry, D-10117 Berlin, Germany, and
Department of Histology and Embryology, Center of Biostructure Research, The Medical University of Warsaw,
02-004 Warsaw, Poland
Proteasomes play an important role in protein turnover
in living cells. The inhibition of proteasomes affects cell
cycle processes and induces apoptosis. Thus, 20 S protea-
somal inhibitors are potential tools for the modulation of
neoplastic growth. Based on MG132, a potent but nonspe-
cific 20 S proteasome inhibitor, we designed and synthe-
sized 22 compounds and evaluated them for the inhibition
of proteasomes. The majority of the synthesized com-
pounds reduced the hydrolysis of LLVY-7-aminomethyl-
coumarin peptide substrate in cell lysates, some of them
drastically. Several compounds displayed inhibitory ef-
fects when tested in vitro on isolated 20 S proteasomes,
with lowest IC50 values of 58 nM (chymotrypsin-like activ-
ity), 53 nM (trypsin-like activity), and 100 nM (caspase-like
activity). Compounds 16, 21, 22, and 28 affected the chy-
motrypsin-like activity of the 5 subunit exclusively,
whereas compounds 7 and 8 inhibited the 2 trypsin-like
active site selectively. Compounds 13 and 15 inhibited all
three proteolytic activities. Compound 15 was shown to
interact with the active site by x-ray crystallography. The
potential of these novel inhibitors was assessed by cellu-
lar tolerance and biological response. HeLa cells tolerated
up to 1 M concentrations of all substances. Intracellular
reduction of proteasomal activity and accumulation of
polyubiquitinated proteins were observed for compounds
7, 13, 15, 22, 25, 26, 27, and 28 on HeLa cells. Four of these
compounds (7, 15, 26, and 28) induced apoptosis in HeLa
cells and thus are considered as promising leads for anti-
tumor drug development.
The balance of protein synthesis and degradation processes
is essential to maintain cellular homeostasis. Cells possess two
major pathways to fulfill protein degradation: proteins are
digested either by proteolytic enzymes within the lysosomes or
via the ubiquitin-proteasome system. The imbalance of the
protein synthesis and degradation processes causes many
pathological processes (1).
26 S proteasomes, multi-subunit protease complexes, per-
form ATP-dependent degradation of polyubiquitinated proteins
and are responsible for most of the non-lysosomal proteolysis in
eukaryotic cells. They consist of the proteolytic 20 S protea-
some core particle and are capped at one or both ends by 19 S
regulatory particles (2, 3). The 20 S core particle is a cylindrical
assembly of 28 subunits arranged in four stacked heptameric
rings; two rings are formed by 7 -type subunits, and two rings
are build of 7 -type subunits (4, 5). The two inner -rings form
the central cavity of the cylinder and harbor the proteolytic
sites. In contrast to prokaryotic 20 S proteasomes, which con-
tain 14 identical proteolytically active -type subunits, eukary-
otic 20 S proteasomes belong to the family of N-terminal nu-
cleophilic hydrolases (6, 7). They possess only three subunits
with N-terminal active site threonines in the -ring. In addi-
tion, the stimulation of mammalian cells by -interferon causes
the replacement of the three active -subunits 1, 2, and 5
by their immunohomologues 1i, 2i, and 5i, resulting in the
formation of immunoproteasomes, which display modified
cleavage patterns of substrate peptides. The functional integ-
rity of proteasomes is indispensable for a variety of cellular
functions, such as metabolic adaptation, cell differentiation,
cell cycle control, stress response, degradation of abnormal
proteins, and generation of epitopes presented by major histo-
compatibility complex class I receptors (for reviews, see Refs. 8
and 9). However, proteasomes are an important supplier (but
not the exclusive supplier) of antigenic peptides (10, 11).
The deregulation of the ubiquitin-proteasome protein degra-
dation pathway in humans causes several diseases, such as
cancer and neurodegenerative, autoimmune, and metabolic
disorders. Inhibition of proteasomes influences the stability of
many proteins, especially those that are involved in the cell
cycle regulation. In fact, most of the cells treated with protea-
somal inhibitors become sensitive to apoptosis (12, 13). Thus,
selective inhibitors of catalytic proteasome subunits are attrac-
tive targets for drug development (14). Interestingly, tumor
cells are usually more sensitive to proteasomal inhibition than
normal cells. Healthy cells display cell cycle arrest when
treated with proteasomal inhibitors but, in contrast to tumor
cells, are not as susceptible to apoptosis (15, 16). So far, several
proteasomal inhibitors have been characterized, both selective
(4, lactacystin; 5, TMC-95A; and 6, epoxomicin) and nonspecific
(1, dichlorovinyl ester; 3, MG132) (Fig. 1A) (17).
The most prominent proteasomal inhibitor 2 (Bortezomib®,
VELCADETM) is approved by the United States Food and Drug
Administration as a prescription drug for the treatment of
multiple myeloma (18–20). Similar applications of proteasomal
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inhibitors in oncology and neurodegenerative diseases are at
the focus of our interest (21). We intend to develop selective
inhibitors for the three different proteolytic activities of the
20 S proteasome. Our goals may be achieved by creating com-
pounds or reactive moieties, which bind covalently to the
N-terminal threonine.
The proteasomal amide hydrolysis differs from all other
classes of proteases and is performed by N-terminal threonines,
as depicted in Fig. 1B. The crystal structure analysis of the 20 S
proteasome revealed that the Thr-1O functions as the nucleo-
phile and that the N-terminal amino group serves as an acyl
carrier (6). Covalent inhibitors can bind to the active site
through the Thr-1O hydroxyl group or both the free N termi-
nus and Thr-1O (for review, see Ref. 17).
Effective in vivo inhibitors of the 20 S proteasome require
high selectivity and good penetration of the cellular mem-
branes. We decided to address the selectivity problems of 3
(MG132) first. A focused set of peptide analogue aldehydes
13–18 aimed at the proteolytic activity of 5 subunit was syn-
thesized and tested for inhibition of the 20 S proteasome and
-secretase (22, 23). These results encouraged us to address the
design of irreversible and selective proteasome inhibitors. We
concentrated on the nonspecific serine protease inhibitor 1 and
introduced modifications to improve its selective inhibition of
the chymotrypsin-like activity of the 20 S proteasome.
MATERIALS AND METHODS
Isolation of 20 S Proteasomes—20 S proteasomes were isolated from
red blood cells. Cells were lysed with dithiothreitol (1 mM), and the
stroma-free supernatant was applied to DEAE-Sepharose (Toyopearls).
20 S proteasome was eluted with a NaCl gradient in TEAD (20 mM
Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM azide, and 1 mM dithiothreitol)
from 100 to 350 mM NaCl. 20 S proteasome was concentrated by am-
monium sulfate precipitation (between 40 and 70% of saturation) and
separated in a 10–40% sucrose gradient by centrifugation at 40,000
rpm for 16 h (SW40; L7; Beckman & Coulter). Finally, 20 S proteasome
was purified on MonoQ column and eluted with a NaCl gradient at 280
mM NaCl. The fractions containing purified 20 S proteasome were
dialyzed against 50 mM NaCl in TEAD and stored on ice. The purity was
determined by SDS-PAGE.
Protease Assays—Suc-LLVY-AMC,1 Z-VGR-AMC, and LLE-AMC
(Bachem, Calbiochem) were used to estimate chymotrypsin-like, tryp-
sin-like, and caspase-like (post-acidic) activities of the 20 S proteasome,
respectively. Substrates were incubated with 20 S proteasome at 37 °C
in assay buffer (20 mM Tris-HCl, pH 7.2, 1 mM EDTA, and 1 mM
dithiothreitol) for 1 h. 100 ng of 20 S proteasome was preincubated with
0.01–10 M of the inhibitors for 15 min. The reaction was started by
addition of substrate (50 M). The released AMC was detected by
fluorescence emission at 460 nm (excitation at 390 nm) using a TECAN
fluorometer. Activity was estimated in fluorescence units, and the in-
hibition is represented by IC50 values.
Cell Culture—HeLa cells and MeWo cells (human melanoma) were
cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal
calf serum and penicillin/streptomycin at 5% CO2. Inhibitors were
applied from 100 stocks (in Me2SO) at the indicated final concentra-
tions and incubated for variable times.
Sensitivity of Cells against Added Compounds—The viability of
HeLa cells was tested by crystal violet staining after incubation with
inhibitors. The cells were washed once with PBS, fixed with 1% of
glutardialdehyde for 30 min, and washed again. Finally, the fixed cells
were stained with 0.1% crystal violet in PBS for 30 min and subse-
quently washed carefully with water to remove unbound dye. The
remaining dye was eluted by 0.1% Triton X-100 in PBS and determined
at 550 nm.
Inhibition of 20 S Proteasomes within Cells—Cells were harvested
and lysed with 0.1% Nonidet P-40 in TEAD in the presence of the
commercial protease inhibitor mixture Complete (Roche Applied Sci-
ence). The proteasomal activity was measured in 10 l of lysates by
using Suc-LLVY-AMC as a substrate. The protein content was quanti-
fied by Bradford (Protein assay; Bio-Rad).
Detection of Accumulated Polyubiquitinated Proteins—50 g of total
cell lysate was separated by SDS-PAGE and blotted onto polyvinylidene
difluoride membrane (Millipore). Blots were blocked by 5% of milk
suspension. The polyubiquitinated proteins were detected by anti-ubiq-
1 The abbreviations used are: AMC, 7-aminomethylcoumarin; Z, ben-
zyloxycarbonyl; PBS, phosphate-buffered saline.
FIG. 1. A, serine and threonine protease inhibitors. B, hydrolysis by threonine proteases.
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uitin antibody (DAKO) and anti-rabbit peroxidase-labeled as secondary
antibody (DIANOVA) and then visualized by ECL.
Analysis of Cell Cycle—MeWo cells were treated with inhibitor 15
and MG132 for 24 h. Cells were trypsinized, washed with cold PBS,
suspended in 70% ethanol, and fixed at 20 °C for 2 h. Fixed cells were
washed twice with PBS, incubated with RNase A (Sigma) at room
temperature for 20 min, and placed on ice. Propidium iodide was added
to a final concentration of 5 g/ml, and cells were stained at least for 2 h
at 4 °C. The cells were analyzed after staining by flow cytometry (FAC-
SCalibur flow cytometer; BD Biosciences) using CellQuest software.
Statistical significance was determined by the 2 test.
Apoptosis Assay—HeLa cells (10,000 cells/well) were disseminated in
a 96-well plate and treated with 1 M of inhibitors for 20 h. The ongoing
apoptosis was estimated by the Apo-One® assay (Promega).
Co-crystallization—Crystals of 20 S proteasome from Saccharomyces
cerevisiae were grown in hanging drops at 24 °C as described previously
(6) and incubated for 60minwith compound 15. The protein concentration
used for crystallization was 40 mg/ml in Tris-HCl (10 mM, pH 7.5) and
EDTA (1mM). The drops contained 3 l of protein and 2 l of the reservoir
solution, which contained 30 mM magnesium acetate, 100 mM morpholi-
noethanesulfonic acid, pH 7.2, and 10% 2-methylpentane-2,4-diol.
The space group belongs to P21 with cell dimensions of a  135.8 Å,
b  300.1 Å, c  144.4 Å, and   113.1°. Data to 2.8 Å were collected
using synchrotron radiation with   1.05 Å on the BW6-beamline at
DESY (Hamburg, Germany). Crystals were soaked in a cryoprotecting
buffer (30% 2-methylpentane-2,4-diol, 20 mM magnesium acetate, 100
mM morpholinoethanesulfonic acid, pH 6.9) and frozen in a stream of
liquid nitrogen gas at 90 K (Oxford Cryo Systems). X-ray intensities
were evaluated by using the MOSFILM program package (version 6.1),
and data reduction was performed with CCP4 (24). The anisotropy of
diffraction was corrected by an overall anisotropic temperature factor
by comparing observed and calculated structure amplitudes using the
program X-PLOR (25). A total of 2,383,416 reflections yielding
248,616 unique reflections (96.9% completeness) was collected. The
corresponding Rmerge was 8.7% at 2.8 Å resolution (41.9% for the last
resolution shell). Electron density was improved by averaging and
back-transforming the reflections 10 times over the 2-fold noncrys-
tallographic symmetry axis using the program package MAIN (26).
Conventional crystallographic rigid body, positional, and tempera-
ture factor refinements were carried out with X-PLOR using the yeast
20 S proteasome structure as starting model (6). For model building,
the program MAIN was used. The structure was refined to a R-factor
of 21.7% (free R-factor, 24.9%) with root mean square deviations from
target values of 0.007 Å for bonds and 1.30° for angles (27). Modeling
experiments were performed using the coordinates of yeast 20 S
proteasome with the program MAIN (26).
Synthesis—Compounds 7–18 were synthesized as analogues of 3
(MG132) based on the established substrate preferences of -secretase
(23) by standard methodology or as published previously (28). The
condensation of commercial protected dipeptides and amino acids with
FIG. 2. Peptidomimetics designed for 20 S proteasome inhibition.
FIG. 3. Estimation of proteolysis in cell lysates by addition of
MG132 and 7–28. Compounds (10 M) were added to clarified lysates
and preincubated for 30 min on ice prior to the proteolysis assay (black
bars). In parallel, lysate was preincubated with the commercial prote-
ase inhibitor mixture Complete for 30 min, which inhibited most of the
cytosolic serine/aspartate proteases, but not proteasomes (white bars).
This partial inactivation was followed by incubation with the indicated
compounds. The proteolytic activity was determined in 10 l of the
lysates by addition of LLVY-AMC (100 l, 50 M) in TEAD. The AMC
released by non-inhibited lysate was set to 100%. MG132 was used as
inhibition control.
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commercial amino alcohols was followed by oxidation to the aldehydes
by 2-iodooxybenzoic acid in Me2SO.
RESULTS
The intermediate alcohol derivatives 7–12 and the tripep-
tidic aldehydes 13–18 were investigated for enzyme inhibition.
Inhibition of -secretase was rather poor (IC50 200 M),
2 but
several compounds turned out to be potent inhibitors of the 20
S proteasome. Peptide aldehydes generally lack selectivity in
enzyme inhibition. Therefore, other moieties were tested for
their ability to inhibit threonine proteases. The nonselective
dichlorovinyl ester 1, which reacts readily with all sorts of
nucleophiles such as cysteine, serine, and, eventually, threo-
nine, served as our lead, but we intended to reduce the inherent
overactivation. The removal of the acyl group may reduce the
nonspecific hydrolysis by ubiquitous nucleophiles and results
in reasonably stable dichlorovinyl ethers (28). Such ethers (19
and 20) tolerate acidic environment but hydrolyze readily at
pH 11 to be converted into -chloroacetates, which in turn may
react with nucleophiles. This dual reactivity, which is delivered
in a cascade reaction, meets the specific requirements of an
N-terminal threonine protease inhibitor. An analogue dual re-
activity may be observed for propargylic ketones. A similar
compound was synthesized, but unfortunately, the alcohol 21
resisted oxidation to the desired ketone. Therefore, we focused
on transition state mimetics as inhibitors. Lead structures,
such as statines (34), -ketoamides, and chloromethyl ketones,
are well established in protease inhibition. Combination of
these structures with a 5 selective tripeptide furnished the
compounds 22–28 (Fig. 2). Compound 22 was prepared from
commercial Z-LL and chloromethyl leucine. Compounds 23–25
were obtained by a Passerini reaction of MG132 with three
isonitriles. The subsequent oxidation by 2-iodooxybenzoic acid
in Me2SO furnished the -ketoamides 26–28.
All peptide mimetics (7–28) were tested for their ability to
inhibit the 20 S proteasome. Initially, we investigated the
inhibition of cellular soluble proteases. 10 M solutions of com-
pounds 7–28 were added to the cytosolic fraction of HeLa cells
and incubated for 30 min on ice. Subsequently, the proteolytic
process was monitored by addition of the peptidic substrate
Suc-LLVY-AMC. In parallel, the cytosolic fraction was treated
with the broad specific protease inhibitor mixture Complete
(Roche Applied Science) prior to the addition of substrate. This
inhibitor mixture did not affect 20 S proteasomes. 11 of 22
investigated compounds diminished proteolysis in the cytosolic
fraction as well as in the Complete-pretreated lysate (Fig. 3).
The inhibition rates differed drastically. Some of the com-
pounds displayed no inhibition, whereas five of the analyzed
compounds decreased the hydrolysis of Suc-LLVY-AMC
by 75%.
To ensure that the inhibitory effect observed in the cytosolic
fraction was indeed caused by inhibition of 20 S proteasomes,
the inhibitors were added at different concentrations to iso-
lated 20 S proteasomes. The effect of the inhibitors was com-
pared with that of the frequently employed 20 S proteasome
inhibitor 3 (MG132). The chymotryptic-like (Suc-LLVY-AMC),
tryptic-like (Bz-VGR-AMC), and caspase-like (Z-LLE-AMC) ac-
tivities of 20 S proteasomes were determined after incubation
at 37 °C for 1 h. The strongest inhibitory effects were observed
for chymotryptic-like activity. Six of the tested inhibitors (13,
15, 25, 26, 27, and 28) displayed IC50 values of 1 M. The
inhibition of tryptic-like activity was1 M for the inhibitors 7,
13, and 15. Only compounds 7 and 8 showed exclusive inhibi-
tion of tryptic-like activity. The inhibition of caspase-like ac-
tivity was even weaker (Table I). 20 S proteasomes isolated
from HeLa cells contain more constitutive proteasomes than
immunoproteasomes. Therefore, we repeated the inhibition ex-
periments with immunoproteasomes isolated from stably
transfected T2.27 cells. These experiments revealed that im-
munoproteasomes and constitutive proteasomes display simi-
lar sensitivities to the inhibitors (data not shown). 26 S protea-
somes are responsible for ATP-dependent degradation of2 M. Willem, S. Umbreen, and B. Schmidt, unpublished results.
TABLE I
Calculated IC50 values for compounds 7–28.
IC50 values were calculated from inhibition of proteasomes at increasing amounts of inhibitors. Samples were preincubated for 15 min in ice. The
assay was started by addition of 50 M fluorogenic peptide substrate. LLVY-AMC and GLL-AMC for chymotryptic-like, VGR-AMC for tryptic-like,
and LLE-AMC for caspase-like activity. The release of AMC was determined at 460 nm emission (excitation, 390 nm). Calculated IC50 values for
MG132 served as controls.
Inhibitor Access no.
IC50
5 Chymotrypsin-like (Y) 5 Ch-I (L) 2 Trypsin-like (R) 1 Caspase-like (E)
M M M M
7 BSc2114 10 a 0.053 10
8 BSc2117 10  5.481 10
9 BSc2207 10   
10 BSc2195 10   
11 BSc2196 10   
12 BSc2194 10   
13 BSc2115 0.382 0.102 0.495 0.098
14 BSc2128 10 10 10 10
15 BSc2118 0.058 0.031 0.155 1.791
16 BSc2129 7.26  10 10
17 BSc2208    
18 BSc2197 1.731   3.122
19 BSc2158    
20 BSc2166 10 10 10
21 BSc2167 1.303 10  
22 BSc2160 2.196   
23 BSc2159    
24 BSc2185    
25 BSc2186 0.981  4.04
26 BSc2187 0.441  1.72
27 BSc2188 0.350  7.966
28 BSc2189 0.072  10
3 MG132 0.0242 2.240 9.215 2.288
a , no inhibition.
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polyubiquitin-tagged proteins within living cells. They exhib-
ited a similar susceptibility to the most potent inhibitor (15)
in vitro (data not shown).
Protease inhibitors are often very toxic for organisms or
single cells (1). Therefore, selected inhibitors were tested on
cell cultures for cell lysis or cell death. The viability of HeLa
cells in the presence of different compounds was tested in 24-h
cultures. HeLa cells tolerated 1 M concentrations of inhibitory
and non-inhibitory substances (Fig. 4A). The relative survival
rate of the cells was clearly diminished at concentrations of 10
M. This effect was pronounced for the most potent inhibitors
from the in vitro experiments (15, 28, and 27) (Fig. 4B).
The impact of inhibitors on living cells and organisms cru-
cially depends on adequate cell permeability. Therefore, we
analyzed the proteasome function within cells at different in-
hibitor concentrations. The application to cell cultures or ani-
mals required the concentrations of the inhibitors to be as low
as possible. The specific proteasome activity was reduced below
50% (Fig. 5A) in cells treated with 1 M solutions of 15, 22, 25,
26, and 28. Compounds 7, 13, and 27 exhibited weaker effects
on the specific activity, whereas compounds 18 and 21 hardly
inhibited the cellular proteasome at all. Remarkably, inhibitors
15, 22, and 28 reduced the proteolytic activity already at a
concentration of 100 nM (Fig. 5A). Specific inhibition of protea-
somes results in the accumulation of polyubiquitinated pro-
teins. Indeed, the amounts of polyubiquitinated proteins in-
creased during incubation with the inhibitors. First effects
were observed after 2 h for the potent compound 15 (Fig. 5B)
and for compounds 20, 22, 25, and 28 (data not shown). The
accumulation of polyubiquitinated proteins via proteasome in-
hibition depended strongly on the applied concentrations (Fig.
5C). Thus, several of these new inhibitors are able to permeate
cells and affect the activity of proteasomes. The consequences
of proteasome inhibition for distinct cellular functions are sub-
ject to ongoing investigations.
The particular sensitivity of tumor cells to proteasome inhib-
itors (1) was evaluated in the melanoma cell line MeWo at
different concentrations of compound 15 for 72 h. The viability
was compared with MeWo cells treated with MG132 under the
same conditions (Fig. 6A). 50% of the MeWo cells treated with
35 nM MG132 were still alive after 72 h. Very few cells survived
the treatment with inhibitor 15, which demonstrated its po-
tency. Proteasome inhibitors can induce a cell cycle arrest in
the G1/S or G2 phase, therefore the cell cycle progress was
analyzed after 24-h inhibitor treatment of MeWo cells (Fig. 6, B
and C). Compound 15 led to a cell cycle arrest in the G2 phase,
like MG132, albeit at considerably lower concentrations.
Proteasomes determine the delicate balance of life and death
of the cells by controlling transcription factors and proteins
involved in apoptosis. The reduction of proteasomal capacity
FIG. 5. Inhibition of proteasomes within cells. The proteasome
activity and intracellular accumulation of polyubiquitinated proteins in
cells co-cultured with inhibitors were tested in lysed cells. A, HeLa cells
were cultured in the presence of inhibitors for 24 h. After lysis of cells,
the protein concentration was measured according to Bradford to nor-
malize the different cell amounts. Thereafter, Complete (Roche Applied
Science) was added to all lysates, and the proteasomal activity was
determined by hydrolysis of Suc-LLVY-AMC. Lysates of HeLa cells
cultured without inhibitors served as control (black bars) and were
compared with cell lysates cultivated at 100 nM (gray bars) and 1 M
(white bars). B, HeLa cells were cultured with 1 M compound 15 for 2,
4, 6, and 24 h. Cells were lysed, and proteins were separated by
SDS-PAGE in a 10% gel, blotted onto a polyvinylidene difluoride mem-
brane, and detected in Western blot by an anti-ubiquitin antibody
(DAKO). C, HeLa cells were treated with increasing concentrations of
the inhibitors 15, 25, 26, 27, and 28 for 24 h (c, inhibitor concentration).
Cells were lysed, proteins were separated in 15% gels, and the accumu-
lation of polyubiquitinated proteins was controlled by Western blots.
FIG. 4. A, viability of HeLa cells after
incubation with MG132 and 7–28. The
viability of HeLa cells incubated with in-
hibitors (1 M) was determined by crystal
violet staining after 20 h. B, the viability
of HeLa cells is dependent on inhibitor
concentrations. HeLa cells were cultured
in the presence of increasing concentra-
tions (100 nM, gray bars; 1 M, white dot-
ted bars; 10 M, white bars) of inhibitors
for 20 h. Control cells are indicated by
black bars. Cell survival was determined
by crystal violet staining.
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may result in the initiation of apoptosis, as reported for the
proteasome inhibitor MG132 (29). Therefore, HeLa cells co-
cultured with 1 M solutions of the inhibitors 7, 8, 11, 13–16,
18, 20–23, and 25–28 for 24 h were monitored for the induction
of apoptosis by measuring caspase 3/7 activity. Most of the
tested inhibitors did not affect cell viability. In contrast, appli-
cation of the inhibitors 7, 15, 26, and 28 caused an activation of
caspase 3/7, signaling apoptotic events (Fig. 7).
We determined the crystal structure of the yeast 20 S pro-
teasome in complex with inhibitor 15 to reveal the inhibition
mechanism of the most potent inhibitor, 15. This compound
binds in a similar orientation to the active site threonine as
observed for calpain inhibitor I (6). Defined electron density
was found in all active sites, indicating that compound 15 lacks
subunit specificity at the high concentrations employed (10
mM). The functional aldehyde of the inhibitor forms a covalent
hemiacetal bond to the Thr-1O. The peptide backbone of 15
adopts a -conformation and fills the gap between -strands
and generates an anti-parallel -sheet structure (Fig. 8). The
leucine side chain projects into the S1 pocket, whereas the P2
side chain at P2 is not in contact with the protein. The leucine
side chain at P3 closely interacts with the amino acids of the
adjacent -subunit. In general, both S1 and S3 specificity pock-
ets play a prominent role in inhibitor binding as observed in the
crystal structures of the 20 S proteasome in complex with
lactacystin (6) and vinylsulfone (30). The neutral character of
Met-45 in subunit 5 has a dominant role for the specificity of
this subunit. The crystallographic data (Fig. 8) reveal that the
P1-Leu side chain of 15 causes a structural rearrangement of
Met-45. In contrast to the crystal structure of the 20 S pro-
teasome in complex with lactacystin, Met-45 is rearranged by
3 Å, avoiding a clash with the leucine side chain in P1 of 15,
thereby making the S1 pocket more spacious. Remarkably,
the hydrophobic interactions between the Leu residue of the
inhibitor and Met-45 are only weak, thus reducing the mean
residence time of the compound at the active center. The
specificity defining pockets of subunits 1 and 2 have posi-
tive and negative charges, respectively, which destabilize the
protein-ligand interactions. However, the inherent reactivity
of the aldehyde in compound 15 causes binding to all proteo-
lytically active sites. These observations indicate that the
functional group of this inhibitor plays the dominant role in
binding.
DISCUSSION
Proteasomes are involved in a number of different cellular
processes. They are important for control of the cell cycle and
protect cells from apoptosis by maintaining the balance of
anti-apoptotic and pro-apoptotic proteins (9, 31, 32). The inter-
est in potent and specific inhibitors that may be used as poten-
tial drugs against cancer or neoplastic growth is very high.
Here we report the synthesis of inhibitors based on the protea-
somal peptide inhibitor MG132, which is a potent yet nonspe-
cific inhibitor. We assumed that side chain modifications of the
tripeptide might offer higher potency, selectivity, and site-
specific inhibition of the 20 S proteasome. This assumption is
based on a couple of known and potent peptidic inhibitors (16,
17, 33, 35).
All novel compounds were tested for their inhibitory capacity
in cell lysates. Therefore, serine proteases, cysteine proteases,
and metalloproteases were blocked by the protease inhibitor
mixture Complete (Roche Applied Science) during the assay
with the synthesized mimetics. The proteolysis of the hydro-
phobic Suc-LLVY-AMC substrate was diminished by 11 of the
investigated compounds in two assays. The specific inhibition
of a single catalytic site is of special interest for drug develop-
ment; therefore, we analyzed the inhibition of the different
proteasomal activities. The different cleavage preferences of
proteasomes were determined by specific substrates for the
hydrophobic (chymotrypsin-like), trypsin-like, and post-acidic
(caspase-like) activities on isolated proteasomes. 12 of 22 de-
rivatives inhibited proteasomal activities with IC50 values be-
low 10 M. The peptidic aldehydes 13 and 15 inhibited all
proteasomal hydrolytic activities, whereas four compounds (18,
24, 25, and 26) inhibited the chymotryptic and caspase-like
sites. However, the purpose of this investigation was the iden-
tification of fully selective inhibitors of proteasomal activity.
The tripeptidic alcohol 7 (and with lower potency, 8) specifi-
cally reduced the trypsin-like activity, and compounds 16, 21,
22, and 28 resulted in an exclusive reduction of chymotryptic
FIG. 6. Higher susceptibility of hu-
man melanoma cells to inhibitor 15.
A, human melanoma cells (MeWo) were
treated with increasing concentrations of
inhibitor 15 or 3 (MG132) for 72 h. The
viability of the cells after treatment with
15 (gray diamonds) or MG132 (white
squares) was estimated by crystal violet
staining. Statistical significance (aster-
isks) was calculated by Student’s t test.
B and C, investigation of cell cycle arrest.
MeWo Cells were cultured with inhibitors
15 and 3 (MG132) for 24 h. The harvested
cells were washed and fixed in 70% etha-
nol. Subsequently, the cells were incu-
bated with RNase A. DNA was stained by
addition of propidium iodide to a final
concentration of 5 g/ml. DNA was ana-
lyzed by fluorescence-activated cell sort-
ing (FACSCalibur flow cytometer; BD
Biosciences). Statistical significance was
calculated by the 2 test. The relative dis-
tribution of cells that resided in G1 (black
bar), S (white bar), or G2 phase (checkered
bar) is shown for inhibitor 15 in B and for
MG132 in C.
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FIG. 8. Stereoview of a 30 Å sector of
the crystal structures of the (top
panel) 1, (middle panel) 2, and (bot-
tom panel) 5 active sites of the yeast
20 S proteasome in complex with the
aldehyde 15. 15 is depicted in yellow and
shown for each subunit with its unbiased
electron density. The active site Thr-1 is
highlighted in black, and the covalent
bond between 15 and Thr-1O is high-
lighted in pink. Residues that are partic-
ularly responsible for the character of the
S1 subsite are drawn in green.
FIG. 7. Proteasomal inhibition by 7,
15, 26, and 28 resulted in induction of
apoptosis. HeLa cells treated with 1 M
of the indicated inhibitors for 20 h were
incubated with caspase substrates (Apo-
One®; Promega) for 2 h. The activation of
caspase 3/7 was measured at 538 nm (ex-
citation, 485 nm). Treatment of cells with
tumor necrosis factor  (TNF) or MG132
(M) served as positive controls; controls
without treatment are indicated as co.
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activity. Notably, the most potent of the new inhibitors feature
IC50 values below 100 nM (7, 15, and 28). This is in the range of
novel proteasomal inhibitors, which are in clinical trials (33).
Remarkably, the tetrapeptide inhibitor PSI (Z-IE(OtBu)AL-
CHO) is structurally related to our component 15 (Z-LD(Ot-
Bu)L-CHO) (36), which is among the strongest inhibitors (IC50,
60 nM). Moreover, it exhibited low toxicity and was able to
permeate cellular membranes. The comparison of our inhibi-
tors indicates the major contributions of the ligand side chains
to the specific tight interactions with the various proteolyti-
cally active sites (Fig. 8). Similar observations were made for
the alcohol derivates, with compound 7 being more effective
than the other six compounds. Furthermore, very potent inhib-
itors were identified in the chloromethyl ketone (22) and in
compounds 25–28.
Tumor cells with their accelerated and neoplastic growth are
often more sensitive to proteasomal inhibitors than normal
cells. The clinically approved proteasomal inhibitor Bort-
ezomib® causes growth arrest and apoptosis in the sensitive
tumor cells, whereas “normal” cells tolerate higher inhibitor
concentrations (37). The restriction to myeloma tumors may be
overcome by more specific inhibitors, such as PSI, which blocks
angiogenesis and modulates the growth of solid tumors (36).
The differences in cellular features and the predictable resist-
ance mechanisms require continuous development of new pro-
teasomal inhibitors. Efficient cell permeation, stability in
aquatic systems, and potent induction of cellular events are all
mandatory for clinical applications. Therefore, we tested the
permeation ability of our compounds and their in vivo impact
on proteasomes, and we monitored the accumulation of polyu-
biquitinated proteins in cultured cells. A 50% reduction of
cellular proteasome activity was observed for five of the new
inhibitors (15, 22, 25, 26, and 28). The most potent inhibitions
were achieved by compounds 15, 26, and 28, which reduced the
proteasome activity to 10% at a concentration of 1 M. Even 50
nM solutions of compound 15 arrested 70% of the melanoma
cells. Our results indicate potency, membrane permeation, and
sufficient stability throughout the incubation period for the
inhibitors 15, 22, 25, 26, and 28. The cellular proteasomal
activity was clearly reduced and accompanied by strong induc-
tion of apoptosis after 20 h treatment with 1 M of inhibitors
(15, 26, and 28). The prevalent enhanced sensitivity of tumor
cells toward proteasomal inhibition was confirmed for inhibitor
15. Compound 15 exerts its effects at considerably lower con-
centrations than MG132 and exhibits an almost identical in-
hibitory profile as Bortezomib®, which is characterized by a
lower Ki value. The low toxicity of our new compounds and the
effective proteasome inhibition encourage us to continue our
evaluation of the lead compounds, 15, 26, and 28.
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Syntheses of Peptidomimetics 
Chemistry. General Comments. The 1H- and 13CNMR spectra were recorded on a Bruker 
AC 300 spectrometer at 300 (75). Chemical shifts are reported as ‰ values (ppm) downfield 
from Me4Si. Mass spectrometry was performed on a Bruker-Franzen Esquire LC mass 
spectrometer. Flash column chromatography was carried out using Merck silica gel 60 (40-63 
and 15-40 ?m) and 60G (5-40 ?m). Thin-layer chromatography (TLC) was carried out using 
aluminum sheets precoated with silica gel 60 F254 (0.2 mm; E. Merck). Chromatographic 
spots were visualized by UV and/or spraying with an acidic, ethanolic solution of p-
anisaldehyde or an ethanolic solution of ninhydrin followed by heating. For preparative TLC, 
plates precoated with silica gel 60 F254 (2.0 mm; E. Merck) were used. Amino acid 
derivatives were bought from Fluka Chemie (Switzerland), NovaBiochem (Switzerland), or 
Bachem (Switzerland). THF was dried and distilled from sodium and benzophenone. DMF 
was stored over 3 Å molecular sieves. All other commercial chemicals were used without 
further purification. 
7 (BSc 2114). Ethyl-3-(3´-dimethylaminopropyl)carbodiimide hydrochloride (EDAC, 191 
mg, 1.0 mmol) and N-hydroxybenzotriazole hydrate (HOBt, 183 mg, 1.2 mmol) were added 
to a solution of  Z-Asp(OtBu)-OH (29, 323 mg, 1.0 mmol) dissolved in CH2Cl2 (10 mL). The 
resulting mixture was stirred at ambient temperature for 5 min, then treated with L-leucinol 
(117 mg, 1.0 mmol) and triethylamine (151 mg, 1.5 mmol) for 24 h. CH2Cl2 (20 mL) was 
added and the solution was washed with HCl (0.1 N, 5 x 30 mL), NaOH (0.1 N, 3 x 30 mL), 
brine (1 x 30 mL), dried over Na2SO4, and concentrated to obtain the product 31 (350 mg, 
83%). A solution of 31 (422 mg, 0.8 mmol) in ethanol (10 mL, abs.) was treated with 
palladium on activated carbon (100 mg) under hydrogen atmosphere at room temperature. 
The suspension was filtered after 3 h and the solvent was removed in vacuo to yield 33 (228 
mg, 100%). EDAC (157 mg, 0.82 mmol) and HOBt (132 mg, 0.98 mmol) were added to the 
solution of Boc-Leu-OH (189 mg, 0.82 mmol) in CH2Cl2 (10 mL). The resulting mixture was 
stirred at ambient temperature for 5 min, then treated with 33 (228 mg, 0.82 mmol) and 
triethylamine (124 mg, 1.23 mmol) for 24 h. DCM (20 mL) was added and the solution was 
washed with HCl (0.1 N, 5 x 30 mL), NaOH (0.1 N, 3 x 30 mL), and brine (1 x 30 mL). The 
solvent was removed after drying (Na2SO4) in vacuo to yield (400 mg, 97%) 7 (BSc2114).
1H-NMR (CDCl3, 300 MHz): ? = 7.65 (d, 1H, 3J = 8.3 Hz), 6.8 (d, 1H, 3J = 8.3 Hz), 5.03 (d, 
1H, 3J = 8.3 Hz), 4.55-4.45 (m, 1H), 3.99-3.89 (m, 2H), 3.57 (dd, 1H, 3J = 3.3 Hz, 2J = 11.0 
Hz), 3.47 (dd, 1H, 3J = 3.3 Hz, 2J = 11.0 Hz), 2.99 (d, 1H, 3J = 4.3 Hz), 2.58 (d, 1H, 3J = 4.3 
Hz), 2.48 (d, 1H, 3J = 4.3 Hz), 2.15-2.14 (m, 2H), 1.44 ( s, 9H), 1.34 (s, 9H), 0.90-0.87 (m, 
6H), 0.80-0.75 (m, 6H) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 173.0, 171.5, 170.5, 156.3, 
81.9, 81.0, 65.6, 54.3, 50.6, 50.5, 40.8, 39.7, 35.9, 28.4, 28.0, 24.9, 23.2, 22.2, 21.6, 21.1 ppm. 
MS (EI): m/z = 501 (M+).
13 (BSc2115). Compound 7 (BSc2114) (400mg, 0.8 mmol) was oxidized with IBX (2-
oodoxybenzoic acid, 268 mg, 0.95 mmol) in DMSO (5 mL) at room temperature for 6 h. 
CH2Cl2 (30 mL) was added and the solution was washed with water (3 x 30mL), NaHCO3
solution (3 x 30 mL, sat.), and brine (1 x 30 mL). The solvent was removed after drying 
(Na2SO4) under vacuum to yield 13 (BSc2115) (390 mg, 98%). 1H-NMR (CDCl3, 300 MHz): 
? = 9.4 (s, 1H), 7.54 (d, 1H, 3J = 8.3 Hz), 7.27 (d, 1H, 3J = 8.3 Hz), 4.89 (d, 1H, 3J = 8.3 Hz), 
4.66-4.56 (m, 2H), 4.22-4.15 (m, 2H), 3.99 (dd, 1H, 3J = 3.3 Hz, 2J = 11.0 Hz), 2.99 (dd, 1H,
3J = 3.3 Hz, 2J = 11.0 Hz), 2.90 (d, 1H, 3J = 4.3 Hz), 2.58 (d, 1H, 3J = 4.3 Hz), 2.48 (d, 1H, 3J
= 4.3 Hz), 1.66-1.55 (m, 1H),1.47-1.45 (m, 1H), 1.44 (s, 9H), 1.34 (s, 9H), 0.9-0.86 (m, 6H,), 
0.80-0.76 (m, 6H) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 200.1, 172.6, 171.6, 170.9, 156.2, 
82.0, 80.8, 54.3, 50.6, 50.5, 40.8, 39.7, 35.9, 28.4, 28.0, 24.9, 23.2, 22.2, 21.6, 21.1 ppm. MS
(EI): m/z = 499 (M+).
14 (BSc2128). TFA (1 mL) was added to the stirred solution of 7 (BSc2114. 390 mg, 0.78 
mmol) in CH2Cl2 (4 mL). The solvent was evaporated after 3h (260 mg, 97%) to obtain 14
(BSc2128). 1H-NMR (DMSO-d6, 300 MHz): ? = 9.37 (s, 1H), 8.85 (d, 1H, 3J = 8.3 Hz), 8.19 
(d, 1H, 3J = 8.3 Hz), 4.67-4.56 (m, 1H), 4.05-3.89 (m, 2H), 3.77-3.65 (m, 2H), 3.70-3.67 (m, 
1H), 2.89 (dd, 1H, 3J = 4.1 Hz, 2J = 16.0 Hz), 2.78 (d, 1H, 3J = 4.1 Hz, 2J = 16.0 Hz), 2.58 (d, 
1H, 3J = 4.1 Hz), 2.48 (d, 1H, , 3J = 4.1 Hz), 1.60-1.58 (m, 1H), 1.46-1.44 (m, 1H), 0.80-0.76 
(m, 6H), 0.70-0.66 (m, 6H) ppm. 13C-NMR (DMSO-d6, 75 MHz): ? = 200.1, 171.1, 171.0, 
169.9, 55.2, 53.8, 50.4, 40.8, 39.7, 35.9, 23.2, 22.2, 21.6, 21.1 ppm . MS (ESI): m/z = 343.4 
(M+).
Compounds 16 BSc2129, 9 BSc2207, 17 BSc2208, 18 BSc2197, and 12 BSc2194 were 
generated by analogue procedures. 
1.) EDAC, HOBt, CH2Cl2 31: Pd / H2, EtOH
R3-Leu-OH,
EDAC, HOBt,
CH2Cl2, Et3N
2.) Et3N, L-Leucinol
IBXTFA
DCM DMSO
R1 Asp(OR2) OH R1 Asp(OR2) N
H
OH H Asp(OR2) N
H
OH
Leu Asp(OR2) N
H
OHR3Leu Asp(OH) N
H
O
R3
7 BSc2114: R2 = tBu, R3 = Boc (97%)
8 BSc2117: R2 = tBu, R3 = Z
9 BSc2207: R2 = tBu, R3 = Ac
10 BSc2195: R2 = Bn, R3 = Ac (97%)
11 BSc2196: R2 = Bn, R3 = Z (97%)
12 BSc2194: R2 = Bn, R3 = Boc
13 BSc2115: R2 = tBu, R3 = Boc (98%)
15 BSc2118: R2 = tBu, R3 = Z (97%)
17 BSc2208: R2 = Bn, R3 = Ac (96%)
18 BSc2197: R2 = Bn, R3 = Z (95%)
14 Bsc2128: R3 = Boc
16 BSc2129: R3 = Z
29: R1 = Z, R2 = tBu
30: R1 = Boc, R2 = Bn
32: TFA, CH2Cl2
31: R1 = Z, R2 = tBu (83%)
32: R1 = Boc, R2 = Bn
33: R2 = tBu (100%)
34: R2 = Bn
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Scheme 1 Synthesis of tripeptide mimetics
8 (BSc2117). The title compound was prepared from 33 according to the same procedure in 
80% yield. 1H-NMR (CDCl3, 300 MHz): ? =7.51 (d, 1H, 3J = 8.3 Hz),7.29-7.19 (m, 5H), 6.70 
(d, 1H, 3J = 8.3 Hz), 5.35 (d, 1H, 3J = 8.3 Hz), 5.50 (s, 2H), 4.60-4.58 (m, 1H), 4.10-4.75 (m,
1H), 3.95-3.87 (m, 1H), 3.58 (dd, 1H, 3J = 3.3 Hz, 2J = 11.0 Hz), 3.45 (dd, 1H, 3J = 3.3 Hz, 2J
= 11.0 Hz), 2.89 (dd, 1H, 3J = 4.1 Hz, 2J = 16.0 Hz), 2.80 (d, 1H, 3J = 4.1 Hz, 2J = 16.0 Hz), 
2.59 (d, 1H, 3J = 4.3 Hz,), 2.50 (d, 1H, 3J = 4.3 Hz,), 2.0-1.96 (m, 2H), 1.55-1.53 (m, 1H), 
1.34 (s, 9H), 1.25-1.23 (m, 1H), 0.89 (dd, 6H, 3J = 4.3 Hz, 3J = 7.0 Hz), 0.80 (dd, 6H, 3J = 4.3 
Hz, 3J = 7.0 Hz) ppm. 13C-NMR (CDCl3, 75 MHz): ? =167.0, 166.2, 165.1, 151.4, 130.4, 
123.3, 123.1, 123.1, 122.8, 77.1, 62.2, 60.2, 49.0, 45.8, 45.2, 35.6, 34.4, 31.1, 22.7,  22.7, 
22.7,  21.6, 21.1, 19.5, 17.8 ppm. MS (EI): m/z = 535(M+).
15 (BSc2118). The title compound was prepared from 8 (BSc2117) according to the same
procedure in 94% yield. 1H-NMR (CDCl3, 300 MHz):?? = 9.49 (s, 1H), 7.48 (d, 1H, 3J = 8.3 
Hz), 7.35-7.33 (m, 5H), 7.25 (d, 1H, 3J = 7.3 Hz), 5.23-5.22 (m, 1H), 5.12 (s, 2H), 4.80-4.79 
(m, 1H), 4.38-4.37 (m, 1H), 4.15-4.14 (m, 1H), 3.00 (d, 1H, 3J = 3.3 Hz), 2.98 (d, 1H, 3J = 3.3 
Hz), 2.60 (d, 1H, 3J = 6.3 Hz), 2.55 (d, 1H, 3J = 6.3 Hz), 2.30-2.28 (m, 1H), 2.23-2.22 (m, 
1H), 2.05-1.99 (m, 2H), 1.77-1.76 (m, 1H), 1.44 (s, 9H), 1.35-1.34 (m, 1H), 0.89-0.86 (m, 
6H), 0.80-0.78 (m, 6H) ppm. 13C-NMR (CDCl3, 75 MHz): ? =200, 172.1, 171.6, 170.8, 67.4, 
156.6 , 135.9, 128.7, 128.4, 128.1, 122.8, 82.1, 57.5, 54.5, 49.8, 45.8, 45.2, 41.1, 37.4, 36.5, 
28.0, 28.0, 28.0, 24.5, 23.3, 23.0, 21.7 ppm. MS (ESI): m/z = 533 (M+).
16 (BSc2129). The title compound was prepared from 15 (BSc2118) according to the same 
procedure in 84% yield. 1H-NMR (DMSO-d6, 300 MHz):?? = 9.8 (s, 1H), 9.37 (s, 1H), 8.30 
(d, 1H, 3J = 8.3 Hz), 8.24 (d, 1H, 3J = 7.3 Hz), 7.36-7.34 (m, 5H), 5.22-5.21 (m, 1H), 5.12 (s, 
2H), 4.80-4.79 (m, 1H), 4.5-4.45 (m, 1H), 4.15-4.10 (m, 1H), 3.30-3.29 (m, 1H), 2.98-2.97 
(m, 1H), 2.60-2.59 (m, 1H), 2.55-2.54 (m, 1H), 2.30-2.29 (m, 1H), 2.23-2.22 (m, 1H), 2.05-
1.99 (m, 2H), 1.77-1.76 (m, 1H), 1.35-1.34 (m, 1H), 0.89-0.88 (m, 6H), 0.80-0.79 (m, 6H) 
ppm. 13C-NMR (DMSO-d6, 75 MHz): ? =200, 172.1, 171.6, 170.8, 67.4, 156.6, 135.9, 128.7, 
128.4, 128.1, 122.8, 82.1, 57.5, 54.5, 49.8, 45.8, 45.2, 41.1, 37.4, 36.5, 24.5, 23.3, 23.0 , 21.7 
ppm. MS (ESI): m/z = 476 (M+).
9 (BSc2207). The title compound was prepared from 33 according to the same procedure in 
93% yield. 1H-NMR (CDCl3, 300 MHz): ? =7.67 (d, 1H, 3J = 8.3 Hz), 7.4 (d, 1H, 3J = 9.2 
Hz), 7.26 (d, 1H, 3J = 8.4 Hz), 4.7-4.63 (m, 2H), 4.43-4.33 (m, 2H), 4.04-3.94 (m, 2H), 3.59-
3.54 (m, 1H), 3.53-3.43 (m, 1H), 3.30 (dd, 1H, 3J = 4.8 Hz, 2J = 17.0 Hz), 2.8 (dd, 1H, 3J = 
4.8 Hz, 2J = 17.0 Hz), 2.65-2.55 (m, 1H), 2.54-2.45 (m, 1H), 2.15-2.05 (m, 2H), 2.0 (d, 3H, 3J
= 15.0 Hz), 1.44 (s, 9H), 0.9-0.87 (m, 6H), 0.80-0.78 (m, 6H) ppm. 13C-NMR (CDCl3, 75 
MHz): ? = 172.5, 172.3, 171.6, 169.9, 82.0,  66.6, 53.4, 50.4, 49.5, 40.8, 39.7, 35.9, 28.4, 
25.0, 24.7, 22.9, 23.2, 22.1 ppm. MS (EI): m/z = 443 (M+).
10 (BSc2195). The title compound was prepared from 34 according to the same procedure in 
88 % yield. 1H-NMR (CDCl3, 300 MHz):?? = 8.26 (d, 1H, 3J = 7.2 Hz), 7.59 (m, 5H, ArH), 
6.70 (d, 1H, 3J = 7.3 Hz), 6.35 (d, 1H, 3J = 7.0 Hz), 5.20 (s, 2H), 4.62-4.48 (m, 1H), 4.44-4.42 
(m, 1H), 4.01-4.00 (m, 1H), 3.98-3.97 (m, 1H), 3.91-3.90 (m, 1H), 2.89-2.88 (dm, 1H), 2.80-
2.78 (m, 1H), 2.59-2.58 (m, 1H), 2.50-2.49 (m, 1H), 2.0-1.99 (m, 2H), 1.55-1.54 (m, 1H), 
1.34 (s, 3H), 1.25-1.24 (m, 1H),  0.89 (dd, 6H, 3J = 3.8 Hz, 6.7 Hz), 0.80 (dd, 6H, 3J = 3.8 Hz, 
6.7 Hz) ppm. 13C-NMR (CDCl3, 75 MHz):?? = 175.5, 173.7, 173.0, 169.7, 128.8, 128.3, 68.5, 
66.5, 41.4, 40.8, 40.2, 35.6, 34.4, 31.1, 23.5, 22.1, 23.9, 23.6, 22.9 ppm. MS (EI): m/z = 477 
(M+).
17 (BSc2208). The title compound was prepared from 10 (BSc2195) according to the same 
procedure  in 74% yield. 1H-NMR (CDCl3, 300 MHz): ? = 9.40 (s, 1H), 8.26 (d, 1H, 3J = 7.0 
Hz), 7.28-7.19 (m, 5H), 6.70 (d, 1H, 3J = 7.0 Hz), 5.65 (d, 1H, 3J = 7.0 Hz), 5.30 (s, 2H), 
4.82-4.81 (m, 1H), 4.35-4.33 (m, 1H), 3.96-3.95 (m, 1H), 2.80-2.79 (m, 1H), 2.75-2.74 (m, 
1H), 2.49-2.48 (m, 1H), 2.45-2.44 (m, 1H), 2.0-1.98 (m, 2H), 1.51-1.50 (m, 1H), 1.30 (s, 3H), 
1.25-1.24 (m, 1H),  0.89 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz), 0.80 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz) 
ppm. 13C-NMR (CDCl3, 75 MHz):?? = 200, 174.5, 173.5, 173.0, 166.7, 128.6, 128.3, 68.5, 
41.4, 40.8, 40.2, 35.6, 34.4, 31.1, 23.5, 22.1, 23.9, 23.6, 22.9. MS (EI): m/z = 475 (M+).
11 (BSc2196). The title compound was prepared from 34 according to the same procedure in 
77 % yield. 1H-NMR (CDCl3, 300 MHz):?? = 7.29-7.19 (m, 10H), 6.65 (d, 1H, 3J = 7.0 Hz), 
6.33 (d, 1H, 3J = 7.0 Hz), 5.35 (d, 1H, 3J = 7.0 Hz), 5.28-5.17 (m, 4H), 4.22-4.21 (m, 1H), 
4.0-3.99 (m, 1H), 3.74-3.73 (m, 1H), 3.66-3.65 (m, 1H), 3.22-3.21 (m, 1H), 2.99-2.98 (m, 
1H), 2.92-2.91 (m, 1H), 2.62-2.60 (d, 1H), 2.50-2.51 (d, 1H,), 2.4-2.3 (m, 2H), 1.57-1.56 (m, 
1H), 1.24-1.23 (m, 1H),  0.87 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz), 0.80 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz) 
ppm. 13C-NMR (CDCl3, 75 MHz):?? = 172.4, 172.0, 170.2, 156.8, 142.8, 135.8, 128.7, 68.5, 
67.2, 62.2, 52.0, 49.8, 49.2, 41.6, 40.4, 33.1, 22.4, 22.1, 21.6, 21.1, 19.5, 18.3 ppm. MS (EI): 
m/z = 569 (M+).
18 (BSc2197). The title compound was prepared from 11 (BSc2196) according to the same 
procedure in 74% yield. 1H-NMR (CDCl3, 300 MHz):?? = 9.33 (s, 1H), 7.26-7.19 (m, 10H), 
7.03 (d, 1H, 3J = 7.0 Hz), 6.41 (d, 1H, 3J = 7.0 Hz), 5.66 (d, 1H, 3J = 7.0 Hz), 5.23-4.95 (m, 
4H), 4.26-4.13 (m, 1H), 4.12-4.03 (m, 1H), 3.57-3.54 (m, 1H), 2.94 (d, 1H, 3J = 7.3 Hz), 2.72 
(d, 1H, 3J = 7.3 Hz ), 2.02 (d, 1H, 3J = 10.0 Hz), 1.99 (d, 1H, 3J = 10.0 Hz), 1.57-1.44 (m, 
2H), 1.45-1.42 (m, 1H), 1.24-1.99 (m, 1H),  0.87 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz ), 0.80 (dd, 6H, 
3J = 3.8 Hz, 6.4 Hz) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 200, 173.4, 172.6, 171.2, 156.8, 
142.8, 138.8, 128.7, 128.7, 66.5, 65.2, 52.0, 49.7, 48.2, 41.7, 40.6, 33.5, 22.6, 22.3, 21.9, 21.5, 
19.4, 18.0 ppm. MS (ESI): m/z = 567 (M+).
12 (BSc2194). The title compound was prepared from 34 according to the same procedure in 
90 % yield. 1H-NMR (CDCl3, 300 MHz): ? = 7.32-7.28 (m, 5H), 7.01 (d, 1H, 3J = 7.0 Hz), 
6.33 (d, 1H, 3J = 7.0 Hz), 5.32 (s, 2H), 4.91 (d, 1H, 3J = 7.0 Hz), 4.25-4.22 (m, 1H), 4.08-4.06 
(m, 1H), 3.98-3.97 (m, 1H), 3.68-3.65 (dd, 2H), 2.99-2.97 (m, 1H), 2.92 (d, 1H, 3J = 7.3 Hz), 
2.59 (d, 1H, 3J = 7.3 Hz), 2.50 (d, 1H, 3J = 7.3 Hz), 1.97-1.87 (m, 2H), 1.55-1.54 (m, 1H), 
1.34 (s, 9H), 1.24.1.23 (m, 1H),  0.89 (dd, 6H, 3J = 3.8 Hz, 6.4 Hz), 0.80 (dd, 6H, 3J = 3.8 Hz, 
6.4 Hz) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 172.8, 172.4, 170.1, 155.8, 135.4, 128.6, 77.1 
, 76.6, 67.2, 62.2, 49.0, 45.8, 45.2, 35.6, 34.4, 33.1, 23.7, 22.4, 22.1, 21.6, 21.1, 19.5, 18.3 
ppm. MS (EI): m/z = 535 (M+).
19 (BSc2158). A suspension of NaH in mineral oil (60%, 291 mg, 7.3 mmol) in THF (2 mL, 
abs.) was treated with (S)-(-)-phenylglycinol (500 mg, 3.6 mmol) at -15°C under argon 
atmosphere and stirred for 20 min. The mixture was cooled to -55°C prior to the addition of 
trichloroethylene (400 ?l, 4.5 mmol) in THF (2 mL). The mixture was warmed to ambient 
temperature within 5 h, quenched with water (40 mL) and extracted with Et2O (60 mL). The 
organic layer was separated, washed with brine (40 mL), dried (Na2SO4), and concentrated. 
The crude oil was purified by LC to give dichlorovinyl ether 35 (347 mg, 56%).
To a mixture of Z-Leu-Leu-OH (378 mg, 1.0 mmol), EDAC (192 mg, 1.0 mmol) and HOBt 
(170 mg, 1.1 mmol) DMF (2 mL) was added. The resulting solution was stirred vigorously for 
10 min, then dichlorovinyl ether 35 (200 mg, 1.2 mmol) and Et3N (0.28 mL, 2.0 mmol) were 
added. The solution was stirred for 2 h. DCM (40 mL) was added and washed with 
hydrochloric acid (0.1 N, 3 x 30 mL), aqueous NaHCO3 (sat., 3 x 30 mL), and water (3 x 30 
mL). The organic layer was dried (Na2SO4) and the solvent removed under vacuum to yield 
19 (BSc2158) (403 mg, 77%). 1H-NMR (DMSO-d6, 300 MHz): ? = 8.52 (d, 1H, 3J = 8.3 Hz), 
8.33 (d, 1H, 3J = 8.3 Hz), 7.44 (d, 1H, 3J = 8.2 Hz, NH-Leu1), 7.40-7.28 (m, 10H), 6.07 (s, 
1H), 5.19-5.12 (m, 1H), 5.00 (s, 2H), 4.45-4.40 (m, 1H), 4.22-4.11 (m, 2H), 4.08-4.01 (m, 
1H), 1.65-1.35 (m, 6H), 0.90-0.78 (m, 12H) ppm. 13C-NMR (DMSO-d6, 75 MHz): ? = 172.0, 
171.5, 155.8, 142.2, 138.4, 136.9, 128.2, 127.7, 127.6, 127.4, 127.5, 126.9, 97.7, 73.0, 65.2, 
53.0, 51.4, 50.8, 40.8, 40.6, 24.1, 24.0, 22.6, 21.9, 21.6, 21.3 ppm. MS (EI): m/z = 480 (Z-
Leu-Leu-C8H9+), 371 (CO-Leu-C10H10Cl2NO+).
20 (BSc2166). Dichlorovinyl ether 36 (178 mg, 25%) was synthesized from (S)-(-)-leucinol 
(400 mg, 3.4 mmol) according to the synthesis of dichlorovinyl ether 35. The reaction was 
started at -70°C, warmed to ambient temperature over night, then stirred for another 60 h.
Coupling of 36 (100 mg, 0.47 mmol) with Z-Leu-Leu-OH (100 mg, 0.47 mmol) afforded 
product 20 (BSc2166) (143 mg, 63%). 1H-NMR (DMSO-d6, 300 MHz): ? = 7.92 (d, 1H, 3J = 
5.1 Hz), 7.70 (d, 1H, 3J = 5.1 Hz), 7.48 (d, 1H, 3J = 4.2 Hz), 7.40-7.31 (m, 5H), 6.05 (s, 1H), 
5.05 (s, 2H), 4.33-4.29 (m, 1H), 4.08-4.03 (m, 2H), 3.87-3.85 (m, 2H), 1.60-1.41 (m, 9H,)
0.90-0.88 (m, 18H) ppm. 13C-NMR (DMSO-d6, 75 MHz): ? = 171.9, 171.5, 155.8, 142.9, 
137.0 128.2, 127.7, 127.5, 97.9, 73.3, 65.3, 53.1, 50.9, 45.7, 40.9, 40.0, 39.8, 24.11, 24.08, 
23.85, 23.16, 22.92, 22.87, 21.80, 21.50, 21.5 ppm. MS (EI): m/z = 460 (Z-Leu-Leu-
C6H14N+), 295 (CO-Leu-C4H6Cl2NO+).
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Scheme 2 Synthesis of dichlorovinyl ethers 19 (BSc2158) and 20 (BSc2166) 
21 (BSc2167). An oven dried round bottom flask was charged with Zn(OTf)2 (168 mg, 0.45 
mmol) and (-)-ephedrine (84 mg, 0.50 mmol) under argon atmosphere. Et3N (51 mg, 70 ?L,
0.50 mmol) was added in dry toluene (2 mL) and stirred at room temperature for 2 h. 3
(MG132) (200 mg, 0.42 mmol) and phenylacetylene (52 mg, 56 ?L, 0.50 mmol) were added 
after further 15 min and stirred at 60°C for 20 h. CH2Cl2 (40 mL) and an aqueous 
KH2PO4/Na2HPO4-buffer (30 mL, pH = 5.5) were added, the organic layer was separated and 
the aqueous phase extracted with CH2Cl2 (2 x 30 mL). The combined organic layers were 
dried (Na2SO4) and the solvent removed in vacuo. The crude product was purified by LC to 
yield 21 (BSc2167) (260 mg, 54%). 1H-NMR (DMSO-d6, 300 MHz): ? = 8.46-8.37 (m, 1H), 
7.50-7.47 (m, 1H), 7.43-7.19 (m, 10H), 5.20-5.11 (m, 1H), 5.00-4.95 (m, 2H), 4.57-4.49 (m, 
2H), 4.13-4.03 (m, 2H), 1.80-1.24 (m, 9H), 0.90-0.53 (m, 18H) ppm. 13C-NMR (DMSO-d6,
75 MHz): ? = 174.2, 174.7, 156.9, 139.5, 131.2, 127.9, 127.8, 127.6, 127.3, 126.5, 126.3, 
98.1, 80.0, 63.1, 62.8, 54.5, 52.9, 46.8, 40.9, 40.3, 36.9, 24.7, 24.2, 24.0, 23.2, 23.1, 22.9, 
21.4, 21.2, 20.7 ppm. MS (EI) m/z = 446 (Z-Leu-Leu-C5H11+), 257 (CO-Leu-C6H13O+).
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Scheme 3 Addition of phenylacetylene to aldehyde 3 (MG132) 
22 (BSc2160). Z-Leu-Leu-OH (151 mg, 0.4 mmol) and (S)-3-amino-1-chloro-5-methylhexan-
2-one (80 mg, 0.4 mmol) were coupled as described for 19 (BSc2158). The crude product 
was purified by LC to give 22 (BSc2160) (32 mg, 16%). 1H-NMR (CDCl3, 300 MHz): ? =
7.35-7.19 (m, 5H), 6.81-6.73 (m, 1H), 6.41-6.32 (m, 1H), 5.16 (d, 1H, 3J = 5.1 Hz), 5.03 (s, 
2H), 4.64-4.61 (m, 1H), 4.35-4.06 (m, 3H), 1.87-1.40 (m, 9H), 0.92-0.73 (m, 18H) ppm. 13C-
NMR (CDCl3, 75 MHz): ? = 201.4, 172.7, 172.3, 156.6, 136.2, 128.6, 128.3, 128.0, 67.2, 
55.0, 53.8, 51.8, 47.1, 41.4, 40.6, 39.6, 24.9, 24.8, 23.3, 22.9, 22.7, 22.6, 22.3, 22.2, 21.5 ppm.
MS (EI): m/z = 488 (Z-Leu-Leu-Leu-CH2+), 432 (OCO-Leu-Leu-Leu-CH2Cl+).
Z-Leu-Leu,
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Scheme 4 Synthesis of ?-chloromethyl ketone 22 (BSc2160) 
23 (BSc2159). 3 (MG132) (300 mg, 0.63 mmol), benzyl isonitrile (116 ?l, 0.95 mmol), and 
pyridine (204 ?l, 2.53 mmol) were dissolved in CH2Cl2 (2.0 mL) and cooled to          -10°C. 
Trifluoroacetic acid (97 ?L, 1.26 mmol) was added dropwise (T < 0°C) under argon 
atmosphere over 15 min. Cooling was maintained for 2 h, followed by additional 72 h at room 
temperature. CH2Cl2 (50 mL) was added and washed with hydrochloric acid (0.1 N, 3 x 30 
ml), aqueous NaHCO3 (sat., 3 x 30 mL) and brine (3 x 40 ml). The organic phase was dried 
(Na2SO4) and purified by LC to give 23 (BSc2159) (191 mg, 50%). 1H-NMR (CDCl3, 300 
MHz): ? = 7.51-7.27 (s, 1H), 7.26-7.14 (m, 10H), 6.91-6.80 (m, 1H) 5.82-5.63 (m, 2H), 5.02-
4.90 (m, 2H), 4.35 (d, 1H, 3J = 10.7 Hz), 4.30-4.01 (m, 5H), 1.55-1.31 (m, 9H), 0.81-0.73 (m, 
18H) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 173.3, 172.7, 172.6, 157.5, 138.0, 136.2, 128.9, 
128.8, 128.6, 128.1, 127.9, 127.8, 73.5, 67.3, 53.9, 52.0, 51.7, 43.2, 42.4, 41.6, 25.0, 24.8, 
23.3, 23.0, 22.1, 22.0, 21.6 ppm. MS (EI): m/z = 610 (M+).
24 (BSc2185). 3 MG132 (145 mg, 0.3 mmol) and 3-picolyl isonitrile (52 mg, 0.45 mmol) 
were converted into ?-hydroxyl amide 24 (BSc2185) according to the preparation of 23
(BSc2159). Purification by LC resulted 24 (BSc2185) (103 mg, 56%). 1H-NMR (CDCl3, 300 
MHz): ? = 8.62-8.36 (m, 2H), 7.71-7.50 (m, 2H), 7.28-7.20 (m, 6H), 7.05-6.96 (m, 1H) 5.92-
5.57 (m, 2H), 5.00 (s, 2H), 4.72-4.56 (m, 1H), 4.46-4.10 (m, 5H), 1.79 (s, 1H), 1.62-1.18 (m, 
9H), 0.92-0.73 (m, 18H) ppm. 13C-NMR (DMSO-d6, 75 MHz): ? = 172.4, 171.9, 171.2, 
155.8, 148.9, 147.9, 137.0, 135.2, 135.0, 128.2, 127.7, 127.6, 123.2, 73.8, 65.2, 53.0, 51.0, 
49.2, 42.8, 40.6, 37.1, 24.1, 23.7, 22.2, 23.0, 21.8, 21.7, 21.6, 21.1 ppm. MS (EI) m/z = 611 
(M+).
25 (BSc2186). 3 MG132 (200 mg, 0.42 mmol) and phenyl isonitrile (65 mg, 0.63 mmol) were
converted into ?-hydroxyl amide 25 (BSc2186) according to the preparation of 23 (BSc2159). 
The crude product was purified by LC to give 25 (BSc2186) (70 mg, 28%). 1H-NMR
(DMSO-d6, 300 MHz): ? = 8.27 (s, 1H), 7.72-7.57 (m, 2H), 7.37-7.20 (m, 7H), 7.11-7.01 (m, 
2H), 6.11-6.08 (m, 1H), 5.95-5.92 (m, 1H), 5.07 (s, 2H), 4.30-4.24 (m, 2H), 4.07-3.99 (m, 
2H), 1.57-1.32 (m, 9H), 0.88-0.61 (m, 18H) ppm. 13C-NMR (DMSO-d6, 75 MHz): ? = 172.0, 
171.1, 171.0, 155.7, 138.3, 137.0, 128.4, 128.2, 127.6, 127.5, 123.5, 119.5, 65.2, 52.7, 52.9, 
49.2, 40.5, 40.3, 40.0, 24.1, 23.9, 23.8, 23.1, 23.0, 22.6, 22.0, 21.3, 21.2 ppm. MS (EI) m/z =
596 (M+).
26 (BSc2187). ?-Hydroxyl amide 23 (BSc2159) (40 mg, 0.065 mmol) and IBX (36 mg, 0.13 
mmol) were dissolved in DMSO and stirred at room temperature for 12 h. DCM (40 mL) and 
water (30 mL) were added prior to filtration The organic layer was separated and washed with 
water (2 x 40 mL), aqueous NaHCO3 (1 x 40 mL, 0.05 N) and water (1 x 30 mL). The organic 
layer was dried (Na2SO4) and the solvent removed in vacuo to give 26 (BSc 2187) (22 mg, 
56%). 1H-NMR (CDCl3, 300 MHz): ? = 7.50-7.41 (m, 1H), 7.41-7.14 (m, 10H), 6.91-6.80 
(m, 1H) 5.58-5.54 (m, 1H), 5.27-5.21 (m, 1H), 5.03-4.94 (m, 2H), 4.43-4.31 (m, 3H), 4.19-
4.03 (m, 2H), 1.64-1.12 (m, 9H), 0.92-0.74 (m, 18H) ppm. 13C-NMR (CDCl3, 75 MHz): ? =
191.8, 172.6, 171.8, 161.4, 156.4, 136.9, 136.3, 128.9, 128.9, 128.6, 128.3, 128.1, 128.0, 67.2, 
53.6, 53.3, 51.6, 43.4, 41.5, 40.86, 40.0, 25.3, 24.8, 23.8, 23.7, 23.3, 23.0, 22.8, 22.4, 22.1, 
21.5 ppm. MS (EI) m/z = 474 (Z-Leu-Leu-C6H12NO+).
27 (BSc2188). 24 (BSc2185) was oxidized according to the synthesis of 26 (BSc2187). 
Purification by LC afforded 27 (BSc2188) (60 mg, 49%). 1H-NMR (CDCl3, 300 MHz): ? =
8.46-8.44 (m, 2H), 7.64-7.47 (m, 2H),  7.24-7.12 (m, 6H), 6.85-6.82 (m, 1H), 5.54-5.47 (m, 
1H), 5.22-5.15 (m, 1H), 5.04-4.93 (m, 2H), 4.46-3.99 (m, 4H), 1.62-1.16 (m, 9H), 0.92-0.76 
(m, 18H) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 196.4, 172.6, 171.9, 159.8, 156.4, 149.3, 
149.2,  136.2, 135.9, 133.0, 128.7, 128.3, 128.0, 123.8, 67.2, 53.7, 53.3, 51.5, 41.4, 40.8, 40.6, 
39.9, 25.0, 24.8, 23.3, 23.0, 22.1, 22.0 ppm. MS (EI): m/z = 609 (M+), 474 (Z-Leu-Leu-
C6H12NO+).
28 (BSc2189). 25 (BSc2185) (200 mg, 0.35 mmol) was oxidized according to the synthesis of 
26 (BSc2187). Purification by LC afforded 28 (BSc2189) (30 mg, 50%). 1H-NMR (CDCl3,
300 MHz): ? = 8.58 (s, 1H), 7.56-7.54 (m, 2H), 7.29-7.19 (m, 7H), 7.11-7.00 (m, 1H), 6.75 
(d, 1H, 3J = 9.0 Hz), 6.63 (d, 1H, 3J = 9.1 Hz), 5.36-5.28 (m, 2H), 5.07 (s, 2H), 4.51-4.41 (m, 
1H), 4.19-4.11 (m, 1H), 1.97-1.41 (m, 9H), 0.93-0.77 (m, 18H) ppm. 13C-NMR (CDCl3, 75 
MHz): ? = 196.8, 172.5, 171.8, 157.2, 156.4, 136.3, 136.2, 129.3, 129.2, 128.7, 125.5, 120.0, 
67.3, 53.7, 53.0, 51.6, 41.3, 40.6, 40.9, 25.4, 25.4, 24.8, 23.3, 23.0, 22.8, 22.2, 22.1, 21.5 ppm.
MS (EI): m/z = 474 (Z-Leu-Leu-C6H12NO+).
3 MG132
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 CH2Cl2
2.) triflouroacetic acid
R =
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DMSO
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Scheme 5 Passerini reaction and following oxidation to ?-keto amides.
2-Iodoethanols from aldehydes, diiodomethane and
isopropylmagnesium chloride
Hannes A. Braun, Reinhard Meusinger and Boris Schmidt*
Darmstadt Technical University, Clemens Scho¨pf-Institute for Organic Chemistry and Biochemistry, Petersenstr. 22,
D-64287 Darmstadt, Germany
Received 18 January 2005; revised 15 February 2005; accepted 16 February 2005
Abstract—Diiodomethane and iodoform react with i-PrMgCl by halogen–metal exchange. The resulting magnesium reagents toler-
ate several functional groups, but aldehydes are converted selectively into iodoethanols in good to high yields. These mild reagents
preserve racemization prone centres. The substrate controlled diastereoselectivity provides straightforward access to important
intermediates of peptidomimetics.
 2005 Elsevier Ltd. All rights reserved.
Amino acid derived epoxides and 2-haloethanols are
extremely versatile intermediates for the synthesis of
protease inhibitors.1–3 Several synthetic strategies are
known, but they are either lengthy, require diazo-
methane or harsh conditions. Most organic chemists
have rather mixed feelings using diazomethane for the
synthesis of the intermediate a-chloroketones. The less
hazardous siladiazomethane is signiﬁcantly more expen-
sive and therefore limited to small scale reactions. How-
ever, it can be replaced by dimethylsulfoxonium
methylide.4 Nevertheless, a reliable, straightforward
and inexpensive approach is still very desirable. Some
of these requirements are fulﬁlled by lithium organyls,5
their strong basicity impedes the conversion of di- and
oligopeptides, yet they provide access to a-chloro-
ketones from N,N-dibenzylated amino acid esters.15
The umpolung of ClCH2I or CH2I2 and subsequent
addition to aldehydes provides access to epoxides,6 but
requires methyllithium at 78 C. The deprotonation
of CH2Cl2 by n-BuLi and addition to ketones furnished
tertiary b-dichloroalcohols.7 A more recent approach to
the respective iodo species utilized diiodomethane or
iodoform and air-sensitive and expensive SmI2, which
can be replaced by metallic samarium and iodoform.8,9
Here we report the eﬃcient synthesis of 2-iodoethanols
and 2,2-diiodoethanols from safe and convenient pre-
cursors. Seeking a safer replacement of methyllithium,
we decided to investigate i-PrMgCl, which has a remark-
able potential for iodine–magnesium exchanges. The
late G. Ko¨brich already reported the halogen–metal
exchange of bromoform and dibromomethane with
n-BuLi. On the contrary, the analogous chloro com-
pounds react by deprotonation.10 The former reactivity
continues in diiodomethane and iodoform, and may be
improved by magnesium alkyls. We expected these mag-
nesium reagents to favour late transition states, to toler-
ate a wide range of functional groups, to display reduced
basicity, and thus allow stereoselective conversion of
polyfunctional peptides.11 The rate of the halogen–metal
exchange depends on the electron density to a great ex-
tent that the stepwise activation of geminal diiodides is
feasible. The detailed kinetics and energetics were re-
ported by Hoﬀmann and the potential of this reaction
was revealed in a number of publications already.12–14
The activation of iodoform or diiodomethane by
i-PrMgCl proceeded rapidly in tetrahydrofuran at
78 C (Scheme 1).
The addition of i-PrMgCl to aldehydes was considerably
slower at this temperature. Addition of an aldehyde
after complete iodo-magnesium exchange (15 min)
resulted in similar yields and selectivities as obtained
for the simultaneous addition (Table 1). Both C1
nucleophiles, which are derived from long-lived ate
complexes,12 reacted with aldehydes (1a–d) at 78 C
0040-4039/$ - see front matter  2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.tetlet.2005.02.093
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to the b-iodo-(2a–d) and b-diiodo compounds (3a and
b). The formation of epoxides was not observed even
at 0 C for 2 h. These results are similar to the samarium
methodology,8 but complement the diiodomethane
derived lithium reagents, which provide epoxides.6
The turnover of 1e was remarkably slow, it reacted just
marginally under these conditions. Consequently, the
formylacetophenone 1d underwent iodomethylation at
the aldehyde only. The benzoic anhydride 1f underwent
rapid conversion into a multitude of unidentiﬁed prod-
ucts. The conversion of the acid chloride 1g did not take
place, but reactivity could have been enhanced by either
chelation assistance or the reported trans-metallation
into a copper reagent.15 The diﬀerences between the
two nucleophilic reagents (Scheme 1) became apparent
in the reaction with cinnamic aldehyde, which was con-
verted into the cyclopropyl-methanol 2b by diiodome-
thane and into the anticipated diiodinated allyl alcohol
3b by CHI3. Two pathways lead to the cyclopropane
2b: (a) an initial Michael addition is followed by cycliza-
tion and iodomethylation,16 or (b) an iodomethylation
of the aldehyde is followed by a Simmons–Smith-like
cyclopropanation, which is reported to occur with high
syn-stereoselectivity, but modest yields for CH2I2/
i-PrMgCl and allyl alcohols.17 Therefore, we have moni-
tored the reaction at diﬀerent ratios of aldehyde and
CH2I2/i-PrMgCl to establish the mode of action. The
allyl alcohol 4 (Scheme 2) was identiﬁed as the dominant
intermediate, which was converted into 2b by a second
equivalent of CH2I2/i-PrMgCl. The exclusive anti con-
ﬁguration of the cyclopropane was determined by
NMR spectroscopy and revealed the dormant carbenoid
reactivity. The relative conﬁguration of the alcohol was
tentatively assigned in analogy to the results of Bolm
and Pupowicz.17
The reaction of the Evans imide 5 with CH2I2/i-PrMgCl
(Scheme 3) resulted in the unexpected, selective iodome-
thylation of the urethane to furnish the iodoacetate 6,
initially in low yield. However, when the reaction mix-
ture was kept at 25 C for three days we obtained 6
as a single product. There is precedence for this reactiv-
ity of Evans imides.18 Vinylmagnesium chloride reacted
in a similar fashion to result in vinylation of the ure-
thane. A tetrahedral intermediate, similar to Weinreb-
amides, was suggested for this monoalkylation.
Ph
O
Ph
OH
I
1b
CH2I2 / iPrMgCl (1.1 equiv) 
THF, 2h, -78˚C
 68% conversion 4
Scheme 2.
O N
OO
Ph
CH2I2 / iPrMgCl
(4 equiv), 
THF, -78˚C / 15 h, 
-25˚C / 3d
82%
O
H
NI
O
O
Ph
5 6
Scheme 3.
Table 1. Reactions of aldehydes, ketones and carboxylic acid deriva-
tives according to Scheme 1 with 2.0 equiv of CH2I2 or CHI3 and
i-PrMgCl
Reagent Aldehyde Product Yielda
[%]
CH2I2/i-PrMgCl Ph
O
1a
Ph
OH
I
2a
96
CH2I2/i-PrMgCl Ph
O
1b
Ph
I
OH
2b
91b
CH2I2/i-PrMgCl
Ph
1c
O
Ph
OH
I
2c
73
CH2I2/i-PrMgCl
O
O
1d
O
I
OH
2d
69
CH2I2/i-PrMgCl Ph
O
1e
Conversion < 10c
CHI3/i-PrMgCl Ph
O
1a
Ph
OH
I
I3a
91
CHI3/i-PrMgCl Ph
O
1b
Ph
OH
I
I3b
82d
CH2I2/i-PrMgCl Ph O
O O
Ph
1f
Sluggish reaction
CH2I2/iPrMgCl Ph Cl
O
1g
No reaction
a Isolated yields.
b Diastereomeric mixture: syn/anti 96:4, assigned by NMR.17
c Determined by HPLC.
d Contains 4% of 2,2-diiodo-1-(2-iodo-3-phenylcyclopropyl)ethanol
(mixture of diastereomers, d.r. > 3:1) and 3% of 2,2-diiodo-1-(2-
phenylcyclopropyl)ethanol.
R
OH
I
-78˚C, 15 min
0˚C, 1-2 h
R
OH
I
-78˚C, 15 min
0˚C, 1-2 h I
2a-d
3a,b
O
R
O
R
iPrMgCl, CH2I2, THF
iPrMgCl, CHI3, THF
1a-d
1a,b
Scheme 1.
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After these initial experiments we addressed the
iodomethylation of peptide aldehydes, which are impor-
tant intermediates for the synthesis of protease inhibi-
tors. The deprotonation of the acidic amides required
5-fold excess of the reagent. This was not a nuisance, be-
cause the deprotonation froze the conﬁguration of the
P1–P3 positions of the tripeptide mimetics 7a–d. The
aldehydes were used as 3:1 mixtures of diastereomers,
as obtained from the oxidation of alcohols by IBX in
DMSO, followed by aqueous work up. The iodomethyl-
ation and diiodomethylation provided the compounds
8a–d and 9 (Scheme 4), apparently without epimeriza-
tion of the P1 position as judged by HPLC. The diaste-
reoselectivity of the reaction was always better than 2:1
as judged by HPLC.
The diastereoselectivity of the iodomethylation was
investigated for the phenylalanine derived aldehyde 10
(Scheme 5). The conversion into b-iodoalcohol 11 was
followed by substitution of the iodide with diethylamine.
The product 12 was deprotected and the resulting amino
alcohol was treated with triphosgene to give oxazolidi-
none 13 and care was taken not to separate the
diastereomers.
NMR spectroscopy (13C NMR: c-eﬀect,19 NOE) con-
ﬁrmed the relative conﬁguration (anti/syn d.r. = 86:14).
This is in accordance with a chelation controlled Cram
transition state and complements the samarium method-
ology20 which provides access to the diastereomer when
the nitrogen is dibenzylated. The substrate controlled
diastereoselectivity provides straightforward access to
important intermediates of peptidomimetics. The chiral
induction by additional ligands is subject to ongoing
investigations.
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2-Iodoethanols from aldehydes, diiodomethane
and iso-propylmagnesium chloride 
Hannes A. Braun, Reinhard Meusinger, Boris Schmidt* 
Darmstadt Technical University, Clemens Schöpf-Institute for Organic Chemistry and 
Biochemistry, Petersenstr. 22, D-64287 Darmstadt, Germany 
1-Iodo-4-phenylbutan-2-ol (2a). iPrMgCl (4.0 mmol, 2.0 mL of a 2.0 M solution in Et2O)
was added dropwise to a solution of diiodomethane (1.07 g, 4.0 mmol) in THF (8 mL, abs.) at 
-78°C under argon atmosphere. A solution of 3-phenylpropanal (274 mg, 2.04 mmol) in THF 
(1 mL, abs.) was added and the resulting mixture was stirred at the same temperature for 15 
min and at 0°C for 1 h. The mixture was quenched with aqueous NH4Cl (5 mL, sat.) and 
extracted with CH2Cl2 (3x 20 mL). The combined organic layers were dried (Na2SO4) and 
concentrated under vacuum. The crude product was purified by LC (CHCl3) to give alcohol 
2a (541 mg, 96%). 1H-NMR (CDCl3, 300 MHz): ? = 7.37-7.01 (m, 5H), 3.46-3.41 (m, 1H), 
3.31-3.26 (m, 1H), 3.19-3.13 (m, 1H), 2.75-2.59 (m, 2H), 1.99 (s, 1H), 1.82-1.75 (m, 2H) 
ppm. 13C-NMR (CDCl3, 75 MHz): ? = 141.4, 128.7, 128.6, 126.2, 70.3, 38.3, 32.1, 16.7 ppm. 
MS (EI): m/z = 276 (M+).
(S)-2-Acetamido-3-phenylpropyl 2-iodoacetate (6). iPrMgCl (2.3 mmol, 1.15 mL of a  
2.0 M solution in THF) was added dropwise to a solution of diiodomethane (616 mg, 2.3 
mmol) in THF (4 mL, abs.) at -78°C under argon atmosphere. A solution of (S)-3-acetyl-4-
benzyloxazolidin-2-one (100 mg, 0.46 mmol) in THF (1 mL, abs.) was added and the 
resulting mixture was stirred at the same temperature for 15 h and at -25°C for 3 d. The 
mixture was quenched with aqueous NH4Cl (5 mL, sat.) and extracted with CH2Cl2 (3x 20 
mL). The combined organic layers were dried (Na2SO4) and concentrated under vacuum. The 
crude product was purified by LC (CHCl3) to give acetate 6 (138 mg, 82%). 1H-NMR
(CDCl3, 300 MHz): ? = 7.27-7.12 (m, 5H), 5.70 (d, J = 6.0 Hz, 1H), 4.44-4.34 (m, 1H), 4.11-
4.00 (m, 2H), 3.65 (s, 2H), 2.89-2.74 (m, 2H), 1.89 (s, 3H) ppm. 13C-NMR (CDCl3, 75 MHz): 
? = 169.9, 168.9, 136.9, 129.3, 128.8, 127.0, 66.0, 49.6, 37.4, 23.5, -5.7 ppm. MS (EI): m/z =
361.2 (M+). 
(4S,5S)-5-((Diethylamino)methyl)-4-benzyloxazolidin-2-one (13). iPrMgCl (3.08 mmol, 
1.54 mL of a 2.0 M solution in THF) was added dropwise to a solution of diiodomethane (825 
mg, 3.08 mmol) in THF (8 mL, abs.) at -78°C under argon atmosphere. A solution of benzyl 
(S)-1-formyl-2-phenylethylcarbamate 10 (248 mg, 0.88 mmol) was added and the resulting 
mixture was stirred at the same temperature for 15 min and at 0°C for 90 min. The mixture 
was quenched with aqueous NH4Cl (5 mL, sat.) and extracted with CH2Cl2 (3x 20 mL). The 
combined organic layers were dried (Na2SO4) and concentrated under vacuum. The crude 
product was purified by LC (CHCl3) to give alcohol 11 (292 mg, 78%). Alcohol 11 (244 mg, 
0.57 mmol) was dissolved in EtOH (5 mL, abs.) and HNEt2 (419 mg, 5.7 mmol). The mixture 
was heated under argon atmosphere to 60°C for 2 h and under reflux for 2 h. The crude 
product was purified by LC (system CHCl3 to CHCl3/MeOH 10:1) to afford amine 12 (201 
mg, 95%). Amine 12 (201 mg, 0.54 mmol) was stirred with Pd/C catalyst (200 mg, 10wt%) in 
EtOH (4 mL, abs.) under H2 atmosphere for 3 d to yield the deprotected compound (128 mg, 
quant.). The product (52 mg, 0.22 mmol) was dissolved in THF (8 mL, abs.). Triphosgene 
(130 mg, 0.44 mmol) was added and the reaction mixture was heated under reflux (argon 
atmosphere) for 15 h. After 4 h and 8 h further triphosgene (2x 130 mg, 0.44 mmol) was 
added. Ethyl acetate (50 ml) was added and washed with aqueous K2CO3 (3x 30 mL, conc.). 
The organic layer was dried (Na2SO4) and concentrated under vacuum. The crude product 
was purified by LC (CHCl3) to give oxazolidinone 13 (57 mg, 98%). 1H-NMR (CDCl3, 300 
MHz): ? = 7.29-7.10 (m, 5H), 5.51 (s, 1H), 4.28 (q, J = 5.8 Hz, 1H), 3.76 (q, J = 6.0 Hz 1H), 
2.87-2.72 (m, 2H), 2.62-2.37 (m, 6H), 0.88 (t, 6H) ppm. 13C-NMR (CDCl3, 75 MHz): ? = 
158.7, 136.4, 129.2, 129.0, 127.2, 80.5, 57.6, 55.9, 47.9, 41.8, 12.0 ppm. MS (EI): m/z =
262.2 (M+). 
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Abstract: The exact cause of Alzheimer’s disease is still unknown; despite the dramatic progress in
understanding. Most gene mutations associated with Alzheimer’s disease point to the amyloid precursor
protein and amyloid β. The α-, β- and γ-secretases are the three executioners of amyloid precursor protein
processing. Significant progress has been made in the selective inhibition of these proteases, regardless of the
availability of structural information. Several peptidic and non-peptidic leads were identified and first drug
candidates are in clinical trials. Cholesterol lowering drugs and metal chelators are also in advanced clinical
stages as disease modifiers. Successful trials demand either large cohorts or reliable markers for Alzheimer’s
disease. Therefore, several radiomarkers are under investigation to support such clinical trials.
Keywords: Alzheimer’s disease, secretase, copper, statine, aspartic protease, cholesterol, imaging.
INTRODUCTION Established Therapies and Novel Approaches
Alzheimer's disease (AD), the most common dementia in
elderly people, affects nearly 2% of the population in
industrialised countries (http://www.alz.org). This epidemic
neurodegenerative disorder claims millions of victims per
year, not just erasing the memory of the patient, but effecting
severe implications on the social environment. The AD
prevalence equals 5.5 % above 60 years of age and increases
for elderly people (clinical AD: 16% 85y, 22% 90y) [1, 2].
The onset of Alzheimer's disease is usually after 65 years of
age, though earlier onset is not uncommon. As age
advances, the incidence increases rapidly and roughly
doubles every 5 years [1]. Age is the dominant risk factor
overruling even the positive impacts of nutrition (low-fat
diets), nutritional supplements after onset or education [3-5].
The socio-economic impact of AD, the care needed for
disabled and chronically wasting patients, the consequences
for patients, relatives and caretakers alike is a major social
and financial issue for the coming decades. Current annual
AD related expenditures total $83.9 billion in the US [6]. 14
million Americans are likely to be stricken by 2050 [7].
Despite all efforts, the exact cause of Alzheimer's disease is
still unknown, but the pathways towards and away from
Alzheimer’s disease become better understood [8]. The
process results in neuron and synapse degeneration,
reduction of brain regions, memory loss and ultimately in
death. There is progress in the definite diagnosis of AD prior
to a post-mortem diagnosis. Problems arise from other
causes of memory loss (e.g. vascular dementia). Several
steps in the process offer potential for intervention, these
include the amyloid cascade and plaque-related proteins [9],
hyperphosphorylated tau protein [10, 11], zinc, copper and
aluminium cations [12-14].
Some 500 compounds are in development to treat
neurodegenerative diseases. At least 10% of these are related
to AD [15, 16]. The targets derive from a whole range of
sometimes well-known receptors and enzymes: GSK-3, PDE
4 and muscarinic M1. nACh modulators, AChE inhibitors,
NMDA modulators, 5-HT agonists and several vaccination
projects (e.g. Elan, Cytos Biotechnology) are in advanced
stages of research or development. The early rush on fibril
formation inhibition resulted in a number of potent
inhibitors thereof. However, the activities were confined to in
vitro experiments or limited by poor DMPK properties,
which excluded further development [17, 18]. Few drug
candidates (e.g. SKF-74652, 1 [19], Scheme 1) went beyond
animal testing and convincing clinical data are still wanted.
Furthermore, the view on Aβ toxicity has changed
dramatically. Plaques were seen as the true culprit and their
removal was one of the therapy goals until 2001. Now,
soluble Aβ and early oligomers have to take the blame for
the Aβ associated effects. Thus, mature Aβ plaques may
rather rest in peace.
O
Cl
O
O O
N NH2 HCl
1 SKF-74652 2 memantine hydrochloride
Scheme 1. Aβ fibril formation inhibitor and memantine
hydrochloride: NMDA receptor antagonist.
Cholinesterase inhibitors (AChEI) produce small
improvements in cognitive and global assessments [20-23],
but galanthamine, tacrine, donepezil and rivastigmine do not
address the severe mortality in the final stages of AD. 565
patients with mild to moderate Alzheimer's disease entered a
12-week run-in period, in which they were randomly
allocated to donepezil or placebo. There were no significant
benefits for the 486 patients who completed the 2nd period
until the primary endpoints: entry to institutional care and
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Scheme 2. NSAIDs effect Aβ levels [28, 29].
progression of disability [24, 25]. This outcome contradicts
a previous report: the chosen AChEI was not cost effective,
with benefits below minimally relevant thresholds [22].
Tacrine is losing ground to the other 3 AChE inhibitors
because of hepatotoxic effects [6]. The message of these
studies is obvious: better drugs are needed to target the cause
of Alzheimer's disease.
Thus, a causal therapy is still in utter demand, as no
existing therapy effectively stops or even cures the disease.
The incidence of early-onset of Alzheimer’s disease in
Down's syndrome patients indicated chromosome 21 as a
likely hotspot for gene location. Mutations linked to early-
onset Alzheimer’s disease afflicted families in London and
Sweden, and additional polymorphisms, that either cause or
further AD, provided some insight into the biological
pathways and the involvement of the amyloid precursor
protein (APP) [41-44]. The genetic background of AD is
quite heterogeneous; a large number of gene associations has
been made with localisations on almost every chromosome
[45]. Replicated or confirmed associations are few: the late-
onset AD is linked to the ε4-allele of APOE, but its
presence is neither necessary nor sufficient to cause the
disease, but there is a dose-dependent relation to the age of
onset [46]. Another cluster of mutations is located on
chromosome 14, on the gene encoding for presenilin 1 [47].
Mouse models expressing mutated human APP and
presenilin 1 display many symptoms of AD, although no
model represents the full range of pathologies of the human
disease. Particularly, the inflammation processes in humans
and mice do not adequately relate to each other [48]. The
observed loss of neurons (mice [49]) is accompanied by
Memantine hydrochloride (2), first made in 1960 by Ely
Lilly as an anti-diabetic agent, protects neurons against
overactivation of N-methyl-D-aspartate receptors and was
approved for the treatment of moderate to severe Alzheimer’s
disease in 2002 as first of its class [26]. Previous attempts
utilising this non-competitive antagonism failed. This was
due to CNS side effects such as hallucinations. Memantine
hydrochloride was tested in a 28 weeks trial at 20 mg/day
against placebo, indicating a significant cognitive
improvement. The current strategy to use memantine
hydrochloride in combination therapy with the AChEI
donezepil was concluded from the outcome of a 24 week trial
against placebo. The combinations halted or showed further
decline, but the magnitude of these effects was modest [6].
Furthermore, these results have become questionable in the
light of the recent extended donezepil trials.
Scheme 3. APP amino acid sequence close to the cleavage sites and point mutations in Aβ numbering.
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plaque formation consisting of amyloid β-peptide in the
human perfrontal cortices. But there is mounting evidence for
a second pool of insoluble Aβ in cholesterol enriched low-
density membranes, where it moderates membrane fluidity
[50].
with structural reorganisation and activity modulation [58].
The two states: open and closed, contribute to selectivity
and activity of the enzyme [59]. Two β-secretases are known
BACE1 (ASP2 or memapsin2) and BACE2 (ASP1 or
memapsin1), with high homology, but subtle differences in
the active site and an additional disulfide bridge for BACE1
[7]. BACE2 causes additional cleavages close to Phe20,
which are reminiscent of α-secretase activity [60, 61].
BACE1 is anchored to the membrane via its transmembrane
domain (455-480) and may be active as a dimer [62].
BACE1 has a pro-peptide domain, which is cleaved by furin-
like proteases to form mature enzyme. The C-terminal
transmembrane domain of ΒΑCE1 is not strictly required for
activity, but the localisation of both enzyme and substrate in
the same membrane enhances kinetics and specificity. The
C-terminal truncation seems to influence enzyme kinetics
even in the absence of membranes. BACE1 maturation
requires cysteine formation (Cys216/Cys420,
Cys278/Cys443, Cys330/Cys380), N-glycosylation and pro-
peptide removal. Cysteine mutants undergo impaired
maturation, but obtain catalytic activity. The
Cys330/Cys380 bridge was found to be the most important
[63]. Crucial for assay development and animal models:
BACE1 -/- knockout mice are fertile and healthy, and
display reduced Aβ levels [64]. Selectivity issues arise not
only by other aspartic proteases, but by the homologous
BACE2, which displays a less pathogenic APP cleavage
pattern and a distinctly different localisation [60, 65, 66].
The Aβ peptide is released by a subsequent proteolysis at
Val711-Ile712 or Ala713-Thr714 by the intramembrane
protease: γ -secretase, resulting in Aβ40 and Aβ42. A detailed
analysis of BACE distribution, structure, species variation,
degradation and properties was published recently [67].
BACE inhibition is not the only way to modulate the
BACE dependent APP cleavage. High levels of ceramide or
improved raft association can extend the half life of BACE1
(16 h) [68].
A rational approach to a successful, causal therapy is
based on the detailed understanding of Aβ formation,
deposition and the inflammatory consequences. Decisive
functions were assigned to the amyloid precursor protein
(APP) and its degrading aspartic proteases β-secretase and
the presenilins. A simplified APP processing is depicted in
(Scheme 3). APP occurs in 3 isoforms: APP695, APP751
and APP771, this includes a large extramembranous
sequence and the crucial membrane spanning domain,
followed by a short cytoplasmic tail. The non-pathological
cleavage occurs between Lys687-Leu688 (resp. K16L17 in
Scheme 3) by the α-secretase, which belongs to the ADAM
family and is suspected to be TACE or ADAM10.
This dominating event leaves just 10% of the APP
behind for the β-secretase, produces α-APP and ultimately
leads to the fragments p3 and C83. The α-secretase is
sensitive to membrane cholesterol levels and can thus be
modulated [51]. The most relevant point mutations for Aβ
formation are K670-M671->NL and V717->Phe (Stockholm
or Indiana), which cause familial Alzheimer’s dementia
(FAD). The molecular basis of these point mutations is
explained by their modulation of the secretases. The rate
limiting β-secretase usually cleaves between the Met671-
Asp672 residues, but prefers the preceding amino acids
Asn670-Leu671 of the Swedish mutation over Lys670-
Met671. The V717->Phe mutation accelerates cleavage after
Ala714, which leads to the notorious Aβ42, the decisive
factor in plaque formation. The released C-terminal fragment
interacts in the cytoplasm with an adapter protein, Fe65, and
finally induces apoptosis in H4 cells [52, 53]. It seemed too
obvious to address Aβ deposits directly, either by inhibition
of plaque formation or by enhanced plaque degradation.
Several companies pursued strategies related to “plaque
busters” [54], but clinical data for this mode of action are
still lacking, and there is mounting evidence that plaques are
not the real culprit, e.g. AD does not correlate well with
total plaque load [247]. Both soluble Aβ and early
oligomers are now commonly blamed to be toxic,
particularly in the presence of copper cations (see copper
section below). This hypothesis has its merits and is hard to
falsify in vivo, as neither copper nor early fibrils are
detectable at the necessary sub-cellular resolution by
antibodies or atomic absorption spectroscopy (AAS) of brain
slices. Fortunately, there is evidence for a common
mechanism in amyloidogenic diseases. The identification of
minimal amyloidic sequences and the detailed understanding
of protein misfolding may hold the key to treat Aβ, tau and
PrPSc associated pathologies [55, 56].
Fig. (1). BACE complexed to OM99-2 (8).
-Secretase
-Secretase Inhibitors
β-Secretase was identified as an aspartic protease, despite
the initial lack of selective inhibitors [57]. The key features
of an aspartic protease were confirmed: the flexible flap
region, which is crucial for substrate docking. The kinetics
of statine-based inhibitors revealed a two state mechanism
Several inhibitors for β-secretase were identified in
cellular assays, but more often than not, the true nature of the
inhibition mechanism was not reported. Broad spectrum
protease inhibitors such as pepstatin 7, known aspartic
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Fig. (2). BACE complexed to OM99-2 (8).
hydrogen bonds are established between OM99-2 (8), the
binding pocket and the flap region. Despite the analogies to
other aspartic proteases, there are significant differences in the
side chain preferences. S4, S3’ are hydrophilic and readily
accessible by water. The hydrophilic S4’, which holds the
phenylalanine, is located at the surface and contributes little
to binding. The subsite specificity was revealed by the
cleavage rates of combinatorial substrate mixtures and
selective inhibitors. This resulted in Glu-Leu-Asp-Ψ (Leu-
Ala)-Val-Glu-Phe (9, OM00-3, Ki = 0.31 nM), which is still
the most potent inhibitor of β-secretase. The hydroxyl group
of OM00-3 (9) is coordinated by the two active site
aspartates Asp32 and Asp228 through four hydrogen bonds
(PDB: 1M4H) [75, 77]. Although very similar to OM99-2
(8, Glu-Val-Asn-Ψ (Leu-Ala)-Ala-Glu-Phe), the P3, P2, and
P2’ residues are exchanged, resulting in a more linear and
extended conformation at either end. The replacement of the
P2’ alanine by valine facilitates binding and allows re-
orientation of the P3’ glutamate and the P4’ phenylalanine.
This shifts the C-terminal residue towards the surface of the
enzyme and exposes it to the solvent.
The crystal structure of free BACE (1SGZ) revealed a part
of the flap to be locked in an "open" position [76]. The
structure is essentially the same as BACE1 bound to an
inhibitor, but the flap positions differ by 4.5 Å at the tips.
The open position of the flap is stabilised by two intraflap
hydrogen bonds and is anchored by a new hydrogen bond
involving Tyr71 in a novel orientation. The resulting gorge
may contribute to sequence and shape selection. A
gatekeeper function was evident from the unusually small
substituent Ala in P2’ (8, 1FKN). Thr72 forms the
narrowest point (6.5 Å in apo BACE) [248] between the flap
and Arg235, Ser328, and Thr329 on the opposite side, and
thus contributes to the specificity of BACE. This gatekeeper
blocks the access of peptides carrying larger residues in this
position, although pocket P1’ provides more than enough
space for a significantly larger residue [76]. The small
interaction of the C-terminal end of the octapeptides OM99-2
(8) and OM00-3 (9) with the enzyme inspired the design of
shorter peptidic inhibitors (10-13). Different peptidic
inhibitors featuring the hydroxyethylene moiety and flanked
by multitude of amino acid residues were published
protease inhibitors from Renin and HIV protease programs,
or cocktails thereof, had little inhibitory effect and gave
misleading results. To this date, several reviews on secretase
inhibition were published [67, 69-73]. And yet, potent non-
peptidic inhibitors of β-secretase are still few. Several
peptide-based inhibitors were patented or published
immediately after the disclosure of BACE-inhibitor complex
X-ray structures [67, 72-75] (Fig. 1 and 2 show fragments of
a homodimeric structure). The active BACE1 used for co-
crystallisation lacked the transmembrane and intracellular
domains, and some flexible N-terminal regions were not
resolved. The high affinity complex of Glu-Val-Asn-Ψ (Leu-
Ala)-Ala-Glu-Phe (8, OM99-2, Ki = 1.6 nM) and β-secretase
resulted in complete inhibition of β-secretase activity and
allowed crystallisation and structure determination at 1.9 Å
resolution (PDB: 1FKN, Fig. 1 and Fig. 2) [67, 74-76].
The inhibitor is located in the active site as intended by
design, and the hydroxyethylene is coordinated by four
hydrogen bonds to the two catalytic aspartates. Further 10
A          B
Fig. (3). (a) Isophthalamide 18 (yellow) and (b) resorcylate 27 (yellow) above the flap. MOE 2004.10 GaussConolly surface green:
hydrophobic, blue: hydrophilic (PDB: 1W51, 1TQF).
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Scheme 4. BACE inhibitors I.
(Schemes 4 and 5) [78-82]. Remarkably, the compact P1’-
Ala of potent inhibitors has never been replaced by a
sterically more demanding group.
terminal dicarboxylic acid and displayed high activity in
vitro and in vivo (BACE1-HEK293 cells EC50 = 0.20 μM)
[83]. Chen et al. synthesised Ψ (Phe-Ala)-based pentapeptide
mimetics like 12 (IC50 = 35 nM) and came to similar
conclusions [84, 85]. The SAR of these two series
postulated a benzyl or a 3,5-difluorobenzyl residue to occupy
the P1 position as realised in compound 13 [86, 87]. A
good part of the peptidic heritage was replaced by an
isophthalamide [88], which functions as the N-terminus in
Several scaffolds are known to provide inhibitors for
aspartic proteases. Statines, norstatines, hydroxyethylamines
and hydroxyethylureas can be employed as transition state
mimetics, yet with dramatic differences in potency. The Kiso
inhibitor 11 (KMI-370, IC50 = 3.4 nM) featured a short C-
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the compounds 14-21. The switch from the statine core to
the hydroxyethylene isoster allowed the replacement of the
carboxylic acids by smaller groups, and resulted in the
compact inhibitors (16-19) with reduced molecular mass and
fewer hydrogen bond donors.
99], Astex [100] and a Sunesis employee (21) [101]. But the
amino alcohol 18 held a little surprise, despite the R-
configuration of the alcohol, it was far more potent than its
S-configured diastereomer or the parent ketone, and thus
contradicted previous SAR of the absolute configuration.
The neighbouring amine receives a proton from the catalytic
Asp228 and places its benzyl substituent in the S2´ pocket.
One of the N-propyl groups of the isophthalamide occupies
the S3 pocket and is directed towards the phenyl ring in the
S1 pocket. The phenyl rings in both the S1 and the S2’
pocket interact with Tyr71. The C-terminal methoxyphenyl
is positioned in the S2’ pocket. This success in high-
throughput crystallography enabled ASTEX to license out
this programme to GSK in 2003.
The Elan compounds (13-19) have lost a good part of
their peptidic origin, which is mandatory to obtain sufficient
oral absorption and blood brain barrier penetration [89, 90].
Significant information was revealed by a novel BACE
complexed to a transition state mimetic [91]. Soaking of apo
BACE crystals (PDB: 1W50) with small peptidomimetics,
which were known to be moderate inhibitors in FRET or
cellular assays, resulted in the incorporation of 18 in the
active site (PDB: 1W51, Fig. 3a). This peptide mimetic
features the isophthalamide to mimic the S2-S4 section and
was claimed to have an IC50 = 200 nM. Some 750 close
analogues were revealed in patents by Takeda (20) [92],
Glaxo [93], Upjohn Pharmacia, [94-96] Elan (19) [89, 97-
Despite all efforts by the pharmaceutical companies and
academic groups, non-peptidic leads for BACE inhibition are
still few. The FRET assays of soluble BACE deliver false
positive hits to such a degree, that it is mandatory to profile
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potential hits in a reliable secondary assay, such as a
radioligand displacement [102, 103]. This progress in assay
development allowed to identify peptidic and non-peptidic
leads. Takeda reported a tetraline (22, Scheme 6), which is
not an obvious scaffold for protease inhibition and is likely
to stem from high-throughput screening efforts [104]. The
activity is poor (IC50 ≥ 1 μM) and the mode of action was
not confirmed. Neurologic’s diacid (24) [105] is unlikely to
be an easy lead for AD. Latifolin (23), isolated from the
heartwood of Dalbergia sissoo, was reported to inhibit the
Aβ synthesis with an IC50 of 180 μM, again a rather weak
and unsecured activity [106]. Vertex reported [107] the
biphenylpiperazine (25) as BACE inhibitor (IC50 = 3 μM)
and it was docked into the BACE structure by Park and Lee
[108]. An unfortunate error improved it to 3 nM, which
makes the outcome of this docking very questionable. Yet,
similar biphenylated amines (26) were revealed by Actelion
[109, 110]. MSD undertook the rational design [81, 111-
113] of BACE inhibitors like many others [114-116].
crystallisation with 27 (PDB: 1TQF, Fig. 3b), which
occupies the S1-S4 subsites. Quite unusually, the S’ sites
and the active site have no direct contact with the inhibitor.
The acetamide is engaged in a hydrogen bond to the
catalytic water, which is placed between the two aspartates.
The 4-fluorophenyl moiety wedges the novel S3 subpocket
open and the aminopentyl coils back into the S1 pocket.
The S1 and S3 substituents may be linked together to result
in macrolactams with reduced rotational freedom, the only
way to improve activity [112]. Extension towards the active
site, occupation of P1 by a phenyl group and placement of a
cyclopropyl in P1’ improved the inhibition to 11 nM for 29
and retained 500-fold selectivity towards cathepsin D [118].
The compound was co-crystallised with BACE, but there
was no entry in the PDB by 11/2004. DeNovo reported
several scaffolds and mimetics: sulfonamides, 1-
piperazinylpropan-2-ols and the triazine 28, which may offer
additional imaging of Aβ fibrils [119-122].
-SecretaseMore innovation was obtained by an Automated Ligand
Identification System (ALIS): a novel resorcylic acid scaffold
[117]. The amino pentyl derivative 27 was obtained after
subtle modifications of the lead structure and displayed a
moderate inhibition of BACE 1 (IC50 = 1.4 μM) and good
selectivity towards cathepsin D (IC50 > 500 μM). A
modified BACE 1 (K75A, E77A) was used for co-
Paradoxical: despite being the secretase reported first, the
identity of γ -secretase was for a long time a subject debate
and the detailed structure is still unknown. The close
relation to the Notch pathway, which is important in
embryonic development, became less hazy over the years.
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Notch 1, an integral membrane receptor, is processed by
proteases upon ligand binding. The intramembranous
cleavage is similar to the APP cleavage and requires PS1.
The released intracellular domain migrates to the nucleus,
where it finally activates Notch target genes [123]. The
crossover to the Notch pathway hampered attempts towards
PS-/- knockout animals, which do not pass the embryonic
state, but embryonic stem cells may fill a part of the gap
[124]. The intracellular trafficking of Notch in human CNS
neurons is reduced by PS1 inhibitors, and results in
dramatic changes in neurite morphology. Maybe the Notch
dysregulation causes the neuritic dystrophy observed in AD
brain tissue [125]. Several other substrates are known to be
cleaved by γ -secretase, which seems to be the “proteasome
of the membrane” [126]. The relevance of the presenilin co-
factors: Pen-2, Aph-1, Nicastrin is well established [8], and
even isoforms of these co-factors have been studied at detail
[127]. The Nicastrin association to FAD was questioned
recently [128]. Cell free γ -secretase assays are still an art,
despite the progress in kinetics and feasibility [129].
Substrate optimisation was crucial for both β-secretase and
γ -secretase assays [130, 131]. The localisation of the active
site within the membrane and the cleavage within the
membrane anchor of C99 turns γ -secretase inhibition into a
rather slippery fish. Currently, there is only one related
enzyme: the signal peptide peptidase, which shares a number
of the features and problems, but is inserted into the
membrane by 7 transmembrane helices [132]. A proposal for
the arrangement of the transmembrane helices has been made,
but it does not explain the observed cleavage pattern of APP
[133]. Moreover, the importance of the cytoplasmic tail is
not acknowledged in this model; two sequences of this tail
are required for ER-retention and Nicastrin binding [134].
The active site of γ -secretase is known at some detail and
the concerted action of all co-factors is still a subject of
debate. The replacements of both Asp257 and Asp385
within the transmembrane regions of PS1 (and the analogue
replacements in PS2) inhibit γ -secretase activity [135, 136].
Furthermore, both Asp modifications significantly inhibited
the Notch pathway. The Notch pathway may be a druggable
target on its own; however, applications in oncology were
claimed already [137, 138].
-Secretase Inhibitors
Non-peptidic inhibitors of γ -secretase are known from the
patents by Elan/Eli Lilly, Bristol Myers Squibb and
DuPont. Peptidic PS1 inhibitors, like Merck’s L-685,458
(30) [139] are still the most potent inhibitors and were
patented [140] prior to publication in scientific journals
[141, 142]. Lipophilic di- and tripeptides with bulky N-
terminal protection are common inhibitors for γ -secretase
and β-secretase. Lacking specificity and the inhibition of
serine and cysteine proteases makes the use of these
aldehydes rather cumbersome, because the general protease
inhibition results in complex concentration activity
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relationships. Obviously, this structural motif serves just a
tool for assay development and labelling [143-150], e.g.
difluoro ketones were used to block endoproteolysis of PS1
and to differentiate γ -secretase activity and Notch cleavage by
selective modulation [151, 152]. The inhibition by several
difluoro ketones supported the point mutation analysis and
confirmed the phenylalanine scan of the APP transmembrane
domain [133]. This scan strongly supported a unique α−
helical presentation of the C99 fragment to the γ -secretase.
Initial attempts of α-helix induction by α-amino isobutyric
acid (Aib) were not convincing [153]. Yet, a surprising
activity of an all D-tridecapeptide: Boc-VGAibVVIAibTV-
AIbVIAib-OMe (cell free IC50 = 0.14 nM) was reported by
Wolfe et al. recently [154, 155]. A more druglike
tetrapeptide mimetic Boc-Ψ (Phe-Phe)-Leu-Val-OMe
displayed a cellular IC50 of 0.4 μM [156].
lipophilic binding pockets (P2, P1, P1’, P2’, even P4' and
P7') in proximity to the cleavage site. The inversion of the
hydroxyethylene moiety reduced the inhibition 270fold.
Labelling studies were conducted with different non-
radioactive probes, linking biotin and photoreactive
fragments N- or C-terminally to the core structure to furnish
L-852,505 (32) and L-852,646 (33). The biotin was
introduced to facilitate the isolation and identification of the
irreversibly labelled adducts via their streptavidin-enzyme
linked conjugates. Both attachments of photoreactive
benzophenones (L-852,646 (33), L-852,505 (32)) retained
potent inhibition (IC50 < 1 nM for γ -secretase). Photolysis
in the presence of solubilised γ -secretase provided a protein
of 20 kD (L-852,505, 32) after isolation on a biotin-specific
streptavidin-agarose gel, followed by partial digestion. This
20 kD fragment was shown to be the C-terminal fragment of
presenilin 1 (PS1-CTF) by specific antibodies. Binding to
wild-type PS1 was negative in a control experiment, yet
binding to the deletion construct PS1ΔE9, which lacks the
cytosolic E9 loop, was positive [157]. Useful information
resulted from the photolysis of L-852,646 (33) in the
A giant leap forward was obtained by the serendipitous
identification of Merck’s L-685,458 (30, Scheme 7). The all-
lipophilic sequence with 3 phenylalanines was somewhat
anticipated, as several studies [133] had indicated the
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presence of solubilised γ -secretase. This resulted in the
isolation of a 34 kD fragment, which was assigned to be an
N-terminal fragment of PS1.
latter study. Moreover, there is evidence for the slow
removal of tau lesions under DAPT treatment [165]. There
were several reports of in vivo toxicity, mainly because
DAPT effects the Notch pathway at higher levels (100-
1000x) [166]. A biotinylated DAPT-based photoaffinity
label (DAPT-BB) was used to investigate the competition of
sulindac-S (4) and L-685,458 (30) for the active site of PS1.
DAPT-BB binds to the PS1 CTF. There was no
competitive replacement by sulindac-S up to 100 μM. The
displacement of DAPT-BB by L-685,458 (30) depended on
the CHAPSO concentration: full displacement at 0.25%
CHAPSO, but only partial displacement at 1% [138].
Further improvements included the stereoselective placement
of the hydroxyl group and the locked spatial arrangement of
two phenyl rings in a caprolactam to result in 39
(LY411575, HEK IC50 < 1 nM), which is still the gold
standard in the field. It halved plasma and cortical Aβ levels
in young mice already at the oral dosage of 1 mg/kg.
LY411575 (39) and a lesser active diastereomer were
administered [167] orally to C57BL/6 and TgCRND8 APP
mice for 15 days at 1-10 mg/kg per day and resulted in the
reduction of Aβ levels. This was accompanied by atrophy of
the thymus and deterioration of the intestinal epithelium.
The Notch/APP selectivity was determined in cellular
assays: Aβ40 IC50 = 0.082 nM, Notch IC50 = 0.39 nM.
This small toxicity window will be a crucial issue for
clinical trials. Curiously, the Aβ lowering abilities of
DAPT-like compounds are not effected by their sometimes
poor blood brain barrier penetration. Thus, inhibition of
APP processing in the periphery or enhanced clearance of
peripheral Aβ by neprelysin [168-170] and other degrading
enzymes [171] may hold a key for causal treatment.
A similar transition-state motif, the hydroxyethylurea
[158], was utilised for activity based affinity purification.
The immobilisation of III-31-C (31, IC50 < 300 nM) on affi-
gel 102 allowed isolation and identification of PS1-CTF,
PS1-NTF and Nicastrin from solubilised γ -secretase
preparations [159]. Initial attempts to free active γ -secretase
from the affinity gel failed. This was probably due to the
high binding affinity of III-31-C (31) to the target protein
complex, and partially due to the deep and narrow binding
site, which required strong denaturing conditions to break up
the binding interactions. A delicate combination of Brij-35
and CHAPSO resulted in the isolation of active γ -secretase.
The co-precipitation of the inhibited γ -secretase with its
substrates C83 and C99 gave rise to speculations about
additional binding sites, where the substrate is recognised
prior to transfer to the active site. These speculations are in
accordance with the observed promiscuous nature of the
cleavage, as they assign the specific recognition to other
domains.
To this day, very little structural information is available
for the γ -secretase complex. Therefore, selective, non-
peptidic γ -secretase inhibitors had to be provided by HTS
efforts. Elan’s DAPT 36 (HEK IC50 = 20 nM) was
developed from a N-dichlorophenylalanine lead, and the
phenylglycine and the difluoro phenylacetic acid are crucial
for activity [160-162]. DAPT is not a prodrug, despite the
labile tertiary butyl ester, which may be cleaved at the low
pH of the gut. The even more labile cyclopropyl methyl
ester 37 displayed similar activity [163]. Replacements of
the ester by amides were tolerated, but primary alcohols were
almost inactive [164]. The subcutaneous application to mice
in a dosage of 100 mg/kg, resulted in a 50% reduction of
cortical Aβ levels within 3 hours. A 40% Aβ reduction was
observed at the dosage of 100 mg/kg orally, again after 3
hours, but no brain levels of DAPT were reported for the
Bristol Myers Squibb and Merck [172] disclosed 1000
derivatives of 4-Chloro-N-(2,5-difluorophenyl)-
benzenesulfonamides 35. 500 of these were reported to be
very good inhibitors of γ -secretase activity. The activity
clustered around the core structure 35, with a wide variation
of the substituent R to modulate bioavailability. Less active
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sulfonamides (34, IC50 = 2 μMol, Scheme 8) were reported
by Amgen and MSD, which featured similar bicycloalkane
skeletons. They share the arylsulfonamide moiety with 35,
but lack the crucial N-alkyl extension [173, 174]. DuPont’s
hybrid structure 38 [175] bears both signatures of a dipeptide
based SAR and the lead, which was identified from a matrix
metalloproteinase (MMP) programme. Removal of the
central amide bond of the parent dipeptide, the replacement
of the hydroxamic acid by an amide and the introduction of a
caprolactam provided good activity and removed some of the
problems associated with dipeptide leads. The potent
compounds (IC50: 20-90 nM) were related to DAPT-like
compounds and hybrids of the two series. The
difluorophenacyl-caprolactam derivative 42, stemming from a
Scios/DuPont cooperation, proved to be the most potent
compound (IC50 = 0.3 nM) [176].
desired effect, and if they do so, they do it by modulation of
γ -secretase. The active NSAIDs interfere with substrate
recognition/cleavage and shift the Aβ cleavage to the Aβ38
fragment. Any derivatisation of the NSAID’s carboxylic acid
results in loss of this activity or inversion of the Aβ38
impact (unpublished results).
Flurbiprofen 3 (10 and 25 mg/kg/d) elicits non-selective
reductions in both Aβ1-40 and Aβ1-42 plasma levels, and was
found to be toxic. It produced small reductions in Aβ1-40 in
the cortex at 25 mg/kg/d, but did not affect Aβ levels in the
hippocampus or CSF. Contrary to previous reports, sulindac
sulfide (4) and ibuprofen (6) were found to be neither toxic
nor efficacious at doses up to 50 mg/kg/d [32]. The striking
discrepancies between these results and the previous reports
by Eriksen [33] and Weggen [28, 29] may be explained by
the different methods used to extract brain Aβ: alkaline
guanidine solution versus 70% formic acid. The kinetics of
Aβ formation in the presence of the two NSAIDs and the
displacement of an active site directed inhibitor support
allosteric, non-competitive modes of action of sulindac-S (4)
and R-flurbiprofen (3) [34] at low concentrations. This
results in selective inhibition of Aβ42 production. However,
both NSAIDs shift their mode of action from modulation to
complete, non-selective inhibition of γ− secretase at high
concentrations. This remarkable pharmacological behaviour
may be explained by the stabilisation of dimeric or
multimeric enzyme. Unfortunately, NSAID derivatives have
escaped photolabelling techniques so far, although they are
known to increase capture efficiency in affinity precipitation.
DuPont Pharmaceuticals, which was taken over by
Bristol-Myers Squibb, went on to elaborate the caprolactam
motif and described a large number of derivatives in a patent
family. Some effort was dedicated to modify the N-terminus,
in order to avoid patent infringement of Elan patents and
resulted in the oxazolylsulfonamide 41 [177, 178]. Another
straightforward attempt to bypass Elan claims is present in a
recent Merck series, which is generalised in compound 40.
Moreover, this series was claimed to be inactive on Notch
signalling [179]. Several other compounds or claims exist
for hybrid structures of 37 and 38. A common feature is an
aza-caprolactam, which places the phenyl groups in a
defined, twisted arrangement. Additional residues can be
attached to the amide, and the glycine is commonly
exchanged for small spirocyclic amino acids or amide
excision peptidomimetics. Unfortunately, activities for these
compounds were not reported yet. Boehringer-Ingelheim
[180, 181] disclosed diaminopyrimidines (43) as non-
peptidic inhibitors of γ -secretase with an IC50 = 4 to 1000
nM. The single patent application is written in German and
the most active compound is therefore hidden well. But the
BI lead resembles flupirtin (44), which displayed beneficial
effects on the cognitive function in humans [182]. MSD
bypassed the BMS claims for sulfonamide (35) by
introduction of a cyclohexyl linker (45, Scheme 9). The
seven-membered lactam re-appeared in several MSD
structures (46-48) [183, 184], but the insufficient Notch
selectivity put an end to the promising candidate 46 [185].
Vaccination
Immunisation therapies against Aβ hold high potential
and are under investigation by several companies [35]. The
most advanced companies in this field: Elan Corp plc and
Wyeth-Ayerst Laboratories, suffered a setback of their joint
clinical development of AN-1792 in March 2002 [36]. The
phase IIa trials were abandoned after observation that 4 out of
372 patients displayed clinical signs consistent with
inflammation in the central nervous system. The alarming
and unexplained brain-shrinkage of 6% on average and the
lack of cognitive improvement backed the decision to end
the trial, but all patients were monitored until December
2002 [37, 38]. Unfortunately, just 13 patients were
monitored afterwards, although a small group displayed
significant improvements in brain volume and cognitive
abilities [39]. These positive results suggest further studies
with improved epitopes or different vaccination strategies.
Aβ vaccination reduces not only extra- and intracellular Aβ
accumulation, but is accompanied by the clearance of early
tau pathology. The tau pathology is reduced by the
proteasome and depends on tau phosphorylation.
Hyperphosphorylated tau aggregates remained unaffected by
this antibody treatment [40]. On the contrary, the clearance
of tau aggregates was reported for immunotherapy and DAPT
treatment. However, Aβ deposits were cleared within 3 days
after injection, versus 5 days it took for the reduction of tau
lesions [40].
Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
Negative outcomes have been reported for the non-
steroidal anti-inflammatory drugs prednisone, diclofenac,
rofecoxib and naproxen [6]. But promising results were
obtained with some COX1 inhibitors [27], both in vitro and
in a prospective, population-based cohort study of 6989
patients [28-30]. These convincing clinical results are still in
need of a sound rational and experimental validation. The
proof of concept is still missing, despite the rapid progress.
Potential modes of action were hinted or reported several
times, but there is much heat and little light: “Non-steroidal
anti-inflammatory drugs may lower amyloidogenic Aβ42” by
inhibition of Rho/ROCK [31]. Yet, the Rho/ROCK
inhibitors were applied at concentrations several magnitudes
higher than the required IC50 for Rho/ROCK inhibition. In
summary, just few NSAIDs (3-6, Scheme 2) display the
Indirect Approaches- or: Do Our Souls Reside in Fat?
Lithium chloride was found [186] to reduce secreted Aβ
levels in 3 different cell lines: COS7, CHO and HEK.
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Unfortunately, lithium displays a small therapeutic window
and the required concentrations of 1-5 mM are well above
tolerated therapeutic plasma levels of 0.8-1.2 mM. The
mediator of the lithium activity is likely to be a better target
for drug development. A similar effect was observed [187] for
kenpaullone (49, Scheme 10), an unselective inhibitor of
glycogen synthase kinase-3 (GSK3) [188]. Control
experiments with other unselective inhibitors for the two
forms of GSK3: GSK3α and GSK3β, suggested GSK3α to
offer indirect modulation of γ -secretase, including Notch
selectivity. These spectacular claims for GSK3α were backed
up by siRNA knock-downs, but are contradicted by a
reported involvement of GSK3β [189].
cholesterol acyltransferase ACAT modulates the generation
of Aβ, and is thus a welcome addition for existing ACAT
programmes [251, 252]. Most ACAT inhibitors were
developed for cardiovascular therapies and still have to prove
their clinical potential to treat AD.
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Copper and Chelators
Scheme 10. Kenpaullone. The copper enhanced Aβ associated toxicity stimulated
investigations of dietary copper and copper homeostasis in
mice and men [13, 198]. The initial hypothesis had to be
revised, as increased copper levels (0.25 g CuSO4.5 H2O/L)
in drinking water turned out to decrease Aβ levels in
transgenic APP mice. A potential mode of action may be
present in the reduced superoxide dismutase 1 activity.
Metal chelators were frequently investigated to moderate
copper levels in brain tissue, which were thought to be
responsible for Aβ toxicity. However, in most in vitro
studies, the copper concentrations required to observe the
effect were magnitudes higher than found in vivo. Studies in
20 patients with clioquinol 52 (Scheme 12), a metal chelator
that crosses the blood-brain barrier readily and has similar
affinity for zinc and copper ions, indicated interesting results.
Brain cholesterol accounts for up to 25% of total body
cholesterol and is turned over within a few months.
Individuals on a high-cholesterol diet are at increased risk to
develop AD, but the cholesterol brain levels were unaffected
in animal models. Some cholesterol lowering drugs such as
pravastatin and lovastatin, resulted in reduced risk for AD in
retrospective trials. Paradoxically, prospective trials resulted
in a rather confusing situation with contradicting outcome,
most prospective trials failed to confirm a risk reduction for
AD [190]. Simvastatin does not reduce risk and pravastatin
exerts the effect regardless of the blood-brain barrier (BBB)
crossing [190-193]. The answer is not simple; both
simvastatin and lovastatin pass the BBB in the prodrug
form, prior to hydrolysis to the active acids, and can be
detected in the CSF. The rationale for this activity is still
subject to debate, but three important observations may hold
the clue for an explanation: 1.) hypercholesterolemia results
in increased levels of extractable total Aβ in mice 2.)
BACE1 was found to be associated with cholesterol
stabilised rafts [194-197] in the plasma membrane and 3.)
the activity of the benign α-secretase is inversely related to
cholesterol levels [195]. The relevance of these different, yet
concerted modes of actions remains to be established in
humans, but transgenic mice respond to hyper-
cholesterolemia by reduction of soluble Aβ [196]. The
pleiotropic, non-lipid-related activities may be caused by the
inhibition of the isoprenoid synthesis downstream of HMG-
CoA reductase, interfering with RAS and thus cell signalling
[50]. A specific inhibitor of squalene synthase can inhibit the
cholesterol biosynthesis, but does not block the isoprenoid
pathway leading to dolichol and ubiquinone. The potential
of such inhibitors was published for the cholesterol-lowering
BM15.766 (50, Scheme 11), which resulted in halved Aβ
brain loads. The plasma Aβ levels correlated well with the
plasma cholesterol [197], but the brain cholesterol went
down by a meagre 11-13%, which may be explained by
uncorrected cholesterol determination. RPR107393 (51) and
its R- and S-enantiomers are potent inhibitors of rat liver
microsomal squalene synthase (IC50 = 0.6 to 0.9 nM) and
modulate Aβ levels in transgenic mice [190]. The
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But the lack of a control group in the study, left ample room
for other explanations, e.g. inflammation stimulus [199,
200]. However, recent data from animal models support a
benign impact of clioquinol on copper homeostasis.
Clioquinol was found to mediate copper uptake and
counteract copper efflux activities of APP [201]. The
improved selectivity of the quinol towards copper was
addressed by Prana Biotechnology [202], who submitted a
multitude of clioquinol analogues to a catalase type assay in
the presence of Aβ. Several inhibitors (53-55) were profiled
in rats and the DMPK properties were communicated in a
patent application.
Diagnostics - Markers for AD
Several genes and small molecules such as 24S-
hydroxycholesterol, were previously linked to the age of
onset and the severity of Alzheimer’s disease [203-205].
Genetic factors are well established and reviewed: e.g. the
ApoE e4 allele, which is a risk factor, but not a deterministic
gene [206]. Currently, all these genes and their derived
products, e.g. inflammatory proteins [207], do not fulfil the
requirements for large scale diagnosis or medical imaging.
Unfortunately, most of the promising, small molecules
require sampling of cerebrospinal fluid (CSF) [208], which
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will be a major obstacle in clinical trials [209-214]. α7-
nAChR levels correlate [215] to the Aβ levels, but the
reliable sampling of indicative cells (e.g. olfactory
neuroblasts) remains to be an issue. Congo red, which is
known to stain amyloid deposits for several decades [216-
218], stimulated the ongoing search for small markers of Aβ
levels. Yet, the detailed mechanism of Congo red binding is
still a subject of investigations [219-224]. Most amyloid
binding dyes do not differentiate between the different
aggregates of Aβ, PHF and PrPSc. This lack of selectivity is
almost irrelevant for the development of aggregation
inhibitors, but is a crucial issue for diagnostic markers. The
Aβ deposits precede the formation of tau positive paired
helical filaments, thus amyloid markers suitable for radio
diagnostic of Alzheimer’s disease have to be selective for
just one of the proteins deposits, which accompany the
pathology. Specifically designed compounds address the
issue of improved brain penetration, and radioactive
compounds were explored for non-invasive imaging: PET
and SPECT. A technetium bipyridyl complex was reported
in 1996, but was not taken up by other groups [225].
Chrysamine-G (56, Scheme 13) [220] overcome some of the
drawbacks of Congo red, particularly the poor BBB
penetration. Furthermore, it indicated a promising inhibition
of Aβ derived toxicity. X-34 (57), and its derivative BSB
(58) were radiolabelled and profiled in rodents [226-229].
The pharmacokinetic properties and their mode of action
justify the abbreviation BSB: beta sheet breaker. But styryl
derivatives with improved properties [230] are available: SB-
13 (73) [231] and BF-168 (72), which display sufficient
fluorescence to be analysed in murine brain slices. Post-
mortem incubation with human brain preparations of
confirmed AD cases indicated unselective binding to Aβ
deposits and neurofibrillary tangles. Thioflavin T (59, Ki =
750 to 2000 nM) does not pass the BBB, but several
uncharged analogues with high affinity to Aβ oligomers do:
IBOX (63) , BTA-1 (62, Ki = 2.8 nM) [232], 6OH-BTA-1
(60) [233, 234], PIB (Pittsburgh probe B, 64, Ki = 7.6 nM),
TZDM (61, Ki = 0.06-02 nM) [229], FDDNP (69) [235],
125IMPY (67, Ki < 1.4 nM), FEM-IMPY (70, Ki = 40 nM)
and FPM-IMPY (68, Ki = 8 nM) [236]. PIB (64) is
probably the best documented probe and PIB load in cortical
areas correlated inversely with cerebral glucose metabolism.
However, the cognitive impairment and amyloid detection
did not correlate well in patients (65 ± 10y) with mild
dementia (Mini-Mental State Examination: 28-29).
Moreover, the older control group (69 ± 7y) was identified as
asymptomatic amyloid-positive [237].
display complex clearance patterns, which are characterised
by polar and non-polar metabolites and substantial skull
incorporation of 18F by the latter two. Yet, the metabolism
of the 18F-FEM-IMPY was slower in rhesus monkey than in
mouse [236]. The post-mortem incorporation of human brain
sections of AD patients with 18F-FEM-IMPY, resulted in
displaceable uptake in grey matter and low non-specific
binding in the white matter. Several of these markers are in
advanced stages of development as AD radio diagnostics,
despite their sometimes striking similarity to estrogen
receptor [241, 242] ligands, which may effect the signal to
noise ratio. Most of these compounds display excitation and
emission between 340 and 440 nm, which differs from the
fluorescence of Thioflavin T (450/480 nm) [243]. The
Novartis probe (74) [244, 250] resembles the dye Disperse
Yellow 332 and introduces a fluorescent coumarin to the Aβ
ligand. This will aid to relate cold imaging of brain slices to
PET or SPECT images, thus, will improve image
calibration and validation. The affinity of these compounds
to Aβ fibrils is uniformly high in the nanomolar range (KD
=0.2 to 10 nM) and selectivity versus tau PHFs is usually
poor, except for PIB (64) [232, 245]. But these values are
misleading in the absence of a well-defined target and the
high number of binding sites per fibril. The whole research
area was moved to solid ground by the identification of three
distinctly different binding sites: BS1-3 for Thioflavin T
analogues. A GlaxoSmithKline team [243] accomplished a
formidable task and evaluated several known compounds in
fluorescence based assays. They determined the highest
affinities to relate to the low capacity BS3, which is present
per every 300 Aβ peptides. The BS1 and BS2 binding sites
are far more abundant (1 per every 4 or 30 Aβ) and are
characterised by similar affinity and partial overlap between
BS1 and BS2. Certain markers: TZDM, TZPI (66, KD =
0.13 nM) [229] and BF-1 (65, KD = 1.6 nM) [229] display
selectivity for BS2. The structural discriminator for
selectivity was assigned to the halogen substituent. The
authors concluded that improved PET probes may be
available in BS2 targeting ligands, because they will display
the highest sensitivity for Aβ.
OUTLOOK
Despite the tremendous progress in the field, a γ -
secretase inhibitor, free of Notch activity is still in utter
demand. The selective inhibition of γ -secretase by NSAIDs
is pointing in the right direction: allosteric modulation of
the active site, which can be identified by additional cleavage
sites mediated by PS1 [246]. Confirmed, non-peptidic β-
secretase inhibitors are few and still have to reveal their true
potential. Several compounds and vaccinations are entering
phase II clinical trials and demand improved AD
diagnostics. Actually, the vaccination may outpace the other
therapies on the way to market. Dietary copper is unlikely to
be a remedy for late stage AD, but may offer inexpensive
prevention.
This is in contrast to the post-mortem incubation with
SB-13 (73), which displayed no in vitro labelling of the age
matched controls [231]. FDDNP (69) binds to two sites on
Aβ40 fibrils with different affinity (KD = 0.012 nM and 1.9
nM) [235] and was the second attempt to image the AD
pathology in humans. The accumulation of FDDNP in
human brains correlated with lower memory performance,
and the brain residence time of the probe was greater in
patients with AD than in control subjects [238]. All reported
IMPYs pass the blood brain barrier rapidly after intravenous
injection. The detailed synthesis suitable for different labels
was published and further derivatives [236, 239, 240] are
accessible by palladium mediated iodine/amine exchange.
123/125IMPY, 18F-FEM-IMPY (70) and 18F-FPM-IMPY
ACKNOWLEDGEMENTS
B.S., H.B. and R.N. thank the DFG SPP1085
SCHM1012-3-1/2 and the EU contract LSHM-CT-2003-
503330 (APOPIS) for support of this work.
Drug Development and PET-Diagnostics Current Medicinal Chemistry, 2005, Vol. 12, No. 14 1691
REFERENCES β1-6 antigen epitopes conjugated with virus-like particles. WO
2004016282, 2004.
[36] Schenk, D.; Games, D.; Seubert, P. Neurosci. News 2000, 3, 46.[1] WHO, The World Health Report 2001 Mental Health: New
Understanding, New Hope. [37] Nicoll, J. A.; Wilkinson, D.; Holmes, C.; Steart, P.; Markham, H.;
Weller, R. O. Nat. Med. 2003, 9, 448.[2] Polvikoski, T.; Sulkava, R.; Myllykangas, L.; Notkola, I. L.;
Niinisto, L.; Verkkoniemi, A.; Kainulainen, K.; Kontula, K.;
Perez-Tur, J.; Hardy, J.; Haltia, M. Neurology 2001, 56, 1690.
[38] Greenberg, S. M.; Bacskai, B. J.; Hyman, B. T. Nat. Med. 2003, 9,
389.
[39] Abbott, A. Nature 2004, 430, 715.[3] Gil Gregorio, P.; Ramirez Diaz, S. P.; Ribera Casado, J. M. J.
Nutr. Health Aging 2003, 7, 304. [40] Oddo, S.; Billings, L.; Kesslak, J. P.; Cribbs, D. H.; LaFerla, F. M.
Neuron 2004, 43, 321.[4] Thorsett, E. D.; Latimer, L. H. Curr. Opin. Chem. Biol. 2000, 4,
377–382. [41] Saunders, A. M. Pharmacogenomics 2001, 2, 239.
[42] Holmes, C. Br. J. Psychiatry 2002, 180, 131.[5] Grant, W. B. J. Alzheimer's Dis. 1999, 1, 197.
[43] Tanzi, R. E.; Bertram, L. Neuron 2001, 32, 181.[6] Cummings, J. L. N. Engl. J. Med. 2004, 351, 56.
[44] Hardy, J. PNAS 1997, 94, 2095.[7] Chou, K.-C. J. Proteome Res. 2004, 3, 1969.
[45] Hardy, J.; Myers, A.; Wavrant-De Vrieze, F. Neurodegenerative
Diseases 2004, 1, 213.
[8] Mattson, M. P. Nature 2004, 430, 631.
[9] Czech, C.; Adessi, C. Curr. Neuropharmacol. 2004, 2, 295.
[46] Bertram, L.; Tanzi, R. E. J. Mol. Neurosci. 2001, 17, 127.[10] Mandelkow, E.-M.; Mandelkow, E. Trends Cell Biol. 1998, 8, 425.
[47] Fraser, P. E.; Yang, D.-S.; Yu, G.; Lévesque, L.; Nishimura, M.;
Arawak, S.; Serpell, L. C.; Rogaev, E.; George-Hyslop, P. S.
Biochim. Biophys. Acta (BBA) - Molecular Basis of Disease 2000,
1502, 1.
[11] Augustinack, J. C.; Schneider, A.; Mandelkow, E.-M.; Hyman, B.
T. Acta Neuropathologica 2002, 103, 26.
[12] Ritchie, C. W.; Bush, A. I.; Mackinnon, A.; Macfarlane, S.;
Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q. X.;
Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.;
Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R. E.; Masters, C. L.
Arch. Neurol. 2003, 60, 1685.
[48] Janus, C.; Westaway, D. Physiol. Behav. 2001, 73, 873.
[49] Schmitz, C.; Rutten Bart, P. F.; Pielen, A.; Schafer, S.; Wirths, O.;
Tremp, G.; Czech, C.; Blanchard, V.; Multhaup, G.; Rezaie, P.;
Korr, H.; Steinbusch Harry, W. M.; Pradier, L.; Bayer Thomas, A.
Am. J. Pathology 2004, 164, 1495.
[13] Bush, A. I.; Masters, C. L.; Tanzi, R. E. PNAS 2003, 11193.
[14] Altmann, P. Alum. Alzheimer's Dis. 2001, 1.
[50] Eckert, G. P.; Kirsch, C.; Leutz, S.; Wood, W. G.; Muller, W. E.
Pharmacopsychiatry 2003, 36 Suppl 2, S136.
[15] Fischer, F.; Matthisson, M.; Herrling, P. Neurodegenerative
Diseases 2004, 1, 50.
[51] Moss, M. L.; White, J. M.; Lambert, M. H.; Andrews, R. C. Drug
Discov. Today 2001, 6, 417.
[16] Kwon, M.-O.; Fischer, F.; Matthisson, M.; Herrling, P.
Neurodegenerative Diseases 2004, 1, 113.
[52] Kinoshita, A.; Whelan, C. M.; Smith, C. J.; Berezovska, O.;
Hyman, B. T. J. Neurochemistry 2002, 82, 839.
[17] Luond, R. M.; Banziger, M.; Frey, P. Preparation of piperidine and
piperazine derivatives as inhibitors of the Aβ fibril formation. WO
0047571, 2000. [53] Kinoshita, A.; Whelan, C. M.; Berezovska, O.; Hyman, B. T. J.
Biol. Chem. 2002, 277, 28530.[18] Goldsbury, C. S.; Wirtz, S.; Muller, S. A.; Sunderji, S.; Wicki, P.;
Aebi, U.; Frey, P. J. Struct. Biol. 2000, 130, 217. [54] Soto, C. Mol. Med. Today 1999, 5, 343.
[55] Kayed, R.; Glabe, C. G. Immunogens and corresponding
antibodies specific for high molecular weight aggregation
intermediates common to amyloids formed from proteins of
differing sequence. WO 2004024090, 2004.
[19] Howlett, D. R.; Perry, A. E.; Godfrey, F.; Swatton, J. E.; Jennings,
K. H.; Spitzfaden, C.; Wadsworth, H.; Wood, S. J.; Markwell, R.
E. Biochem. J. 1999, 340, 283.
[20] Courtney, C.; Farrell, D.; Gray, R.; Hills, R.; Lynch, L.; Sellwood,
E.; Edwards, S.; Hardyman, W.; Raftery, J.; Crome, P.; Lendon,
C.; Shaw, H.; Bentham, P. Lancet 2004, 363, 2105.
[56] Kayed, R.; Head, E.; Thompson, J. L.; McIntire, T. M.; Milton, S.
C.; Cotman, C. W.; Glabe, C. G. Science 2003, 300, 486.
[57] Capell, A.; Steiner, H.; Willem, M.; Kaiser, H.; Meyer, C.; Walter,
J.; Lammich, S.; Multhaup, G.; Haass, C. J. Biol. Chem. 2000, 275,
30849.
[21] Jacobsen, J. S. Curr. Top. Med. Chem. 2002, 2, 343.
[22] Ikeda, S.; Yamada, Y.; Ikegami, N. Dementia Geriatr. Cognit.
Disord. 2002, 13, 33.
[58] Marcinkeviciene, J.; Luo, Y.; Graciani, N. R.; Combs, A. P.;
Copeland, R. A. J. Biol. Chem. 2001, 276, 23790.
[23] Carlson, M. C.; Brandt, J.; Steele, C.; Baker, A.; Stern, Y.;
Lyketsos, C. G. J. Gerontol. A Biol. Sci. Med. Sci. 2001, 56, M567.
[59] Leung, D.; Abbenante, G.; Fairlie, D. P. J. Med. Chem. 2000, 43,
305.
[24] Schneider, L. S. The Lancet 2004, 363, 2100.
[25] AD2000Collaborative  Group. The Lancet 2004, 363, 2105.
[60] Farzan, M.; Schnitzler, C. E.; Vasilieva, N.; Leung, D.; Choe, H.
PNAS 2000, 97, 9712.
[26] Witt, A.; Macdonald, N.; Kirkpatrick, P. Nat. Rev. Drug Discov.
2004, 3, 109.
[61] Yan, R.; Munzner, J. B.; Shuck, M. E.; Bienkowski, M. J. J. Biol.
Chem. 2001, 276, 34019.
[27] Serradji, N.; Bensaid, O.; Martin, M.; Kan, E.; Dereuddre-
Bosquet, N.; Redeuilh, C.; Huet, J.; Heymans, F.; Lamouri, A.;
Clayette, P.; Chang Zhi Dong; Dormont, D.; Godfroid, J.-J. J.
Med. Chem. 2004, 47, 6410.
[62] Westmeyer, G. G.; Willem, M.; Lichtenthaler, S. F.; Lurman, G.;
Multhaup, G.; Assfalg-Machleidt, I.; Reiss, K.; Saftig, P.; Haass,
C. J. Biol. Chem. 2004, 279, 53205.[28] Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.;
Pietrizik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter,
T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H.
Nature 2001, 414, 212.
[63] Fischer, F.; Molinari, M.; Bodendorf, U.; Paganetti, P. J.
Neurochem. 2002, 80, 1079.
[64] Luo, Y.; Bolon, B.; Kahn, S.; Bennett, B. D.; Babu-Khan, S.;
Denis, P.; Fan, W.; Kha, H.; Zhang, J.; Gong, Y.; Martin, L.;
Louis, J.-C.; Yan, Q.; Richards, W. G.; Citron, M.; Vassar, R. Nat.
Neurosci. 2001, 4, 231.
[29] Weggen, S.; Eriksen, J. L.; Sagi, S. A.; Pietrzik, C. U.; Golde, T.
E.; Koo, E. H. J. Biol. Chem. 2003, 278, 30748.
[30] in 't Veld, B. A.; Ruitenberg, A.; Hofman, A.; Launer, L. J.; van
Duijn, C. M.; Stijnen, T.; Breteler, M. M. B.; Stricker, B. H. C. N.
Engl. J. Med. 2001, 345, 1515.
[65] Vassar, R. J. Mol. Neurosci. 2001, 17, 157.
[66] Gruninger-Leitch, F.; Schlatter, D.; Kung, E.; Nelbock, P.; Dobeli,
H. J. Biol. Chem. 2002, 277, 4687.[31] Zhou, Y.; Su, Y.; Li, B.; Liu, F.; Ryder, J. W.; Wu, X.; Gonzalez-
DeWhitt, P. A.; Gelfanova, V.; Hale, J. E.; May, P. C.; Paul, S. M.;
Ni, B. Science 2003, 302, 1215.
[67] Roggo, S. Curr. Top. Med. Chem. 2002, 2, 359.
[68] Dominguez, D. I.; Hartmann, D.; De Strooper, B. 2004, 1, 168.
[69] Wolfe, M. S.; Haass, C. J. Biol. Chem. 2001, 276, 5413.[32] Lanz, T. A.; Fici, G. J.; Merchant, K. M. J. Pharm. Exp.
Therapeutics 2004, 309, 49. [70] Ishiura, S. Dementia Jpn. 2000, 14, 236.
[71] Citron, M. Trends Pharmacol. Sci. 2004, 25, 92.[33] Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.;
McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.;
Koo, E. H.; Golde, T. E. J. Clin. Investigation 2003, 112, 440.
[72] Varghese, J.; Beck, J. P.; Bienkowski, M. J.; Sinha, S.; Heinrikson,
R. L. J. Med. Chem. 2003, 46, 4625.
[73] Schmidt, B. ChemBioChem 2003, 4, 366.[34] Beher, D.; Clarke, E. E.; Wrigley, J. D. J.; Martin, A. C. L.; Nadin,
A.; Churcher, I.; Shearman, M. S. J. Biol. Chem. 2004, 279,
43419.
[74] Hong, L.; Koelsch, G.; Lin, X.; Wu, S.; Terzyan, S.; Ghosh, A. K.;
Zhang, X. C.; Tang, J. Science 2000, 290, 150.
[75] Hong, L.; Turner, R. T. III.; Koelsch, G.; Shin, D.; Ghosh, A. K.;
Tang, J. Biochemistry 2002, 41, 10963.
[35] Bachmann, M. F.; Tissot, A.; Ortmann, R.; Lueoend, R.;
Staufenbiel, M.; Frey, P. Vaccine compositions containing amyloid
[76] Hong, L.; Tang, J. Biochemistry 2004, 43, 4689.
1692 Current Medicinal Chemistry, 2005, Vol. 12, No. 14 Schmidt et al.
[77] Hong, L.; Turner, I. R. T.; Koelsch, G.; Ghosh, A. K.; Tang, J.
Biochem. Soc. Trans. 2002, 30, 530.
and for screening agents for treatment of Alzheimer's disease and
cerebrovascular amyloidosis. US 2003125257, 2003.
[78] Tung, J. S.; Davis, D. L.; Anderson, J. P.; Walker, D. E.; Mamo,
S.; Jewett, N.; Hom, R. K.; Sinha, S.; Thorsett, E. D.; John, V. J.
Med. Chem. 2002, 45, 259.
[103] Brockhaus, M.; Doebeli, H.; Grueninger, F.; Huguenin, P.; Kitas,
E. A.; Nelboeck-Hochstetter, P. Assay for identifying beta
secretase inhibitors. US 20030125257, 2003.
[79] Shuto, D.; Kasai, S.; Kimura, T.; Liu, P.; Hidaka, K.; Hamada, T.;
Shibakawa, S.; Hayashi, Y.; Hattori, C.; Szabo, B.; Ishiura, S.;
Kiso, Y. Bioorg. Med.Chem. Lett. 2003, 13, 4273.
[104] Miyamoto, M.; Matsui, J.; Fukumoto, H.; Tarui, N. Preparation of 2-
[2-amino- or 2-(N-heterocyclyl)ethyl]-6-(4-biphenylylmethoxy)-
tetralin derivatives as β secretase inhibitors. WO 0187293, 2001.
[80] Tamamura, H.; Kato, T.; Otaka, A.; Fujii, N. Org. Biomol. Chem.
2003, 1, 2468.
[105] Qiao, L.; Etcheberrigaray, R. Preparation of phosphinylmethyl
and phosphorylmethyl succinic and glutaric acid analogs as β-
secretase inhibitors useful in the treatment of Alzheimer's disease.
WO 2002096897, 2002.
[81] Brady, S. F.; Singh, S.; Crouthamel, M.-C.; Holloway, M. K.;
Coburn, C. A.; Garsky, V. M.; Bogusky, M.; Pennington, M. W.;
Vacca, J. P.; Hazuda, D.; Lai, M.-T. Bioorg. Med. Chem. Lett.
2004, 14, 601.
[106] Ramakrishna, N. V. S.; Kumar, E. K. S. V.; Kulkarni, A. S.; Jain,
A. K.; Bhat, R. G.; Parikh, S.; Quadros, A.; Deuskar, N.; Kalakoti,
B. S. Indian J. Chem., Sect. B: Org. Chem. Incl. Med. Chem.
2001, 40B, 539.
[82] Ghosh, A. K.; Bilcer, G.; Harwood, C.; Kawahama, R.; Shin, D.;
Hussain, K. A.; Hong, L.; Loy, J. A.; Nguyen, C.; Koelsch, G.;
Ermolieff, J.; Tang, J. J. Med. Chem. 2001, 44, 2865. [107] Bhisetti, G. R.; Saunders, J. O.; Murcko, M. A.; Lepre, C. A.; Britt,
S. D.; Come, J. H.; Deninger, D. D.; Wang, T. Preparation of β-
carbolines and other inhibitors of BACE-1 aspartic proteinase
useful against Alzheimer's and other BACE-mediated diseases.
WO 2002088101, 2002.
[83] Kimura, T.; Shuto, D.; Kasai, S.; Liu, P.; Hidaka, K.; Hamada, T.;
Hayashi, Y.; Hattori, C.; Asai, M.; Kitazume, S.; Saido, T. C.;
Ishiura, S.; Kiso, Y. Bioorg. Med. Chem. Lett. 2004, 14, 1527.
[84] Chen, S.-H.; Lamar, J.; Guo, D.; Kohn, T.; Yang, H.-C.; McGee,
J.; Timm, D.; Erickson, J.; Yip, Y.; May, P.; McCarthy, J. Bioorg.
Med. Chem. Lett. 2004, 14, 245.
[108] Park, H.; Lee, S. J. Am. Chem. Soc. 2003, 125, 16416.
[109] Boss, C.; Bur, D.; Fischli, W.; Jenck, F.; Weller, T. Preparation of
piperidines for the treatment of central nervous system disorders.
WO 2004009549, 2004.
[85] Lamar, J.; Hu, J.; Bueno, A. B.; Yang, H.-C.; Guo, D.; Copp, J. D.;
McGee, J.; Gitter, B.; Timm, D.; May, P.; McCarthy, J.; Chen, S.-
H. Bioorg. Med.Chem. Lett. 2004, 14, 239. [110] Boss, C.; Bur, D.; Fischli, W.; Jenck, F.; Weller, T. Preparation of
substituted 3- and 4-(aminomethyl)piperidines for use as β-
secretase inhibitors in the treatment of Alzheimer's disease. WO
2004002483, 2004.
[86] Hu, B.; Fan, K. Y.; Bridges, K.; Chopra, R.; Lovering, F.; Cole, D.;
Zhou, P.; Ellingboe, J.; Jin, G.; Cowling, R.; Bard, J. Bioorg. Med.
Chem. Lett. 2004, 14, 3457.
[87] Hom, R. K.; Fang, L. Y.; Mamo, S.; Tung, J. S.; Guinn, A. C.;
Walker, D. E.; Davis, D. L.; Gailunas, A. F.; Thorsett, E. D.;
Sinha, S.; Knops, J. E.; Jewett, N. E.; Anderson, J. P.; John, V. J.
Med. Chem. 2003, 46, 1799.
[111] Coburn, C. A.; Stachel, S. J.; Vacca, J. P. Preparation of
phenylcarboxamide derivatives as β-secretase inhibitors for the
treatment of Alzheimer's disease. WO 2004043916, 2004.
[112] Coburn, C. A.; Stachel, S. J.; Vacca, J. P. Preparation of
macrocyclic β-secretase inhibitors for treatment of Alzheimer's
disease. WO 2004062625, 2004.
[88] Hom, R. K.; Gailunas, A. F.; Mamo, S.; Fang, L. Y.; Tung, J. S.;
Walker, D. E.; Davis, D.; Thorsett, E. D.; Jewett, N. E.; Moon, J.
B.; John, V. J. Med. Chem. 2004, 47, 158. [113] Holloway, M. K.; Culberson, J. C.; Shpungin, J.; Munshi, S.;
Coburn, C. A.; Stachel, S. J.; Jones, K. G.; Loutzenhiser, E.;
Gregro, A. R.; Lai, M.-T.; Crouthamel, M.-C.; Pietrak, B. L.
Abstracts of Papers, 228th ACS National Meeting, Philadelphia,
PA, United States, August 22-26, 2004 2004.
[89] Maillaird, M.; Hom, C.; Gailunas, A.; Jagodzinska, B.; Fang, L. Y.;
John, V.; Freskos, J. N.; Pulley, S. R.; Beck, J. P.; Tenbrink, R. E.
Preparation of substituted amines to treat Alzheimer's disease.
WO 200202512, 2002.
[90] Beck, J. P.; Gailunas, A.; Hom, R.; Jagodzinska, B.; John, V.;
Maillaird, M. Compounds to treat alzheimer's disease. WO
0202520, 2002.
[114] Rajamani, R.; Reynolds, C. H. Bioorg. Med. Chem. Lett. 2004, 14,
4843.
[115] Rajamani, R.; Reynolds, C. H. J. Med. Chem. 2004, 47, 5159.
[91] Patel, S.; Vuillard, L.; Cleasby, A.; Murray, C. W.; Yon, J. J. Mol.
Biol. 2004, 343, 407.
[116] Tounge, B. A.; Reynolds, C. H. J. Med. Chem. 2003, 46, 2074.
[117] Coburn, C. A.; Stachel, S. J.; Li, Y.-M.; Rush, D. M.; Steele, T. G.;
Chen-Dodson, E.; Holloway, M. K.; Xu, M.; Huang, Q.; Lai, M.-
T.; DiMuzio, J.; Crouthamel, M.-C.; Shi, X.-P.; Sardana, V.; Chen,
Z.; Munshi, S.; Kuo, L.; Makara, G. M.; Annis, D. A.; Tadikonda,
P. K.; Nash, H. M.; Vacca, J. P. J. Med. Chem. 2004, 47, 6117.
[92] Uchikawa, O.; Aso, K.; Koike, T.; Tarui, N.; Hirai, K. Preparation
of benzamide derivatives as β-secretase inhibitors. WO
2004014843, 2004.
[93] Demont, E. H.; Faller, A.; MacPherson, D. T.; Milner, P. H.;
Naylor, A.; Redshaw, S.; Stanway, S. J.; Vesey, D. R.; Walter, D.
S. Preparation of hydroxyethylamine derivatives for the treatment
of Alzheimer's disease. WO 2004050619, 2004.
[118] Stachel, S. J.; Coburn, C. A.; Steele, T. G.; Jones, K. G.;
Loutzenhiser, E. F.; Gregro, A. R.; Rajapakse, H. A.; Lai, M.-T.;
Crouthamel, M.-C.; Xu, M.; Tugusheva, K.; Lineberger, J. E.;
Pietrak, B. L.; Espeseth, A. S.; Shi, X.-P.; Chen-Dodson, E.;
Holloway, M. K.; Munshi, S.; Simon, A. J.; Kuo, L.; Vacca, J. P. J.
Med. Chem. 2004, 47, 6447.
[94] Pulley, S. R.; Beck, J. P.; Tenbrink, R. E.; Jacobs, J. S. Preparation
of macrocycles useful in the treatment of Alzheimer's disease.
WO 2002100399, 2002.
[95] Reeder, M. R. Processes for the synthesis of amino acid-related
benzyl epoxides used in the production of pharmaceutical agents.
WO 2002085877, 2002.
[119] Willems, H. Preparation of piperazines as β-amyloid converting
enzyme (BACE) inhibitors for the treatment of Alzheimer's
disease. WO 2004020422, 2004.
[96] Tenbrink, R.; Maillard, M.; Warpehoski, M. Preparation of
substituted hydroxyethyl-amines as β-secretase inhibitors. WO
0350073, 2003.
[120] Willems, H.; Gordon, R. Protected amino acid derivatives for the
treatment of Alzheimer's disease. GB 2392443, 2004.
[121] Willems, H.; Harris, W.; John, D. E. A preparation of
triazinoindole derivatives as inhibitors of β-secretase (BACE),
useful in the treatment of Alzheimer's disease. WO 2004063196,
2004.
[97] Fang, L. Y.; Hom, R.; John, V.; Maillaird, M. Preparation of
substituted amines for treating Alzheimer's disease. WO 0202505,
2002.
[98] Fang, L. Y.; John, V. Compounds to treat Alzheimer's disease.
WO 0202506, 2002.
[122] Willems, H.; Harris, W. H. Preparation of N-sulfonyl amino acid
derivatives for the treatment of Alzheimer's disease. WO
2004020402, 2004.[99] Fobian, Y. M.; Freskos, J. N.; Jagodzinska, B. A preparation of
1,3-diamino-2-hydroxypropane derivatives as β-secretase
enzyme inhibitors. WO 2004022523, 2004.
[123] De Strooper, B.; Annaert, W. J. Cell Biol. 2001, 152, F17.
[124] Herreman, A.; Serneels, L.; Annaert, W.; Collen, D.; Schoonjans,
L.; Strooper, B. D. Nat. Cell Biol. 2000, 2, 461.[100] Vuillard, L. M. M.; Patel, S. J.; Yon, J. R.; Cleasby, A.; Hamilton,
B. J.; Shah, A. Crystal structure of human β-secretase mutants and
drug discovery applications. WO 2004011641, 2004.
[125] Figueroa, D. J.; Morris, J. A.; Ma, L.; Kandpal, G.; Chen, E.; Li,
Y. M.; Austin, C. P. Neurobiol. Dis. 2002, 9, 49.
[101] Yang, W. Preparation of amino carboxamide derivatives as
aspartyl protease inhibitors. WO 2004147454, 2004.
[126] Kopan, R.; Ilagan, M. X. G. Nat. Rev. Mol. Cell Biol. 2004, 5, 499.
[127] Shirotani, K.; Edbauer, D.; Prokop, S.; Haass, C.; Steiner, H. J.
Biol. Chem. 2004, 279, 41340.[102] Brockhaus, M.; Doebeli, H.; Grueninger, F.; Huguenin, P.; Kitas,
E. A.; Nelboeck-Hochstetter, P. Fluorescence and competitive
radioligand binding assays for identifying β-secretase inhibitors
Drug Development and PET-Diagnostics Current Medicinal Chemistry, 2005, Vol. 12, No. 14 1693
[128] Cousin, E.; Hannequin, D.; Mace, S.; Dubois, B.; Ricard, S.;
Genin, E.; Brun, C.; Chansac, C.; Pradier, L.; Frebourg, T.; Brice,
A.; Campion, D.; Deleuze, J.-F. Neurosci. Lett. 2003, 353, 153.
Quinn, K. P.; Sacchi, K. L.; Seubert, P. A.; Shopp, G. M.; Thorsett,
E. D.; Tung, J. S.; Wu, J.; Yang, S.; Yin, C. T.; Schenk, D. B.;
May, P. C.; Altstiel, L. D.; Bender, M. H.; Boggs, L. N.; Britton, T.
C.; Clemens, J. C.; Czilli, D. L.; Dieckman-McGinty, D. K.;
Droste, J. J.; Fuson, K. S.; Gitter, B. D.; Hyslop, P. A.; Johnstone,
E. M.; Li, W. Y.; Little, S. P.; Mabry, T. E.; Miller, F. D.; Ni, B.;
Nissen, J. S.; Porter, W. J.; Potts, B. D.; Reel, J. K.; Stephenson, D.;
Su, Y.; Shipley, L. A.; Whitesitt, C. A.; Yin, T.; Audia, J. E. J.
Neurochem. 2001, 76, 173.
[129] Edbauer, D.; Winkler, E.; Regula, J. T.; Pesold, B.; Steiner, H.;
Haass, C. Nat. Cell Biol. 2003, 5, 486.
[130] Turner, R. T.; Loy, J. A.; Nguyen, C.; Devasamudram, T.; Ghosh,
A. K.; Koelsch, G.; Tang, J. Biochemistry 2002, 41, 8742.
[131] Farmery, M. R.; Tjernberg, L. O.; Pursglove, S. E.; Bergman, A.;
Winblad, B.; Naslund, J. J. Biol. Chem. 2003, 278, 24277.
[132] Weihofen, A.; Binns, K.; Lemberg, M. K.; Ashman, K.; Martoglio,
B. Science 2002, 296, 2215.
[161] Audia, J. E.; Britton, T. C.; Droste, J. J.; Folmer, B. K.; Huffman,
G. W.; John, V.; Latimer, L. H.; Mabry, T. E.; Nissen, J. S.; Porter,
W. J.; Reel, J. K.; Thorsett, E. D.; Tung, J. S.; Eid, C. N.; Scott, W.
L. Preparation of N-(phenylacetyl)di- and tripeptide derivatives
for inhibiting β-amyloid peptide release. WO 9822494, 1998.
[133] Lichtenthaler, S. F.; Wang, R.; Grimm, H.; Uljon, S. U.; Masters,
C. L.; Beyreuther, K. PNAS 1999, 96, 3053.
[134] Kaether, C.; Capell, A.; Edbauer, D.; Winkler, E.; Novak, B.;
Steiner, H.; Haass, C. EMBO J. 2004, 23, 4738. [162] Audia, J. E.; Britton, T. C.; Droste, J. J.; Folmer, B. K.; Huffman,
G. W.; Varghese, J.; Latimer, L. H.; Mabry, T. E.; Nissen, J. S.;
Porter, W. J.; Reel, J. K.; Thorsett, E. D.; Tung, J. S.; Wu, J.; Eid,
C. N.; Scott, W. L. Methods and compounds for inhibiting β-
amyloid peptide release and/or its synthesis. US 6191166, 2001.
[135] Wolfe, M. S.; Xia, W.; Ostaszewski, B. L.; Diehl, T. S.; Kimberly,
W. T.; Selkoe, D. J. Nature 1999, 398, 513.
[136] Kimberly, W. T.; Xia, W.; Rahmati, T.; Wolfe, M. S.; Selkoe, D. J.
J. Biol. Chem. 2000, 275, 3173.
[137] Paris, D.; Mullan, M. J. Anti-angiogenic and anti-tumoral
properties of beta and gamma secretase inhibitors. WO
2004073630, 2004.
[163] Larbig, G.; Zall, A.; Schmidt, B. Helvetica Chimica Acta 2004, 87,
2334.
[164] Garofalo, A. W.; Wone, D. W. G.; Phuc, A.; Audia, J. E.; Bales,
C. A.; Dovey, H. F.; Dressen, D. B.; Folmer, B.; Goldbach, E. G.;
Guinn, A. C.; Latimer, L. H.; Mabry, T. E.; Nissen, J. S.; Pleiss, M.
A.; Sohn, S.; Thorsett, E. D.; Tung, J. S.; Wu, J. Bioorg. Med.
Chem. Lett. 2002, 12, 3051–3053.
[138] Kan, T.; Tominari, Y.; Rikimaru, K.; Morohashi, Y.; Natsugari,
H.; Tomita, T.; Iwatsubo, T.; Fukuyama, T. Bioorg. Med. Chem.
Lett. 2004, 14, 1983.
[139] Shearman, M. S.; Beher, D.; Clarke, E. E.; Lewis, H. D.; Harrison,
T.; Hunt, P.; Nadin, A.; Smith, A. L.; Stevenson, G.; Castro, J. L.
Biochemistry 2000, 39, 8698.
[165] Hutton, M.; Lewis, J.; Dickson, D.; Yen, S. H.; McGowan, E.
Trends Mol. Med. 2001, 7, 467.
[140] Nadin, A. J.; Stevenson, G. I. Preparation of peptides as γ-
secretase inhibitors. WO 0177144, 2001.
[166] Hadland, B. K.; Manley, N. R.; Su, D.-M.; Longmore, G. D.;
Moore, C. L.; Wolfe, M. S.; Schroeter, E. H.; Kopan, R. PNAS
2001, 98, 7487.[141] Nadin, A.; Owens, A. P.; Castro, J. L.; Harrison, T.; Shearman, M.
S. Bioorg. Med. Chem. Lett. 2003, 13, 37. [167] Wong, G. T.; Manfra, D.; Poulet, F. M.; Zhang, Q.; Josien, H.;
Bara, T.; Engstrom, L.; Pinzon-Ortiz, M.; Fine, J. S.; Lee, H.-J. J.;
Zhang, L.; Higgins, G. A.; Parker, E. M. J. Biol. Chem. 2004, 279,
12876.
[142] Nadin, A.; López, J. M. S.; Neduvelil, J. G.; Thomas, S. R.
Tetrahedron 2001, 57, 1861.
[143] Moore, C. L.; Leatherwood, D. D.; Diehl, T. S.; Selkoe, D. J.;
Wolfe, M. S. J. Med. Chem. 2000, 43, 3434. [168] Iwata, N.; Tsubuki, S.; Takaki, Y.; Shirotani, K.; Lu, B.; Gerard,
N. P.; Gerard, C.; Hama, E.; Lee, H.-J.; Saido, T. C. Science 2001,
292, 1550.
[144] Wolfe, M. S. J. Mol. Neurosci. 2001, 17, 199.
[145] Campbell, W. A.; Iskandar, M. K.; Reed, M. L.; Xia, W.
Biochemistry 2002, 41, 3372. [169] Iwata, N.; Tsubuki, S.; Takaki, Y.; Watanabe, K.; Sekiguchi, M.;
Hosoki, E.; Kawashima-Morishima, M.; Lee, H.-J.; Hama, E.;
Sekine-Aizawa, Y.; Saido, T. C. Nat. Med. 2000, 6, 143.
[146] Petit, A.; Bihel, F.; Alves da Costa, C.; Pourquie, O.; Checler, F.;
Kraus, J.-L. Nat. Cell Biol. 2001, 3, 507.
[147] Zhang, L.; Song, L.; Terracina, G.; Liu, Y.; Pramanik, B.; Parker,
E. Biochemistry 2001, 40, 5049.
[170] Iwata, N.; Saido, T. C. Dementia Jpn. 2000, 14, 80.
[171] Abraham, C. R.; McGraw, W. T.; Slot, F.; Yamin, R. Ann. N. Y.
Acad. Sci. 2000, 920, 245.[148] Berezovska, O.; Jack, C.; McLean, P.; Aster, J. C.; Hicks, C.; Xia,
W.; Wolfe, M. S.; Kimberly, W. T.; Weinmaster, G.; Selkoe, D. J.;
Hyman, B. T. J. Neurochem. 2000, 75, 583.
[172] Smith, D. W.; Munoz, B.; Srinivasan, K.; Bergstrom, C. P.;
Chaturvedula, P. V.; Deshpande, M. S.; Keavy, D. J.; Lau, W. Y.;
Parker, M. F.; Sloan, C. P.; Wallace, O. B.; Wang, H. H.
Preparation of sulfonamide derivs. as amyloidβ production
inhibitors useful in treating or preventing diseases related to Aβ.
WO 0050391, 2000.
[149] Wolfe, M. S.; Xia, W.; Moore, C. L.; Leatherwood, D. D.;
Ostaszewski, B.; Rahmati, T.; Donkor, I. O.; Selkoe, D. J.
Biochemistry 1999, 38, 4720.
[150] Wolfe, M. S.; Citron, M.; Diehl, T. S.; Xia, W.; Donkor, I. O.;
Selkoe, D. J. J. Med. Chem. 1998, 41, 6. [173] Rishton, G. M.; Retz, D. M.; Tempest, P. A.; Novotny, J.; Kahn, S.;
Treanor, J. J. S.; Lile, J. D.; Citron, M. J. Med. Chem. 2000, 43,
2297.
[151] Doerfler, P.; Shearman, M. S.; Perlmutter, R. M. PNAS 2001, 98,
9312.
[152] Roncarati, R.; Sestan, N.; Scheinfeld, M. H.; Berechid, B. E.;
Lopez, P. A.; Meucci, O.; McGlade, J. C.; Rakic, P.; D'Adamio, L.
PNAS 2002, 99, 7102.
[174] Belanger, P. C.; Collins, I. J.; Hannam, J. C.; Harrison, T.; Lewis,
S. J.; Madin, A.; McIver, E. G.; Nadin, A. J.; Neduvelil, J. G.;
Shearman, M. S.; Smith, A. L.; Sparey, T. J.; Stevenson, G. I.;
Teall, M. R. Synthesis of sulfonamido-substituted bridged
bicycloalkyl derivatives as γ-secretase inhibitors. WO 0170677,
2001.
[153] Das, C.; Wolfe, M. S.; Tsai, J.-Y.; Diehl, T. S. Abstracts of Papers,
223rd ACS National Meeting, Orlando, FL, United States, April 7-
11, 2002 2002, MEDI.
[154] Wolfe, M. S. Helical peptidomimetics as inhibitors of β-amyloid
production, and therapeutic use thereof. WO 2003068168, 2003.
[175] Olson, R. E.; Maduskuie, T. P.; Thomas, L. A. Preparation of
succinoylamino-azepinones and related compounds as inhibitors
of Aβ-peptide production. WO 0007995, 2000.[155] Bihel, F.; Das, C.; Bowman, M. J.; Wolfe, M. S. J. Med. Chem.
2004, 47, 3931. [176] Seiffert, D.; Bradley, J. D.; Rominger, C. M.; Rominger, D. H.;
Yang, F.; Meredith, J. E. Jr.; Wang, Q.; Roach, A. H.; Thompson,
L. A.; Spitz, S. M.; Higaki, J. N.; Prakash, S. R.; Combs, A. P.;
Copeland, R. A.; Arneric, S. P.; Hartig, P. R.; Robertson, D. W.;
Cordell, B.; Stern, A. M.; Olson, R. E.; Zaczek, R. J. Biol. Chem.
2000, 275, 34086.
[156] Bakshi, P.; Wolfe, M. S. J. Med. Chem. 2004, 47, 6485.
[157] McLendon, C.; Xin, T.; Ziani-Cherif, C.; Murphy, M. P.; Findlay,
K. A.; Lewis, P. A.; Pinnix, I.; Sambamurti, K.; Wang, R.; Fauq,
A.; Golde, T. E. FASEB 2000, 14, 2383.
[158] Castro Pineiro, J. L.; Smith, A. L.; Stevenson, G. I. γ-Secretase
inhibitors for treatment or prevention of Alzheimer's disease. WO
0166564, 2001.
[177] Thompson, L. A.; Han, A. Q. Preparation of amino lactam
sulfonamides as inhibitors of Aβ-protein production. WO
0127108, 2001.[159] Esler, W. P.; Kimberly, W. T.; Ostaszewski, B. L.; Ye, W.; Diehl,
T. S.; Selkoe, D. J.; Wolfe, M. S. PNAS 2002, 99, 2720. [178] Thompson, L. A. Amino lactam sulfonamides as inhibitors of Aβ
protein production. WO 0127091, 2001.[160] Dovey, H. F.; John, V.; Anderson, J. P.; Chen, L. Z.; De Saint
Andrieu, P.; Fang, L. Y.; Freedman, S. B.; Folmer, B.; Goldbach,
E.; Holsztynska, E. J.; Hu, K. L.; Johnson-Wood, K. L.; Kennedy,
S. L.; Kholodenko, D.; Knops, J. E.; Latimer, L. H.; Lee, M.; Liao,
Z.; Lieberburg, I. M.; Motter, R. N.; Mutter, L. C.; Nietz, J.;
[179] Teall, M. R. γ-secretase inhibitors. Us 20020013315, 2002.
[180] Fuchs, K.; Romig, M.; Mendla, K.; Briem, H.; Fechteler, K.
Preparation of novel imidazopyridines as β-amyloid formation
inhibitors. WO 2002014313, 2002.
1694 Current Medicinal Chemistry, 2005, Vol. 12, No. 14 Schmidt et al.
[181] Himmelsbach, F.; Fuchs, K.; Briem, H.; Fechteler, K.; Kostka, M.;
Dorner-Ciossek, C.; Bornemann, K.; Klinder, K. Preparation of
diaminopyrimidines as inhibitors of β-amyloid formation or its
release. WO 2003032994, 2003.
[214] Ripova, D.; Strunecka, A. Physiol. Res. (Prague, Czech Repub.)
2001, 50, 119.
[215] Lee, D. H. S.; Reitz, A. B.; Plata-Salaman, C. R.; Wang, H.-Y.
Method of diagnosing neurodegenerative disease. WO 0140261,
2001.[182] Otto, M.; Cepek, L.; Ratzka, P.; Doehlinger, S.; Boekhoff, I.;
Wiltfang, J.; Irle, E.; Pergande, G.; Ellers-Lenz, B.; Windl, O.;
Kretzschmar, H. A.; Poser, S.; Prange, H. Neurology 2004, 62,
714.
[216] Gupta-Bansal, R.; Brunden, K. R. J. Neurochem. 1998, 70, 292.
[217] Ashburn, T.; Hogyu, T. H.; McGuinness, B. F.; Lansbury, Jr. P. T.
Chem. Biol. 1996, 3, 351.
[183] Churcher, I.; Williams, S.; Kerrad, S.; Harrison, T.; Castro, J. L.;
Shearman, M. S.; Lewis, H. D.; Clarke, E. E.; Wrigley, J. D.;
Beher, D.; Tang, Y. S.; Liu, W. J. Med. Chem. 2003, 46, 2275.
[218] Probst, A.; Heitz, P. U.; Ulrich, J. Virchows Archiv. A, Pathol.
Anat. Histol. 1980, 388, 327.
[219] Klunk, W. E.; Debnath, M. L.; Pettegrew, J. W. Neurobiol. Aging
1994, 15, 691.[184] Churcher, I.; Ashton, K.; Butcher, J. W.; Clarke, E. E.; Harrison,
T.; Lewis, H. D.; Owens, A. P.; Teall, M. R.; Williams, S.;
Wrigley, J. D. Bioorg. Med. Chem. Lett. 2003, 13, 179.
[220] Klunk, W. E.; Debnath, M. L.; Koros, A. M. C.; Pettegrew, J. W.
Life Sci. 1998, 63, 1807.
[185] Lewis, H. D.; Perez Revuelta, B. I.; Nadin, A.; Neduvelil, J. G.;
Harrison, T.; Pollack, S. J.; Shearman, M. S. Biochemistry 2003,
42, 7580.
[221] Klunk, W. E.; Pettegrew, J. W.; Mathis, C. A. Jr. Azo compounds
for the antemortem  diagnosis of Alzheimer's disease and in vivo
imaging and prevention of amyloid deposition. WO 9634853,
1996.[186] Sun, X.; Sato, S.; Murayama, O.; Murayama, M.; Park, J. M.;
Yamaguchi, H.; Takashima, A. Neurosci. Lett. 2002, 321, 61. [222] Klunk, W. E.; Pettegrew, J. W.; Mathis, C. A. Jr. Alkyl, alkenyl
and alkynyl Chrysamine G derivatives for the antemortem
diagnosis of Alzheimer's disease and in vivo imaging and
prevention of amyloid deposition. WO 9847969, 1998.
[187] Phiel, C. J.; Wilson, C. A.; Lee, V. M.; Klein, P. S. Nature 2003,
423, 435.
[188] Cohen, P.; Goedert, M. Nat. Rev. Drug Discov. 2004, 3, 479.
[189] Ryder, J.; Su, Y.; Liu, F.; Li, B.; Zhou, Y.; Ni, B. Biochem.
Biophys. Res. Commun. 2003, 312, 922.
[223] Klunk, W. E.; Pettegrew, J. W.; Mathis, C. A. Jr. Compounds for
the antemortem diagnosis of Alzheimer's disease and in vivo
imaging and prevention of amyloid deposition. WO 9924394,
1999.
[190] Eckert, G. P.; Wood, W. G.; Müller, W. E. J. Neural. Transm.
2004, in press.
[191] Cucchiara, B.; Kasner, S. E. J. Neurol. Sci. 2001, 187, 81. [224] Klunk, W. E.; Wang, Y.; Huang, G.-F.; Debnath, M. L.; Holt, D.
P.; Mathis, C. A. Life Sci. 2001, 69, 1471.[192] Fassbender, K.; Simons, M.; Bergmann, C.; Stroick, M.; Lutjohann,
D.; Keller, P.; Runz, H.; Kuhl, S.; Bertsch, T.; Von Bergmann, K.;
Hennerici, M.; Beyreuther, K.; Hartmann, T. PNAS 2001, 98,
5856.
[225] Han, H.; Cho, C.-G.; Lansbury, P. T. Jr. J. Am. Chem. Soc. 1996,
118, 4506.
[226] Link, C. D.; Johnson, C. J.; Fonte, V.; Paupard, M. C.; Hall, D. H.;
Styren, S.; Mathis, C. A.; Klunk, W. E. Neurobiol. Aging 2001, 22,
217.
[193] Simons, M.; Keller, P.; Dichgans, J.; Schulz, J. B. Neurology 2001,
57, 1089.
[194] Riddell, D. R.; Christie, G.; Hussain, I.; Dingwall, C. Curr. Biol.
2001, 11, 1288.
[227] Caltech; Magnetic resonance imaging agents for in vivo labeling
and detection of amyloid deposits. WO 028441, 2002.
[195] Kojro, E.; Gimpl, G.; Lammich, S.; Marz, W.; Fahrenholz, F.
PNAS 2001, 98, 5815.
[228] Skovronsky, D. M.; Zhang, B.; Kung, M.-P.; Kung, H. F.;
Trojanowski, J. Q.; Lee, V. M.-Y. PNAS 2000, 97, 7609–7614.
[196] George, A. J.; Holsinger, R. M. D.; McLean, C. A.; Laughton, K.
M.; Beyreuther, K.; Evin, G.; Masters, C. L.; Li, Q.-X. Neurobiol.
Dis. 2004, 16, 124.
[229] Zhuang, Z. P.; Kung, M. P.; Hou, C.; Skovronsky, D. M.; Gur, T.
L.; Ploessl, K.; Trojanowski, J. Q.; Lee, V. M. Y.; Kung, H. F. J.
Med. Chem. 2001, 44, 1905.
[197] Refolo, L. M.; Pappolla, M. A.; LaFrancois, J.; Malester, B.;
Schmidt, S. D.; Thomas-Bryant, T.; Tint, G. S.; Wang, R.;
Mercken, M.; Petanceska, S. S.; Duff, K. E. Neurobiol. Dis. 2001,
8, 890.
[230] Okamura, N.; Suemoto, T.; Shimadzu, H.; Suzuki, M.; Shiomitsu,
T.; Akatsu, H.; Yamamoto, T.; Staufenbiel, M.; Yanai, K.; Arai,
H.; Sasaki, H.; Kudo, Y.; Sawada, T. J. Neurosci. 2004, 24, 2535.
[231] Kung, M.-P.; Hou, C.; Zhuang, Z.-P.; Skovronsky, D.; Kung, H. F.
Brain Res. 2004, 1025, 98.[198] Bayer, T. A.; Schaefer, S.; Simons, A.; Kemmling, A.; Kamer, T.;
Tepest, R.; Eckert, A.; Schuessel, K.; Eikenberg, O.; Sturchler-
Pierrat, C.; Abramowski, D.; Staufenbiel, M.; Multhaup, G. PNAS
2003, 100, 14187.
[232] Mathis, C. A.; Wang, Y.; Holt, D. P.; Huang, G. F.; Debnath, M.
L.; Klunk, W. E. J. Med. Chem. 2003, 46, 2740.
[233] Wilson, A. A.; Garcia, A.; Chestakova, A.; Kung, H.; Houle, S. J.
Labelled Comp. Radiopharm. 2004, 47, 679.[199] Regland, B.; Lehmann, W.; Abedini, I.; Blennow, K.; Jonsson, M.;
Karlsson, I.; Sjoegren, M.; Wallin, A.; Xilinas, M.; Gottfries, C.-G.
Dement. Geriatr. Cog. Disord. 2001, 12, 408.
[234] Wang, Y.; Klunk, W. E.; Debnath, M. L.; Huang, G.-F.; Holt, D.
P.; Li, S.; Mathis, C. A. J. Mol. Neurosci. 2004, 24, 55.
[200] Melov, S. Trends. Neurosci. 2002, 25, 121. [235] Agdeppa, E. D.; Kepe, V.; Liu, J.; Flores-Torres, S.; Satyamurthy,
N.; Petric, A.; Cole, G. M.; Small, G. W.; Huang, S.-C.; Barrio, J.,
J. Neurosci. 2001, 21, RC189/1.
[201] Treiber, C.; Simons, A.; Strauss, M.; Hafner, M.; Cappai, R.;
Bayer, T. A.; Multhaup, G. J. Biol. Chem. 2004, 279, 51958.
[202] Barnham, K. J.; Gautier, E. C. L.; Kok, G. B.; Krippner, G.
Preparation of 8-hydroxy-quinolines for treatment of neurological
conditions. WO 2004007461, 2004.
[236] Cai, L.; Chin, F. T.; Pike, V. W.; Toyama, H.; Liow, J.-S.; Zoghbi,
S. S.; Modell, K.; Briard, E.; Shetty, H. U.; Sinclair, K.; Donohue,
S.; Tipre, D.; Kung, M.-P.; Dagostin, C.; Widdowson, D. A.;
Green, M.; Gao, W.; Herman, M. M.; Ichise, M.; Innis, R. B. J.
Med. Chem. 2004, 47, 2208.
[203] Khachaturian, Z. S. Neurobiol. Aging. 2002, 23, 509.
[204] Papassotiropoulos, A.; Hock, C. Neurobiol. Aging 2002, 23, 513.
[205] Papassotiropoulos, A.; Lutjohann, D.; Bagli, M.; Locatelli, S.;
Jessen, F.; Buschfort, R.; Ptok, U.; Bjorkhem, I.; von Bergmann,
K.; Heun, R. J. Psychiatr. Res. 2002, 36, 27.
[237] Klunk, W. E.; Engler, H.; Nordberg, A.; Wang, Y.; Blomqvist, G.;
Holt, D. P.; Bergstrom, M.; Savitcheva, I.; Huang, G.-f.; Estrada,
S.; Ausen, B.; Debnath, M. L.; Barletta, J.; Price, J. C.; Sandell, J.;
Lopresti, B. J.; Wall, A.; Koivisto, P.; Antoni, G.; Mathis, C. A.;
Langstrom, B. Ann. Neurol. 2004, 55, 306.
[206] Boss, M. A. Biochim. Biophysica Acta 2000, 1502, 188.
[207] Teunissen, C. E.; de Vente, J.; Steinbusch, H. W.; De Bruijn, C.
Neurobiol. Aging 2002, 23, 485. [238] Shoghi-Jadid, K.; Small, G. W.; Agdeppa, E. D.; Kepe, V.; Ercoli,
L. M.; Siddarth, P.; Read, S.; Satyamurthy, N.; Petric, A.; Huang,
S. C.; Barrio, J. R. Am. J. Geriatr. Psychiatry 2002, 10, 24.
[208] Klunk, W. E. Neurobiol. Aging 2002, 23, 517.
[209] Kawarabayashi, T.; Younkin, L. H.; Saido, T. C.; Shoji, M.; Ashe,
K. H.; Younkin, S. G. J. Neurosci. 2001, 21, 372. [239] Enguehard, C.; Allouchi, H.; Gueiffier, A.; Buchwald, S. L. J.
Org. Chem. 2003, 68, 4367.[210] Couderc, R. Ann. Biol. Clin. 2000, 58, 581.
[211] Montine, T. J.; Kaye, J. A.; Montine, K. S.; McFarland, L.;
Morrow, J. D.; Quinn, J. F. Arch. Pathol. Lab. Med. 2001, 125,
510.
[240] Enguehard, C.; Allouchi, H.; Gueiffier, A.; Buchwald, S. L. J.
Org. Chem. 2003, 68, 5614.
[241] Manas, E. S.; Unwalla, R. J.; Xu, Z. B.; Malamas, M. S.; Miller, C.
P.; Harris, H. A.; Hsiao, C.; Akopian, T.; Hum, W.-T.; Malakian,
K.; Wolfrom, S.; Bapat, A.; Bhat, R. A.; Stahl, M. L.; Somers, W.
S.; Alvarez, J. C. J. Am. Chem. Soc. 2004, 126, 15106.
[212] Pratico, D.; Clark, C. M.; Lee, V. M. Y.; Trojanowski, J. Q.;
Rokach, J.; FitzGerald, G. A. Ann. Neurol. 2000, 48, 809.
[213] Pratico, D.; Clark, C. M.; Liun, F.; Lee, V. Y.; Trojanowski, J. Q.
Arch. Neurol. 2002, 59, 972.
Drug Development and PET-Diagnostics Current Medicinal Chemistry, 2005, Vol. 12, No. 14 1695
[242] Barlaam, B.; Bernstein, P.; Dantzman, C.; Warwick, P.
Preparation of benzoxazoles and benzothiazoles as selective
ligands for human β-estrogen receptor. WO 2002051821, 2002.
[248] apo: The protein component of an enzyme that is separable from
the prosthetic group but that requires the prosthetic group to form
the functioning holoenzyme.
[243] Lockhart, A.; Ye, L.; Judd, D. B.; Merritt, A. T.; Lowe, P.;
Morgenstern, J. L.; Hong, G.; Gee, A. D.; Brown, J. J. Biol. Chem.
2004, 10.1074/jbc.M41205620.
[249] Confaloni, A.; Terreni, L.; Piscopo, P.; Crestini, A.; Campeggi, L.
M.; Frigerio, C. S.; Blotta, I.; Perri, M.; Di Natale, M.; Maletta, R.;
Marcon, G.; Franceschi, M.; Bruni, A. C.; Forloni, G.; Cantafora,
A. Neurosci. Lett. 2003, 353, 61.[244] Auberson, Y. Coumarines useful as biomarkers. WO 03074519,
2003. [250] Hunger, K. In Industrial Dyes, Wiley-VCH 2004, Weinheim. pp.
141[245] Klunk, W. E.; Wang, Y.; Huang, G. F.; Debnath, M. L.; Holt, D.
P.; Shao, L.; Hamilton, R. L.; Ikonomovic, M. D.; DeKosky, S. T.;
Mathis, C. A. J. Neurosci. 2003, 23, 2086.
[251] Puglielli, L.; Konopka, G.; Pack-Chung, E.M.; Ingano, L. A. M.;
Berezovska, O.; Hyman, B. T.; Chang Ta, Y.; Tanzi, R.E.;
Kovacs, D. M. Nat. Cell Biol. 2001, 3, 905.[246] Zhao, G.; Mao, G.; Tan, J.; Dong, Y.; Cui, M.-Z.; Seong-Hun, K.;
Xu, X. J. Biol. Chem. 2004, 279, 50647. [252] Puglielli, L.; Ellis, B. C.; Ingano, L. A. M.; Kovacs, D. M. J. Mol.
Neurosci. 2004, 24, 93.[247] McLean, C. A.; Cherny, R. A.; Fraser, F. W.; Fuller, S. J.; Smith,
M. J.; Beyreuther, K.; Bush, A. I.; Masters, C. L. Ann. Neurol.
1999, 46, 860.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Paper 
 Neurodegenerative Dis 2006;3:290–297 
 DOI: 10.1159/000095269 
 Modulators and Inhibitors of   - and 
  -Secretases 
 Boris Schmidt    Stefanie Baumann    Rajeshwar Narlawar    Hannes A. Braun    
Gregor Larbig  
 Clemens Schöpf Institute for Organic Chemistry and Biochemistry, TU Darmstadt,  Darmstadt , Germany
 
which differ in length from 38 to 42 amino acids, are gen-
erated from the amyloid precursor protein (APP) by two 
aspartic proteases:   -secretase and   -secretase ( fig. 1 ). 
Both secretases are rather promiscuous, they have mul-
tiple substrates and cause several distinctly different 
cleavages of APP. The membrane localization of both en-
zymes is crucial for selectivity, as cell-free conditions 
shift the cleavage pattern or result in additional cleavage 
sites. Usually 90% of APP is degraded by the benign   -
secretase pathway, and a mere 10% of APP is degraded by 
the consecutive cleavages of   - and   -secretases to result 
in the build-up of extracellular A  deposits. Neither the 
pathological consequences of deposited or soluble A  are 
established beyond doubt, nor does plaque formation ad-
equately correlate to the progress of AD. A definite proof 
of the A  hypothesis is still missing for humans.
 BACE Inhibitors 
 Several reviews on BACE inhibition summarize the 
biology and chemical concepts  [2–6] . The majority of po-
tent inhibitors are still peptide-based transition state an-
alogues. Hydroxyethylenes, statins, norstatins, bis-
statins, hydroxyethylamines and hydroxyethylureas were 
employed. The hydroxyethylenes delivered the first high-
ly potent inhibitors. Their subsite specificity was revealed 
by the cleavage rates of substrate mixtures and selective 
inhibitors, resulting in the design of the heptapeptides 
 Key Words 
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inhibitors   Presenilin 
 Abstract 
 Most gene mutations associated with Alzheimer’s disease 
point to the metabolism of amyloid precursor protein as a 
potential cause. The   - and   -secretases are two execution-
ers of amyloid precursor protein processing resulting in am-
yloid-  . Significant progress has been made in the selective 
inhibition of both proteases, regardless of structural infor-
mation for   -secretase. Several peptidic and nonpeptidic 
leads were identified for both targets. 
 Copyright © 2006 S. Karger AG, Basel 
 Introduction 
 Alzheimer’s disease (AD) is the most common pro-
gressive, irreversible dementia with neither definitely as-
signed cause nor an available causal therapy. The symp-
toms of the disease include memory loss, confusion, im-
paired judgment, personality changes, disorientation, 
and loss of language skills  [1] . A hallmark of AD is the 
accumulation of extracellular amyloidic plaques in the 
brain.  The   -amyloid (A  ) peptide, which is the major 
constituent of these amyloid plaques, performs a central 
role in the neuropathology of AD. The A  peptides, 
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Glu-Val-Asn-  (Leu-Ala)-Ala-Glu-Phe (1, OM99-2,  K  i  = 
1.6 n M ,  fig. 2 ) and Glu-Leu-Asp-  (Leu-Ala)-Val-Glu-
Phe (2, OM00-3,  K  i  = 0.31 n M )  [7] . The two inhibitors al-
lowed co-crystallization with BACE and structure deter-
mination at 1.9 Å and 2.1 Å, respectively (PDB: OM99-2, 
1FKN; OM00-3, 1M4H)  [8] . The hydroxyethylenes are 
coordinated by four hydrogen bonds to the two catalytic 
aspartates. Essentially, the structure of the enzyme and 
the backbone conformations from P 3  to P 2   are the same, 
although they differ in side-chain orientation in several 
subsites. 
 The introduction of the isophthalamide was an im-
portant step towards less peptidic compounds 3–6 ( fig. 2 ), 
which is mandatory to obtain sufficient oral absorption 
and blood-brain barrier penetration  [9] . We adopted this 
moiety for our BACE inhibitor program utilizing our 
novel methodology for iodomethanols  [10] . This resulted 
in the stereoselective synthesis of an advanced intermedi-
ate 7. Opening of the epoxide with benzylamines fur-
nished a series of hydroxyethylene isosters (fig. 3), which 
were tested in collaboration with M. Willem, LMU 
München, and F. Hoffmann-La Roche, Basel. Almost all 
compounds displayed poor activity; we attribute this
to the wrong S-stereochemistry of the hydroxyl group. 
However, the epoxide 7 turned out to be an irreversible 
inhibitor of BACE; the irreversibility is apparent from the 
time dependence of the inhibition. Unfortunately, the 
compound displays poor activity in cellular assays; this 
may be due to rapid degradation by other proteases, which 
in turn is an indicator of lacking selectivity  [10] . We cur-
rently revise our synthesis to obtain the necessary diaste-
reomers.
 Despite all efforts in the development of BACE-1 in-
hibitors, two major hurdles have hampered progress: 
blood-brain barrier permeability and oral bioavailability. 
To overcome these problems, novel nonpeptidic lead 
structures are of great interest. For several years, there 
were few structures, usually with an obscure mode of ac-
tion  [11, 12] . However, detailed activities were reported 
by A. Simon for 12  at the Alzheimer/Parkinson confer-
ence in Sorrento, March 2005 (IC 50  = 15 n M BACE-1, 
IC 50  = 230 n M BACE-2, IC 50  = 7,620 n M cathepsin D, 
T 1/2    2.1 h, clearance 76 ml/min/kg, V diss  7.2 l/kg). Fur-
thermore, the compound did not pass the blood-brain 
barrier in mice. A proof of concept was attempted via in-
tracerebroventricular dosage (7.5 mg/kg/day) for 14 days. 
A   40  was reduced by 47% at the end of the trial  [13] . A 
compound with improved properties was reported re-
cently  [14] .
 Acylated tetronic and tetramic acids have been inves-
tigated as aspartic protease inhibitors before  [15] . This 
was due to their similarity to Tipranavir, an active site 
inhibitor of the HIV-1 aspartic protease. Co-crystalliza-
tion with the HIV-1 protease and structure determina-
tion revealed that the acidic hydroxyl of Tipranavir inter-
acts with the catalytic aspartates  [16] . The more compact 
Amyloid
plaques
A 40/42
sAPP
sAPP
P3
 

-Secretase -Secretase
C99 APP C83
 Fig. 1. Processing of APP by secretases. 
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tetronates and tetramic acids may adopt a similar orien-
tation in the active site, placing their substituents into 
lipophilic pockets. At the time we started the synthetic 
program on tetronic and tetramic acids, researchers from 
F. Hoffmann-La Roche identified a broad series of tet-
ronic and tetramic acids with BACE inhibitor activity (13, 
IC 50  = 11   M )  [17] . We explored several synthetic strate-
gies in solution and on polymeric supports. A cyclization/
cleavage strategy allowed to introduce diversity and re-
sulted in more than 70 derivatives. The compounds 14–17 
( fig. 4 ) were tested in collaboration with F. Hoffmann-
La Roche, Basel, and M. Willem at the LMU, München. 
However, the activities were moderate at best. The re-
moval of the acyl substituent or the replacement by a sulf-
oxide reduced the activity (IC 50   1 200   M ) in FRET assays 
on isolated BACE-1 dramatically. The compounds were 
inactive in a radio ligand displacement assay against an 
active site-directed inhibitor. Furthermore, they dis-
played very poor inhibition in cellular assays, which 
points at a weak allosteric mode of action  [18] .
 Fig. 2. BACE inhibitors I. 
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  -Secretase Inhibitors 
 Special features of the   -secretase complex hinder 
crystallization and thus crystallographic analysis of the 
enzyme, which is a major obstacle for structure-based 
drug design. Furthermore, the information available on 
inhibitor-binding sites is still limited. Therefore, all selec-
tive, nonpeptidic   -secretase inhibitors had to be provid-
ed by high throughput screening efforts. Peptidic PS1 in-
hibitors, like Merck’s L-685,458 (18, IC 50  = 17 n M ) (fig. 5), 
are potent inhibitors  [19] . The all-lipophilic sequence 
with 3 phenylalanines was somewhat anticipated, as sev-
eral studies had indicated the lipophilic binding pockets 
(P 2 , P 1 , P 1   , P 2   , even P 4   and P 7   ) in proximity to the cleav-
age site  [20] . It was suggested that compound 18 acts as a 
direct transition-state analogue of the A  1–40 and 1–42 
cleavage sites. Elan’s semipeptidic   -secretase inhibitor 
DAPT (19, IC 50  = 20 n M ) was developed from an  N -di-
chlorophenylalanine lead. Structure activity relation-
ships studies revealed phenylglycine and difluorophenyl-
acetic acid to be crucial for activity  [21] . DAPT has dem-
onstrated robust efficacy in vivo  at relatively high doses. 
Several preclinical studies revealed in vivo toxicity, be-
cause DAPT affects the Notch pathway at higher levels 
(100- to 1,000-fold)  [22] . We speculated in 2002 that 
DAPT may be binding in close contact to the aspartic ac-
 Fig. 3. BACE inhibitors II. 
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ids of the active site and developed a series of acid-labile 
DAPT analogues. The compounds were intended to re-
sult in H +  catalyzed fragmentation and reactive cationic 
intermediates. Some of the DAPT analogues were indeed 
potent inhibitors, but none of the compounds displayed 
the predicted time-dependent inhibition in the assays of 
C. Haass and H. Steiner, LMU München. We concluded 
that there is no irreversible inhibition by these pH sensors 
 [23] . The difluorophenylacetyl moiety in DAPT can be 
replaced by 5-bromopyridin-3-ylacetyl without loss of 
activity. Methylation of the pyridine results in mem-
brane-blocked DAPT analogues; these were evaluated in 
the reconstituted   -secretase assay (C. Haass, H. Steiner, 
LMU München) and cellular assays (K. Baumann, M. 
Brockhaus, F. Hoffmann-La Roche, Basel). All com-
pounds displayed activity in the reconstituted assay, yet 
at a varying degree. The quaternized, membrane-blocked 
compounds lacked activity in the cellular assay. The anal-
ysis of these compounds is ongoing. In the meantime, we 
moved on to immobilize DAPT analogue esters on affigel 
(Biorad) by 3 different linkers of varying length. One of 
the linkers included a photolabile nitrobenzyl ester to al-
low a mild cleavage without denaturation of the assem-
bled complex. However, all affinity gels displayed high 
and unspecific background binding, the isolation of ac-
tive   -secretase by these gels was unsuccessful.
 The   -secretase inhibitors must reduce A  production 
sufficiently to alleviate the cause of AD, but must not to-
tally abolish either its production or the processing of 
other proteins, which have important roles in neuronal 
structure and function. Several substrates must be con-
sidered in addition to APP and Notch: the Notch ligands 
Delta and Jagged, apoER2 lipoprotein receptor, the low-
density lipoprotein receptor-related protein, ErbB4 re-
ceptor tyrosine kinase, CD44, p75 neurotrophin and   -
subunits of voltage-gated sodium channels. The impor-
tant issue is: are there   -secretase inhibitors that reduce 
APP processing without generating an unacceptable side 
 Fig. 4. Nonpeptidic BACE inhibitors. 
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effect? Gleevec (21) inhibits A  production but not Notch 
cleavage  [24] . IC 50  values for A   40 , A   42  and AICD were 
recently reported to be   75   M . The generation of NICD-
Flag was not inhibited, even at  1 10-fold concentrations. 
 Selected nonsteroidal anti-inflammatory drugs 
(NSAIDs) reduce A  production without affecting alter-
native cleavages  [25, 26] . The mechanisms of different 
  -secretase inhibitors were explored in detail  [27, 28] . 
Most of these bind directly to the active site or alter it 
through an allosteric interaction. Torrey Pines Pharma-
ceuticals disclosed a large number of aminothiazol-de-
rivatives (23) with A   42 /A   40 -lowering activity at a con-
centration of about 30   M  [29] . Approximately 60 of these 
structures were claimed to display modulation of   -secre-
tase (activity  ! 0.2   M ). We decided to synthesize com-
pound 24 and to evaluate it in collaboration with C. Haass 
and Hoffman-La Roche, Basel. The substance  did not dis-
play modulation but inhibition: EC 50 (A   38 ) = 1.5   M , 
IC 50 (A   40 ) = 1.8   M , IC 50 (A   42 ) = 1.6   M . A selective   -
secretase modulator (25) was reported by Merck Sharp & 
Dohme  [30] ; the carboxylic acid seems to be relevant for 
the desired ratio of A   38 /A   40 /A   42 . This modulation is 
distinctly different from inhibition as the total A  load 
may be unaffected. This was observed for several NSAIDs 
and is unrelated to COX1 inhibition  [25] . Some COX1 
inhibitors are suitable candidates to improve their ini-
 Fig. 5. Inhibitors and modulators of   -secretase. 
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tially weak activity. The analogy of BMS-299897 to COX1 
inhibitors inspired us to explore derivatives of commer-
cial NSAIDs: sulindac, flurbiprofen, ibuprofen, indo-
methacin, diclofenac, naproxen, carprofen, ketoprofen, 
and diflunisal. We prepared more than 150 derivatives, 
initially esters and amides of the parent carboxylic acids 
and identified several full   -secretase inhibitors. The ve-
ratryl amides obtained from sulindac and diclofenac 
caused reduction of A   38 , A   40  and A   42  in cellular as-
says (IC 50  10–50   M ). However, some amides and esters 
displayed ‘inverse’ NSAID properties: A   38  levels de-
creased, whereas A   40  and A   42  levels increased in cel-
lular assays.   -Secretase modulation was observed as the 
third mode of action: A   38  increased, whereas A   40  and 
A   42  decreased in cellular assays. A structure-activity re-
lationship is already apparent: the carboxylic acid is 
strictly required, and a lipophilic substituent branching 
out from the core structure improves the activity 10- to 
100-fold. The scaffold can either derive from carprofen 
or carbazole. The lipophilic branch can be attached by 
alkylation or by sulfonylation of the aniline. The best 
cores have been attached to biotinylated, photoreactive 
linkers to result in 5 biotinylated compounds (just one 
example is provided in  figure 6 ). However, these com-
pounds turned out to be unsuitable baits for the   -secre-
tase complex, although some displayed significant mod-
ulation of   -secretase activity. They resulted in unspe-
cific binding or no detectable binding at all. A robust bait 
for the successful pull-down of the binding domain with-
in   -secretase is still unknown. 
 Outlook 
 The availability of peptidic and peptidomimetic in-
hibitors for   - and   -secretase inhibitors, both as tool and 
lead structures, made a huge impact on the research area. 
But these potent peptidomimetics come with costly price 
tags: oral availability, cost of goods and blood-brain bar-
rier penetration impose severe obstacles on drug develop-
ment. Despite the extremely rapid progress in the field, 
there are no reports of brain penetrating secretase inhib-
itors in phase II or III (02/2006). The only   -secretase 
inhibitor in phase I has a red flag associated with it. This 
is due to its impact on the Notch pathway. The selective 
modulation of   -secretase by NSAIDs is pointing in the 
right direction: allosteric modulation of the active site, 
which can be identified by additional cleavage sites of 
presenilin-1. 
 Fig. 6. NSAID-derived   -secretase modulators. 
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 Collaborations within the German Research 
Foundation Priority Program 1085 
 A ligand-based approach to Tau aggregation inhibitors was 
conducted in collaboration with the participant E. Mandelkow, 
Hamburg. A manuscript was submitted (30/01/06).
  -Secretase inhibitors,   -secretase inhibitors and modulators, 
20S proteasome inhibitors and targeted screening collections 
were supplied to R. Baumeister, C. Haass, T. Hartmann, U. Mül-
ler, G. Multhaup , J. Walter, S. Weggen, M. Willem. This resulted 
in 6 publications [2, 3, 10, 31–33] and 1 patent application (not yet 
published) .
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Abstract: Most gene mutations associated with Alzheimer’s disease point to the metabolism of amyloid precursor protein
as potential cause. The β- and γ-secretases are two executioners of amyloid precursor protein processing resulting in
amyloid β. Significant progress has been made in the selective inhibition of both proteases, regardless of structural
information for γ-secretase. Several peptidic and non-peptidic leads were identified and first drug candidates are in clinical
trials. This review focuses on the developments since 2003.
Keywords: Alzheimer’s disease, secretase, aspartic protease, inhibitor, presenilin.
INTRODUCTION
Alzheimer's disease (AD) is the most common progres-
sive, irreversible dementia with neither definitely assigned
cause nor an available causal therapy. The symptoms of the
disease include memory loss, confusion, impaired judgment,
personality changes, disorientation, and loss of language
skills Furthermore, it is always fatal [1]. More than 4.5
million Americans are struck by Alzheimer’s disease and
this number may increase to 14 million by 2050.
Approximately 350,000 new cases of Alzheimer's disease are
diagnosed each year and 59,000 patients die of it in the US
alone. A hallmark of Alzheimer's disease is the accumulation
of extracellular amyloidic plaques in the brain [2-3]. The β-
amyloid (Aβ) peptide, which is the major constituent of
these amyloid plaques, performs a central role in the
neuropathology of AD. The Aβ peptides, which differ in
length from 38 to 42 amino acids, are generated from the
amyloid precursor protein (APP) by two aspartic proteases:
β-secretase and γ-secretase (Fig 1). Both secretases are rather
promiscuous, they have a multiple substrates and cause
several distinctly different cleavages of APP. The membrane
localisation of both enzymes is crucial for selectivity, as cell
free conditions shift the cleavage pattern or result in
additional cleavage sites. Usually 90% of the APP is
degraded by the benign α-secretase pathway, and a mere
10% of APP are degraded by the consecutive cleavages of β-
and γ-secretase to result in the build up of extracellular Aβ
deposits. The contribution of these deposits to AD is still
subject to debate. Neither the pathological consequences of
deposited or soluble Aβ are established beyond doubt, nor
does plaque formation adequately correlate to the progress of
AD. A definite proof of the Aβ hypothesis is still missing for
humans.
ESTABLISHED THERAPIES AND NOVEL
APPROACHES
More than 50 compounds are in development to treat AD
[4-5]. They target a whole range of known receptors and
*Address correspondence to this author at the Clemens Schöpf-Institute for
Organic Chemistry and Biochemistry, TU Darmstadt, Petersenstrasse 22, D-
64287 Darmstadt, Germany; E-mail: Schmidt_Boris@t-online.de
enzymes: GSK-3, PDE 4, and muscarinic M1 amongst
others. Several acetylcholine (nACh) modulators, acetylcho-
linesterase (AchE) inhibitors, N-methyl-D-aspartate (NMDA)
modulators, 5-hydroxytryptamine (5-HT) agonists and
vaccination projects are in advanced stages of research or
clinical development. The approved nAChE inhibitors and
Vitamin E or combinations thereof have been marketed as
therapies for AD. Unfortunately, recent clinical studies did
not confirm benefits superior to placebo for vitamin E in
mild cognitive impairment. Donepezil, an approved AChE
inhibitor, slowed the AD progress in the first 12 months of
treatment, but not in the following two years [6].
Some cholesterol lowering drugs such as pravastatin and
lovastatin resulted in reduced risk for AD in retrospective
trials. Paradoxically, prospective trials resulted in a
contradicting outcome, and failed to confirm a risk reduction
for AD. The rationale for this activity was subject to debate,
but three observations suggested an explanation:
1). hypercholesterolemia is accompanied by increased
levels of extractable total Aβ
2). β-secretase is associated to cholesterol stabilized rafts in
the plasma membrane and
3). activity of the benign α-secretase is inversely related to
cholesterol levels [7-9].
This hinted at a connection of AD pathology and
cholesterol levels. The missing link turned out to be the
regulation of cholesterol metabolism by amyloid β, which
modifies the de novo  cholesterol synthesis via 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR) inhibition [10].
The early rush on fibril formation inhibition resulted in a
number of potent inhibitors thereof. However, the activities
were confined to in vitro experiments or limited by poor
drug metabolism and pharmacokinetic (DMPK) properties,
which excluded further development. Several drug
candidates were tested in transgenic mice, but convincing
data were not reported for humans. Furthermore, the view on
Aβ toxicity has changed dramatically. Plaques were seen as
the culprit and their removal was a therapeutic goal until
2001. Now, soluble Aβ and early oligomers have to take the
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Fig. (2). (a) BACE complexed to 13 (PDB: 1W51). (b) Compound
13 in BACE above the flap (PBD: 1W51). (c) Sulfonamide 33 in
BACE with the flap removed (PDB: 2B8L). MOE 2004.10
GaussConolly surface, green: hydrophobic, blue: hydrophilic.
blame for the Aβ associated effects. Thus mature Aβ plaques
may rather rest in peace.
β-SECRETASE (BACE)
BACE-1 seemed to be an ideal target for drug
development, because APP was the only known substrate.
This scenario has changed substantially over the last two
years, when amyloid precursor-like proteins (APLP1 and
APLP2) and other substrates were reported [11]. However,
these substrates can actually improve drug development as
they can be utilized to identify BACE modifiers [12]. β-
Secretase was identified as an aspartic protease long before
selective inhibitors became available [13]. The key feature of
an aspartic protease was confirmed early: the flexible flap
region, which is crucial for substrate docking. The kinetics of
statine-based inhibitors revealed a two state mechanism with
structural reorganisation and activity modulation [14]. The
two states: open and closed, contribute to selectivity and
activity of the enzyme [15]. The flexibility of free and
inhibitor bound BACE was investigated in silico and
revealed several novel aspects of BACE, which are useful
for structure-based, computer-aided inhibitor design [16].
The protonation states of the two active site residues Asp32
and Asp228 were calculated by several groups with different
results [16-19]. Two β-secretases are known: BACE-1
(ASP2 or memapsin 2) and BACE-2 (ASP1 or memapsin 1)
with high homology, yet subtle differences in the active site
and an additional disulfide bridge for BACE-1 [20]. BACE-2
causes additional cleavages close to Phe20, which are
reminiscent of α-secretase activity [21, 22]. BACE-1 is
anchored to the membrane via its transmembrane domain
(455-480) and may be active as a dimer [23]. BACE-1 has a
propeptide domain, which is cleaved by furin-like proteases
to form mature enzyme. The C-terminal transmembrane
domain of BACE-1 is not strictly required for activity, but
the localization of both enzyme and substrate in the same
membrane enhances kinetics and specificity. The C-terminal
truncation influences enzyme kinetics even in the absence of
membranes. BACE-1 maturation requires cysteine bridge
formation (Cys216/Cys420, Cys278/Cys443, Cys330/
Cys380), N-glycosylation and propeptide removal. Cysteine
Fig. (1). Processing of APP by secretases.
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mutants undergo impaired maturation, but retain catalytic
activity. The Cys330/Cys380 bridge was found to be the
most important [4]. Crucial for assay development and
animal models: BACE-1 -/- knockout mice are fertile and
healthy, and display reduced Aβ levels [24]. Selectivity
issues arise from other aspartic proteases, and the
homologous BACE-2, which displays a less pathogenic APP
cleavage pattern and a distinctly different localization [25-
26]. The Aβ protein is released by a subsequent proteolysis
at Val711-Ile712 or Ala713-Thr714 by the intramembrane
protease: γ-secretase, resulting in Aβ40 and Aβ42. A detailed
analysis of BACE distribution, structure, species variation,
degradation and properties was published [27]. There is a
ligand binding pocket within the catalytic domain of BACE
that is distinct from the enzymatic active site [28]. Peptides
binding to this exosite can inhibit proteolysis of APP in
BACE (e.g. Ac-ALYPYFLPISAK-NH2, IC50 = 1.3 μM).
However, BACE inhibition is not the only way to modulate
the BACE dependent APP cleavage. High levels of ceramide
or improved raft association can extend the half-life of
BACE-1 to 16 h [29]. Modest overexpression of BACE
resulted in an enhanced amyloid deposition, while a high
overexpression decreased amyloid deposition and altered the
subcellular localization of BACE cleavage [30].
BACE INHIBITORS
Several reviews on secretase inhibition of BACE have
been published [27, 31-34]. The majority of potent inhibitors
are still peptide-based transition state analogues. Hydroxy-
ethylenes, statines, norstatines, bis-statines, hydroxy-
ethylamines and hydroxyethylureas were employed. The
hydroxyethylenes delivered the first highly potent inhibitors.
Their subsite specificity was revealed by the cleavage rates
of combinatorial substrate mixtures and selective inhibitors,
resulting in the design of the heptapeptides Glu-Val-Asn-
Ψ(Leu-Ala)-Ala-Glu-Phe (1 ,OM99-2, Ki = 1.6 nM, Scheme
1) and Glu-Leu-Asp-Ψ(Leu-Ala)-Val-Glu-Phe (2, OM00-3,
Ki = 0.31 nM) [35-37]. The two Tang-Ghosh inhibitors
allowed co-crystallisation with BACE and structure
determination at 1.9 Å and 2.1 Å, respectively (PDB: OM99-
2, 1FKN; OM00-3, 1M4H) [38-40]. The inhibitors are
located in the active site as intended by design. The
hydroxyethylenes are coordinated by four hydrogen bonds to
the two catalytic aspartates. Essentially, the structure of the
enzyme and the backbone conformations from P3 to P2’ are
the same, although they differ in sidechain configurations of
several subsites. In OM00-3, the P3, P2, and P2’ residues
have been replaced. However, it is the P4 Glu of OM00-3
that resides in a new S4 pocket and the P3’ and P4’ residues
are more extended, leading to a more linear conformation at
both ends of OM00-3 compared to OM99-2. In the latter
complex, a hydrogen bond from the P4 Glu to the P2 Asn is
more favourable than to the P2 Asp in OM00-3. This
hydrogen bond and resulting interactions inspired the design
of a novel inhibitors with low nanomolar potencies
comprising a 14- to 16-membered P2-cycloamide-urethane
[41]. A protein-ligand X-ray structure of compound 3 bound
to memapsin 2 was prepared (resolution 2.8 Å, PDB: 1XS7).
The crystal structure of free BACE (1SGZ) revealed a
flap segment to be locked in an "open" position [42]. The
structure is essentially the same as BACE-1 bound to an
inhibitor, but the flap positions differ by 4.5 Å at the tips.
The open position of the flap is stabilized by two intraflap
hydrogen bonds and is anchored by a new hydrogen bond
involving Tyr71 in a novel orientation. The resulting gorge
may contribute to sequence and shape selection. A
gatekeeper function was evident from the unusually small
substituent Ala in P2’ (1, 1FKN). Thr72 forms the narrowest
point (6.5 Å in apo BACE) between the flap and Arg235,
Ser328, and Thr329 on the opposite side and thus contributes
to the specificity of BACE. This gatekeeper blocks the
access of peptides carrying larger residues in this position,
although pocket P1’ provides more than enough space for a
significantly larger residue. Simulations suggest that BACE
inhibitors should make use of both the open-flap and the
closed-flap conformation, including different hydrogen
bonds to Tyr71 [16].
Another inhibitor Lys-Thr-Glu-Glu-Ile-Ser-Glu-Val-Asn-
(statine)-Val-Ala-Glu-Phe (P10-P4’StatVal, Ki = 40 nM,
PDB: 1XN3) was co-crystallised with BACE [43]. The
crystal structure revealed that the active cleft can
accommodate at least three additional residues P5-P7 at the
N-terminus. The residue preference of the new subsites and
their influence on the hydrolytic activity of BACE were
examined. An inhibitor Arg-Glu-Trp-Trp-Ser-Glu-Val-Asn-
L*A-Ala-Glu-Phe (hydroxyethylene isostere, OM03-4) with
a Ki-value of 0.03 nM was co-crystallized with BACE (PDB:
1XN2).
The small interactions of the C-terminal ends of OM99-2
and OM00-3 co-crystallised with BACE indicated a possible
reduction without loss of activity. This was realised in the
cyclic urethanes and further acyclic derivatives (4), yet with
different degrees of success [44-47]. Hanessian et al.
designed inhibitor 5 (IC50 = 0.039 μM) with a cyclopentane
ring fused to the hydroxyethylene portion and a short Ala-
terminus [48]. Chen et al. synthesised mimetics based on the
Ψ(Phe-Ala) hydroxyethylene such as 6 and arrived at similar
conclusions [49, 50]. Kiso et al. started from large
hydroxymethylcarbonyl isosteres [51]. Inhibitor 7a (KMI-
370, IC50 = 3.4 nM) features a short dicarboxylic acid and
displayed high activity in vitro and in vivo (BACE HEK293
cells IC50 = 0.20 μM) [52]. The tetrazole 7b is a bioisostere
of 7a and exhibits similar activity and improved stability
[53]. In the “Kiso” and the “Chen” series benzyl groups
occupy the P1 position. The introduction of a 3,5-
difluorobenzyl to the S1 pocket and non-peptidic N-termini
made a further chain reduction possible, e.g. compound 8.
The asparagine replacements to the P2-P3 region deleted the
peptidic character of the N-terminus, as realised in
compound 9 by Elan [54-55].
The introduction of the isophthalamide was an important
step towards less peptidic compounds 10-15 (Scheme 2),
which is mandatory to obtain sufficient oral absorption and
blood brain barrier penetration [56, 57]. The modification
also enabled further reduction of the C-terminus and
utilization of different transition state isosteres. Significant
information was revealed by a novel crystal structure of
BACE complexed to hydroxyethylamine 13 [58- 59].
Soaking of apo BACE crystals (PDB: 1W50) with small
peptidomimetics, which were known to be moderate
inhibitors in FRET or cellular assays, resulted in the
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incorporation of 13 in the active site (PDB: 1W51, Fig. 2a,
2b). The inhibitor features the isophthalamide to mimic the
S2-S3 section and was claimed to have an IC50 = 200 nM,
although the secondary alcohol is R-configured and thus has
a different stereochemistry compared to other BACE
transition state mimetics. The secondary amine and
secondary alcohol recognise the active site aspartates in an
unusual fashion. The neighbouring amine receives a proton
from the catalytic Asp228 and places its 3-methoxy benzyl
substituent in the S2’ pocket. One of the N-propyl groups of
the isophthalamide occupies the S3 pocket and is directed
towards the phenyl ring in the S1 pocket. The phenyl rings in
both the S1 and the S2’ pocket interact with Tyr71 of the flap
in a T-shaped stacking. Some 750 close analogues of 13
were revealed in patents by Takeda (14) [60], Glaxo [61],
Upjohn Pharmacia [62-64], Elan [56, 65-68] and a Sunesis
employee (15) [69]. A series of inhibitors by Bristol-Myers
Squibb makes use of benzylic hydroxyethylamines (16, IC50
< 0.1 μM), but rely on more peptidic scaffolds, some of these
compounds display good activity [70].
Scheme 1. BACE inhibitors I.
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Schering-Plough filed patent applications based on
isophthalamide bioisosteres and derivatives such as 17 (IC50
= 1.4 nM) and 18 (IC50 = 1 nM) with isophthalide
replacement by a multitude of other groups, e.g. 5- and 6-
membered cyclic ureas or lactams (Scheme 3) [71]. For the
most part, the C-terminus is a substituted piperazine or
piperazinone. Elan filed additional patents on BACE
inhibitors: dipeptides and a number of smaller inhibitors
were claimed (19, 20) [72-74]. In two Elan patents, the
inhibitors have neither a P2 nor a P3 substituent and the N-
terminus is formed by an acetyl group only (21, 22) [75-78].
The bicyclic inhibitor 23 has a low nanomolar IC50 in both
the cell free and the cellular assay. It displays an oral
bioavailability of 15%, a relative brain uptake (brain /
plasma, 60 min) of 3.5 and an efficacy (efficacy = {1-(total
Aβ concentration in tissue of dose group / total
Aβ concentration in tissue of vehicle control)}x100%, at 100
mg / kg) for the cortex and the plasma of 47% and 63%,
respectively. There are even smaller inhibitors of BACE (24,
25), but 25 exhibits no selectivity toward cathepsin D
(IC50(CatD) / IC50(BACE) = 1.1) [79]. Novartis created
small inhibitors based on the original hydroxyethylene core
[80-82]. The central portion is flanked by a very short alkyl
residue at the C-terminus and a 14-membered macrocyclus at
the N-terminus incorporating a fragment of the
hydroxyethylene and an isophthalamide derivative (26),
mimicking the P1-P3 residues.
Scheme 2. BACE inhibitors II.
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Despite all efforts in the development of BACE-1
inhibitors, two major hurdles have hampered progress:
blood-brain barrier permeability and oral bioavailability. To
overcome these problems novel non-peptidic lead structures
are of great interest. For several years, there were just few
structures, usually with an obscure mode of action [83, 84].
Fluorescence resonance energy transfer (FRET) assays of
soluble BACE delivered false positive hits to such a degree,
that it was mandatory to profile potential hits in a reliable
secondary assay, such as a radioligand displacement assay
[85]. Vertex reported the biphenylpiperazine (27) as BACE
inhibitor (IC50 = 3 μM, Scheme 4) [86] and it was docked
into the BACE structure by Park and Lee [17]. An
unfortunate error improved it to 3 nM, which makes the
outcome of this docking questionable. Yet, Actelion
Pharmaceuticals revealed similar biphenylated amines (28)
[87, 88].
Scheme 3. BACE inhibitors III.
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The Automated Ligand Identification System (ALIS) [89]
enabled MSD researchers to discover a novel resorcylic acid
scaffold as reversible and selective BACE-1 inhibitor [90].
Further modifications lead to an aminopentyl derivative (29),
which displays moderate inhibition of BACE-1 (IC50 = 1.4
μM) and a good selectivity towards cathepsin D (IC50 > 500
μM). Examination of an enzyme/inhibitor complex, which
was obtained by using a modified BACE-1 (K75A, E77A)
for co-crystallisation with 29 (PDB: 1TQF), revealed that the
compound occupies the S4 to S1 subsites and does not have
any interaction with the “prime side” of the enzyme. Most
notably, the active site has no direct contact with the
inhibitor. The acetamide is engaged in a hydrogen bond to
the catalytic water, which is placed between the two
aspartates as observed for the apo crystal structures of other
aspartic proteases [90]. A novel S3sp subpocket was
identified which is created by the orientation of the p-
fluorophenyl ring towards the S3 site. Another notable
finding is that the terminal aminopentyl residue coils back
into the S1 pocket – a discovery that inspired the design of
macrocycles (31, 32) in which the P1 and P3 substituents are
linked together increasing the activity by reduction of
rotational freedom [91, 92].
Further development focused on the direct interaction
with the catalytic aspartates, which is assumed to enhance
activity. The hydroxylamine motif connected to an
isophthalamide backbone improved the inhibition to 11 nM
(33) and retained 500fold selectivity towards cathepsin D
(Scheme 5) [93]. The direct two-pronged interaction -
wherein the hydroxyl functionality of the inhibitor engages
Asp32, while the protonated α-amino group simultaneously
contacts Asp228 – contributes to the increased potency. The
occupation of the S1 subsite and placement of a cyclopropyl,
which is oriented toward the S1’ site of the enzyme, may
have improved the inhibition further. The variation of the P1’
substituent exerts influence on cell permeability only. The
compound was co-crystallised with BACE and the structure
was deposited in the PDB recently (2B8L, Fig. 2c). Slightly
different activities were reported by A. Simon for 33 at the
Alzheimer / Parkinson conference in Sorrento, March 2005
(IC50 = 15 nM BACE-1, IC50 = 230 nM BACE-2, IC50 =
7620 nM cathepsin D, T1/2 ∼ 2.1 hr, clearance 76 ml/min/kg,
Vdiss 7.2 l/kg). Furthermore, the compound did not pass the
blood brain barrier in mice. A proof of concept was
attempted via intracerebroventricular (ICV) dosage (7.5
mg/kg/d) for 14 days. Aβ40 was reduced by 47% at the end
of the trial. Several recent patents focus on the
diversification of the side chains. Yet, there are no hints of
an activity enhancement [94-98]. The Glaxo compound 34
features the same N-terminus, a similar transition state
isostere, and a sulfonamide in the same position as the MSD
compound, but all features are now locked in a tricyclic
indolic ring system. Compound 34 has an activity (IC50) of
less than 1 μM in the Asp-2 inhibitory assay and more than
100fold selectivity for BACE over cathepsin D [99].
DeNovo reported several other scaffolds and mimetics:
sulfonamides, 1-piperazinylpropan-2-ols and the triazine 35,
which may be useful for Aβ fibril imaging [100-103].
Researchers from Hoffmann-La Roche described a broad
series of tetronic and tetramic acids with BACE inhibitor
Scheme 4. Non-peptidic BACE inhibitors I.
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activity (36, IC50 = 11 μM) [104]. Acylated tetronic and
tetramic acids have been investigated as aspartic protease
inhibitors before [105]. This was due to their similarity to
Tipranavir, an active site inhibitor of the HIV-1 aspartic
protease. Co-crystallisation with the HIV-1 protease and
structure determination revealed that the acidic hydroxyl of
Tipranavir interacts with the catalytic aspartates [106]. The
more compact tetronates and tetramic acids may adopt a
similar orientation in the active site, placing their
substituents into lipophilic pockets. The removal of the acyl
substituent or the replacement by a sulfoxide reduced the
activity (IC50 > 200 μM) in FRET assays on isolated BACE1
[107].
Schering-Plough revealed 2-iminoimidazolidin-4-ones
(37, IC50 < 1 μM) as BACE-1 inhibitors [108]. The same
scaffold was described as potent inhibitor for cathepsin D – a
limiting factor for the progression of that substance class into
drug development.
A fragment-based docking procedure followed by
substructure search was used to identify the phenyl-
ureathiadiazole 38 (IC50 > 25 μM BACE-1, EC50 = 2.6 μM
Aβ) [71]. The rigid conformation of BACE-1 in its complex
with OM00-3 inhibitor (PDB: 1M4H) was used for the
docking of 38 into the active site, resulting in the prediction
of two binding modes. The two NH groups are involved in
hydrogen bonds with one of the two catalytic aspartates. The
S1 pocket is occupied by the phenyl group and the
ethylthioether is oriented toward the S2’ site of the enzyme.
In the alternative binding mode, the two NH groups of the
urea are involved in hydrogen bonds with Asp228 instead of
Asp32. The overall orientation is flipped end-to-end. The
phenyl group now occupies the S1’ subsite and the
ethylthioether reaches into the S1 pocket.
γ-SECRETASE
Paradoxical: despite being the secretase reported first, the
identity of γ-secretase was subject to debate for a long time
and the exact topology is still insecure. Now, it is well
established that the γ-secretase is a high molecular weight
protein complex composed of presenilin (PS) 1 or 2,
nicastrin, Aph-1, and Pen-2 [109-113]. There is increasing
evidence that PS – a polytopic transmembrane (TM) protein
of ∼50 kDa with 10 hydrophobic domains (HD) - forms the
catalytic component of the γ-secretase complex [114-116],
but presenilins alone are not sufficient to mediate enzyme
activity [117, 118]. The active site of γ-secretase is known at
some detail and the concerted action of all co-factors is still
subject to debate. The inhibition by peptidomimetic
transition-state analogues pointed to an aspartyl protease at
work [118]. Following this assumption, the sequence
analysis of presenilin revealed two likely candidates: Asp-
257 and Asp-385 [115]. The ten HD may all cross the
membrane, but it is still a controversial issue. The prevalent
view until 2003 held that PS has an eight TM domain
organization. A significant difference for this arrangement
was reported recently. The introduction of glycosylation sites
in PS1 revealed 9 TM domains, with the N-terminus and the
large hydrophilic loop located in the cytosol, and the C-
terminus in the ER lumen or extracellular [119]. Domain
Scheme 5. Non-peptidic BACE inhibitors II.
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swap experiments indicated two domains within the TM1,
which affect presenilinase and γ-secretase activity
differently. These TM1 mutants did not bind to the transition
state mimetic Merck C [120], indicating a conformational
change resulting in loss or reduction of catalytic activity
[121].
In addition to βAPP, several other substrates are known
to be cleaved by γ-secretase, which seems to be the
“proteasome of the membrane” [122]. Generally, such
multiple substrates increase the risk for toxic side effects by
γ-secretase inhibition. In fact, the close relation to the Notch
pathway, which is important in embryonic development,
makes the γ-secretase a rather challenging and risky drug
target. The crossover to the Notch pathway hampered
attempts towards PS -/- knockout animals, which did not
pass the embryonic state, but embryonic stem cells may fill
part of the gap [123]. The intracellular trafficking of Notch
in human CNS neurons is reduced by PS1 inhibitors, and
results in dramatic changes in neurite morphology. A great
task will be the determination of a therapeutic window
between efficacy and any unacceptable toxicity [43]. Similar
IC50s for the competing cleavages of Notch and C99 do not
rule out a safe application per se, as a 10% reduction in Aβ42
production is regarded as the therapeutic goal. And indeed, a
first compound with moderate Notch selectivity is in human
trials [153].
γ-SECRETASE INHIBITORS
Special features of the γ-secretase complex hinder
crystallisation and thus crystallographic analysis of the
enzyme, which is a major obstacle for structure-based drug
design. Furthermore, the information available on inhibitor
binding sites is still limited. Therefore, all selective, non-
peptidic γ-secretase inhibitors had to be provided by high
throughput screening (HTS) efforts. Peptidic PS1 inhibitors,
like Merck’s L-685,458 (39, IC50 = 17 nM) are potent
inhibitors and were patented prior to publication in scientific
journals [124, 125]. The all-lipophilic sequence with 3
phenylalanines was somewhat anticipated, as several studies
had indicated the lipophilic binding pockets (P2, P1, P1’, P2’,
even P4’ and P7’) in proximity to the cleavage site [10]. It
was suggested that compound 39 acts as a direct transition-
state analogue of the Aβ (1-40) and (1-42) cleavage sites
(Scheme 6). The two des-hydroxy analogues displayed
reduced inhibition (270fold) [124]. The core structure of 39
was linked to biotin and photoreactive fragments N- or C-
terminally leading to L-852,505 (41) and L-852,646 (42),
which were suitable for labelling studies. Despite the
attachment of the photoreactive benzophenones, 41 and 42
retained potent inhibition (IC50 < 1 nM for γ-secretase).
Biotin was used to facilitate the isolation and identification
of the reversibly labelled adducts via their streptavidin-
enzyme linked conjugates. Photolysis in the presence of
solubilised γ-secretase and isolation on a biotin-specific
streptavidin-agarose gel provided a protein of 20 kD linked
to L-852,505 (41). This fragment was shown to be the C-
terminal fragment of PS1 (PS1-CTF) by specific antibodies.
In a control experiment, the binding of 41 to wild type PS1
was negative. However, the binding to the deletion construct
PS1ΔE9, which lacks the cytosolic E9 loop, was positive
[126]. Useful information resulted from the photolysis of L-
852,646 (42) in the presence of solubilised γ-secretase. This
resulted in the isolation of a 34 kD fragment, which was
assigned to be an N-terminal fragment of PS1. A similar
transition-state motif, the hydroxyethylurea 40 [127], was
utilised for activity based affinity purification. The
immobilisation of III-31-C (40, IC50 < 300 nM) on affigel
102 allowed isolation and identification of PS1-CTF, PS1-
NTFandNicastrinfromsolubilised γ-secretase preparations128.
Initial attempts to free active γ-secretase from the affinity gel
failed. This was probably due to the high binding affinity of
III-31-C (40) to the target protein complex, and partially due
to the deep and narrow binding site, which required strong
denaturing conditions to break up the binding interactions.
Yet, a delicate combination of Brij-35 (polyoxyethyl lauryl
ether 30% aq. solution) and CHAPSO (3-(cyclohexylamino)-
2-hydroxy-1-propanesulfonic acid) resulted in the isolation
of active γ-secretase. The co-precipitation of the inhibited γ-
secretase with its substrates C83 and C99 gave rise to
speculations about additional binding sites, where the
substrate is recognised prior to transfer to the active site.
These speculations are in accor-dance with the observed
promiscuous nature of the cleavage, as they assign the
specific recognition to other domains. Elan’s semi-peptidic
γ-secretase inhibitor DAPT (43, IC50 = 20 nM) was
developed from a N-dichlorophenylalanine lead. Structural
activity relationships (SAR) studies revealed the
phenylglycine and the difluoro phenylacetic acid to be
crucial for activity [129, 130]. DAPT has demonstrated
robust efficacy in vivo at relatively high doses. The
subcutaneous application to mice in a dosage of 100 mg/kg
resulted in a 50% reduction of cortical Aβ levels within 3
hours. A 40% Aβ reduction was observed at the dosage of
100 mg/kg orally, again after 3 hours, but no brain levels of
DAPT were reported for the latter study [131]. Several
preclinical studies revealed in vivo toxicity, because DAPT
affects the Notch pathway at higher levels (100 – 1000fold)
[132, 133]. These are negative news for future development.
Extensive in vivo  studies have been carried out with the
more potent analogue LY-411575 (44a). A stereoselective
placement of the hydroxyl group and the locked spatial
arrangement of two phenyl rings in a caprolactam increased
the activity 20fold (44a, IC50 < 1 nM). Upon oral dosing of 1
mg/kg in 3 to 5 month-old Tg2576 mice, LY-411575 (44a)
halved plasma and cortical Aβ levels within 3 hours [134]. A
lesser active diastereomer was administered orally to
C57BL/6 and TgCRND8 APP mice for 15 days at 1-10
mg/kg per day and resulted in the reduction of Aβ levels
[135]. This was accompanied by atrophy of the thymus and
deterioration of the intestinal epithelium. The Notch/APP
selectivity was determined in cellular assays: Aβ40 IC50 =
0.082 nM, Notch IC50 = 0.39 nM. This small toxicity
window and the high potency made DAPT and 44a unlikely
candidates to enter clinical trials. Nevertheless, E. Siemers et
al. went on and reported the first phase I study of the γ-
secretase inhibitor 44b, which is less potent than 44a [136].
The oral application of LY450139 (44b) to healthy
volunteers resulted in reduced plasma levels of Aβtotal to
74.3% of the initial baseline at 40 mg/d after 14 days. The
sampling time point was crucial, as a single dose results in
reduction of Aβtotal for 1-3 h and a dramatic overshoot
between 5 and 24 h post dosage. However, cerebrospinal
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fluid (CSF) levels were constant. LY450139 (44b) is claimed
to be mildly selective for γ-secretase cleavage over the Notch
pathway,
DuPont Pharmaceuticals and Scios described a highly
potent difluorophenacyl-caprolactam derivative (45, IC50 =
0.3 nM) [137]. Bristol-Meyers Squibb assumed DuPont, and
continued to elaborate this caprolactam motif. As a result, a
large number of derivatives were described. Some efforts
were dedicated to modify the N-terminus to create non-
infringing structures to the Elan patent. The synthesis of
oxazolylsulfonamide 46 [138] is one such example.
The γ-secretase inhibitors must reduce Aβ production
sufficiently to alleviate the cause of AD, but neither abolish
totally its production nor the processing of other proteins,
which have important roles in neuronal structure and
function [139]. Several substrates must be considered in
addition to APP and Notch: the Notch ligands Delta and
Jagged, apoER2 lipoprotein receptor, the low density
lipoprotein receptor-related protein, ErbB4 receptor tyrosine
kinase, CD44, p75 neurotrophin and β subunits of voltage-
gated sodium channels [140-141]. The important issue is: are
there γ-secretase inhibitors, which reduce APP processing
without generating an unacceptable side effect? Gleevec (47)
inhibits Aβ production but not Notch cleavage (Scheme 7)
[142]. Recently, Fraering et al. reported IC50 values for Aβ40,
Aβ42 and AICD of ~75 μM. Generation of NICD-Flag was
not inhibited, even at >10-fold concentrations. The authors
proposed a potential nucleotide-binding domain on γ-
secretase, because ATP was able to rescue the γ-secretase
Scheme 6. γ-Secretase inhibitors I.
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activity inhibited by a Gleevec formulation. There is strong
support for this hypothesis: γ-secretase binds to ATP-
acrylamide resin through the γ-phosphate [143]. Further-
more, selected nonsteroidal anti-inflammatory drugs reduce
Aβ production without affecting alternative cleavages [124].
Isocoumarin inhibitors (JLK inhibitors) do not inhibit the E-
cadherin processing, BACE-1/2, α-secretase, the proteasome
and GSK2β kinase [144]. BMS-299897 (48) displayed a 15-
fold lower IC50 value for APP than Notch-1-cleavage in vitro
(HEK293 cells, APP IC50: 7.1 nM, Notch IC50: 105.9 nM)
[43]. 2,3-Benzodiazepin-4-diones were designed as peptido-
mimetic inhibitors for γ-secretase [145]. The oral administra-
tion of these triamides in Tg2675 βAPP-Swedish transgenic
mice resulted in a 15% reduction of CNS Aβ levels. Wolfe et
al. explored the mechanisms of different γ-secretase
inhibitors at detail [146]. Most of these bind directly to the
active site or alter it through an allosteric interaction. Some
inhibitors, e.g. the isocoumarins and the Aib-containing
helical peptides, do not block Aβ production by affecting the
active site of the protease, thus they do not target γ-secretase
directly. Signal Peptide Peptidase SPP inhibitors can inhibit
γ-secretase too, showing that SPP and γ-secretase have
similar active sites and are likely to share the proteolytic
mechanism [147].
Neurogenetics (now Torrey Pines Pharmaceuticals)
disclosed a large number of aminothiazol-derivatives (49)
with Aβ42/Aβ40-lowering activity at a concentration of about
30 μM [148]. The compounds derived from α-halogenated
ketones and appropriate thioureas or ureas. Approximately
60 of these structures were claimed to display very good
inhibition (activity < 0.2 μM). Compound 50 displayed
similar activity (EC50(Aβ38) = 1.5 μM, IC50(Aβ40) = 1.8 μM,
IC50(Aβ42) = 1.6 μM) [unpublished data]. The substituted
thiazolamides (51), which resemble the Torrey Pines comp-
ounds, were coupled to a redox chemical delivery system
(RCDS) and may feature enhanced pharmacokinetic proper-
ties [149]. A dihydropyridine RCDS was introduced to
improve the blood brain barrier (BBB) permeation. The
tested compounds exhibited EC50 values ranging from 0.1 to
1.0 μM in cell free assays. Compound 51 displayed an EC50
value of 0.2 μM in cellular assays using APP transfected
HEK 293 cells.
The Elan patent application [149] reported three general
synthetic schemes and about 700 tabulated examples.
Selected N-(oxoazepanyl) benzenesulfonamides showed
promising activities, for example, compound 52 inhibited γ-
secretase with an IC50 within the range of 0.1-25 nM.
Scheme 7. γ-Secretase inhibitors II.
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However, the activities of compound 53 and 54 are unknown
(or not reported).
Roche´s 1,4-benzoxazepin-3-one (55) was prepared by a
cyclocondensation of (formylaryloxy)alkanoic acid, amine
and isonitrile [151]. Compound 55 inhibited γ-secretase with
an IC50 value of 0.18 (no units given). Additionally, Roche
presented malonamide derivatives, where some compounds
display IC 50 values of < 1.0 μM [152]. The aryl cyclohexyl
sulfone (56) [153], developed by Merck, inhibits the
processing of APP by γ-secretase with ED50 values of < 1
μM. Eli Lilly optimized the series of dipeptides to challenge
the amyloid hypothesis in a clinical setting [154]. Vlaams
Interuniversitair Instituut disclosed peptides deriving from
APP that specifically inhibit the γ-secretase cleavage without
affecting the cleavage of Notch [155]. Their most potent
inhibitor, the peptide D7 having the amino acid sequence
VVIATVIVITLVMLK-TP inhibits γ−secretase activity up to
60-40% at a concentration of 1.5 μM. D7 did not affect S3-
cleavage within the transmembrane domain of Notch.
A selective γ-secretase modulator (57) was reported by
MSD [156], the carboxylic acid seems to be important to
achieve the desired ratio of Aβ38/Aβ40/Aβ42. This modulation
is distinctly different from inhibition as the total Aβ load
may be unaffected. This was observed for several NSAIDs
and is unrelated to cyclooxygenase 1 (COX1) inhibition
[157]. Some COX1 inhibitors are suitable candidates to
enhance the initially weak activity.
OUTLOOK
The early availability of peptidic and peptidometimetic
inhibitors for β- and γ-secretase inhibitors, both a tools and
as lead structures, made a huge impact on the research area.
Scheme 8. γ-Secretase inhibitors III.
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These potent peptidomimetics come with costly price tags:
oral availability, cost of goods and blood brain barrier
penetration impose severe obstacles on drug development.
The lessons learned in the renin and HIV programmes
certainly paid off, but the BBB issue multiplied the tasks for
the medicinal chemists. There is a rigorous trend in most
patent families founding on peptidomimetics leads to reduce
the peptidic heritage as much as possible. BACE HTS assays
provided very few non-peptidic scaffolds, but in silico
screens were able to identify scaffolds with the desired
properties. On the contrary, HTS on γ-secretase provided
plenty of non-peptidic leads, but most of these are γ-
secretase inhibitors, not modulators. Several compounds are
close to enter phase I or phase II clinical trials. Despite the
extremely rapid progress in the field, there are no reports of
brain penetrating secretase inhibitors in phase II or III (Dec.
2005). The reported γ-secretase inhibitor in phase I has a red
flag associated to it, this is due to its impact on the Notch
pathway. The selective modulation of γ-secretase by
nonsteroidal anti-inflammatory drugs (NSAIDs) is pointing
in the right direction: allosteric modulation of the active site,
which can be identified by additional cleavage sites of
presenilin 1 (PS1). However, the required concentrations of
most NSAIDs are well above safe levels. The differences of
enantiomeric NSAIDs on COX1 inhibition provide an
opportunity for drug development. Both enantiomers of
flurbiprofen modulate γ-secretase, and the S-enantiomer of
flurbiprofen, which is inactive on COX1 inhibition, is in
development to treat AD. β-Secretase inhibitors do lower
Aβ  levels in mice, but there are no data on clinical trials
available to the general public. The ultimate proof of concept
for both secretases has not been revealed yet.
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Röntgenstrukturanalyse von (S,S)-97
 Table 1. Crystal data and structure refinement for 1037.  
      Identification code               1037 (649 F2B) 
      Empirical formula                 C15 H22 I N O3
      Formula weight                    391.24
      Temperature                       299(2) K
      Wavelength                        0.71073 A
      Crystal system, space group       Monoclinic,  C 2
      Unit cell dimensions              a = 20.303(5) A   alpha = 90 deg.
                                        b = 5.182(2) A    beta = 99.04(2) deg.
                                        c = 16.780(3) A   gamma = 90 deg.
      Volume                            1743.5(9) A^3
      Z, Calculated density             4,  1.490 Mg/m^3
      Absorption coefficient            1.843 mm^-1
      F(000)                            784
      Crystal size                      0.40 x 0.12 x 0.05 mm
      Theta range for data collection   4.20 to 25.67 deg.
      Limiting indices                  -24<=h<=24, -4<=k<=6, -20<=l<=20
      Reflections collected / unique    4902 / 2338 [R(int) = 0.0538]
      Completeness to theta = 25.67     95.4 %
      Absorption correction             Empirical
      Max. and min. transmission        0.992 and 0.567
      Refinement method                 Full-matrix least-squares on F^2
      Data / restraints / parameters    2338 / 2 / 195
      Goodness-of-fit on F^2            1.201
      Final R indices [I>2sigma(I)]     R1 = 0.0820, wR2 = 0.1384
      R indices (all data)              R1 = 0.1433, wR2 = 0.1559
      Absolute structure parameter      0.06(8)
      Largest diff. peak and hole       0.613 and -0.465 e.A^-3
         Table 2.  Atomic coordinates ( x 10^4) and equivalent isotropic
         displacement parameters (A^2 x 10^3) for 1037.
         U(eq) is defined as one third of the trace of the orthogonalized
         Uij tensor.
         ________________________________________________________________
                           x             y             z           U(eq)
         ________________________________________________________________
          I(1)         4044(1)       9938(5)       -888(1)      108(1)
          O(1)         4876(4)       7488(15)      2796(6)       65(3)
          O(2)         2748(3)       9730(20)       134(4)       55(2)
          O(3)         4151(4)       4500(20)      2151(5)       55(2)
          N(1)         4014(4)       8824(17)      1961(5)       44(3)
          C(1)         3871(6)       8200(30)       196(8)       69(4)
          C(2)         3390(4)       9720(30)       619(6)       39(3)
          C(3)         3351(5)       8680(20)      1451(7)       38(3)
          C(4)         2835(4)      10130(40)      1863(6)       53(3)
          C(5)         2820(5)       9300(30)      2718(8)       56(4)
          C(6)         3203(6)      10570(30)      3356(9)       71(5)
          C(7)         3201(8)       9670(60)      4140(8)       92(5)
          C(8)         2843(8)       7610(40)      4310(12)      92(5)
          C(9)         2473(8)       6320(30)      3670(12)      83(5)
          C(10)        2471(6)       7130(30)      2899(10)      70(4)
          C(11)        4331(6)       6660(30)      2292(8)       41(3)
          C(12)        5332(7)       5530(30)      3228(10)      71(5)
          C(13A)       5770(20)      7150(70)      3917(18)     101(17)
          C(13B)       5963(16)      7320(60)      3460(20)      64(12)
          C(14)        4970(8)       4030(30)      3800(9)       96(7)
          C(15)        5612(7)       3910(30)      2649(12)      95(6)
         ________________________________________________________________
            Table 3.  Bond lengths [A] and angles [deg] for 1037.
         ________________________________________________________________
            I(1)-C(1)                     2.107(13)
            O(1)-C(11)                    1.352(14)
            O(1)-C(12)                    1.482(16)
            O(2)-C(2)                     1.423(9)
            O(2)-H(2O)                    0.8200
            O(3)-C(11)                    1.191(15)
            N(1)-C(11)                    1.366(15)
            N(1)-C(3)                     1.480(12)
            N(1)-H(1N)                    0.8600
            C(1)-C(2)                     1.517(17)
            C(1)-H(1A)                    0.9700
            C(1)-H(1B)                    0.9700
            C(2)-C(3)                     1.508(15)
            C(2)-H(2)                     0.9800
            C(3)-C(4)                     1.538(16)
            C(3)-H(3)                     0.9800
            C(4)-C(5)                     1.503(16)
            C(4)-H(4A)                    0.9700
            C(4)-H(4B)                    0.9700
            C(5)-C(6)                     1.387(18)
            C(5)-C(10)                    1.387(19)
            C(6)-C(7)                     1.40(2)
            C(6)-H(6)                     0.9300
            C(7)-C(8)                     1.35(3)
            C(7)-H(7)                     0.9300
            C(8)-C(9)                     1.38(2)
            C(8)-H(8)                     0.9300
            C(9)-C(10)                    1.360(19)
            C(9)-H(9)                     0.9300
            C(10)-H(10)                   0.9300
            C(12)-C(15)                   1.47(2)
            C(12)-C(14)                   1.51(2)
            C(12)-C(13B)                  1.58(2)
            C(12)-C(13A)                  1.58(2)
            C(13A)-H(13A)                 0.9600
            C(13A)-H(13B)                 0.9600
            C(13A)-H(13C)                 0.9600
            C(13B)-H(13D)                 0.9600
            C(13B)-H(13E)                 0.9600
            C(13B)-H(13F)                 0.9600
            C(14)-H(14A)                  0.9600
            C(14)-H(14B)                  0.9600
            C(14)-H(14C)                  0.9600
            C(15)-H(15A)                  0.9600
            C(15)-H(15B)                  0.9600
            C(15)-H(15C)                  0.9600
            C(11)-O(1)-C(12)            118.5(10)
            C(2)-O(2)-H(2O)             109.5
            C(11)-N(1)-C(3)             121.5(9)
            C(11)-N(1)-H(1N)            119.3
            C(3)-N(1)-H(1N)             119.3
            C(2)-C(1)-I(1)              112.8(9)
            C(2)-C(1)-H(1A)             109.0
            I(1)-C(1)-H(1A)             109.0
            C(2)-C(1)-H(1B)             109.0
            I(1)-C(1)-H(1B)             109.0
            H(1A)-C(1)-H(1B)            107.8
            O(2)-C(2)-C(3)              110.8(8)
            O(2)-C(2)-C(1)              109.5(10)
            C(3)-C(2)-C(1)              112.3(10)
            O(2)-C(2)-H(2)              108.0
            C(3)-C(2)-H(2)              108.0
            C(1)-C(2)-H(2)              108.0
            N(1)-C(3)-C(2)              110.1(8)
            N(1)-C(3)-C(4)              109.7(9)
            C(2)-C(3)-C(4)              112.4(9)
            N(1)-C(3)-H(3)              108.2
            C(2)-C(3)-H(3)              108.2
            C(4)-C(3)-H(3)              108.2
            C(5)-C(4)-C(3)              113.9(11)
            C(5)-C(4)-H(4A)             108.8
            C(3)-C(4)-H(4A)             108.8
            C(5)-C(4)-H(4B)             108.8
            C(3)-C(4)-H(4B)             108.8
            H(4A)-C(4)-H(4B)            107.7
            C(6)-C(5)-C(10)             117.5(14)
            C(6)-C(5)-C(4)              120.4(13)
            C(10)-C(5)-C(4)             122.0(13)
            C(5)-C(6)-C(7)              118.8(17)
            C(5)-C(6)-H(6)              120.6
            C(7)-C(6)-H(6)              120.6
            C(8)-C(7)-C(6)              123.2(18)
            C(8)-C(7)-H(7)              118.4
            C(6)-C(7)-H(7)              118.4
            C(7)-C(8)-C(9)              117.6(18)
            C(7)-C(8)-H(8)              121.2
            C(9)-C(8)-H(8)              121.2
            C(10)-C(9)-C(8)             120.8(16)
            C(10)-C(9)-H(9)             119.6
            C(8)-C(9)-H(9)              119.6
            C(9)-C(10)-C(5)             122.1(15)
            C(9)-C(10)-H(10)            119.0
            C(5)-C(10)-H(10)            119.0
            O(3)-C(11)-O(1)             128.1(12)
            O(3)-C(11)-N(1)             125.6(10)
            O(1)-C(11)-N(1)             106.3(11)
            C(15)-C(12)-O(1)            110.2(12)
            C(15)-C(12)-C(14)           113.6(12)
            O(1)-C(12)-C(14)            109.5(12)
            C(15)-C(12)-C(13B)           97(2)
            O(1)-C(12)-C(13B)            98.2(16)
            C(14)-C(12)-C(13B)          126.8(18)
            C(15)-C(12)-C(13A)          124(2)
            O(1)-C(12)-C(13A)           103.4(19)
            C(14)-C(12)-C(13A)           94.7(18)
            C(13B)-C(12)-C(13A)          33.6(18)
            C(12)-C(13A)-H(13A)         109.5
            C(12)-C(13A)-H(13B)         109.5
            C(12)-C(13A)-H(13C)         109.5
            C(12)-C(13B)-H(13D)         109.5
            C(12)-C(13B)-H(13E)         109.5
            H(13D)-C(13B)-H(13E)        109.5
            C(12)-C(13B)-H(13F)         109.5
            H(13D)-C(13B)-H(13F)        109.5
            H(13E)-C(13B)-H(13F)        109.5
            C(12)-C(14)-H(14A)          109.5
            C(12)-C(14)-H(14B)          109.5
            H(14A)-C(14)-H(14B)         109.5
            C(12)-C(14)-H(14C)          109.5
            H(14A)-C(14)-H(14C)         109.5
            H(14B)-C(14)-H(14C)         109.5
            C(12)-C(15)-H(15A)          109.5
            C(12)-C(15)-H(15B)          109.5
            H(15A)-C(15)-H(15B)         109.5
            C(12)-C(15)-H(15C)          109.5
            H(15A)-C(15)-H(15C)         109.5
            H(15B)-C(15)-H(15C)         109.5
           _____________________________________________________________
           Symmetry transformations used to generate equivalent atoms:
     Table 4.  Anisotropic displacement parameters (A^2 x 10^3) for 1037.
    The anisotropic displacement factor exponent takes the form:
    -2 pi^2 [ h^2 a*^2 U11 + ... + 2 h k a* b* U12 ]
    _______________________________________________________________________
              U11        U22        U33        U23        U13        U12
    _______________________________________________________________________
    I(1)     86(1)     169(1)      70(1)      29(1)      14(1)       8(1)
    O(1)     55(6)      34(5)      90(7)       4(5)     -35(5)       1(5)
    O(2)     32(4)      51(6)      74(5)       4(7)     -15(3)      -8(6)
    O(3)     47(5)      24(6)      86(6)       0(5)     -17(4)      -2(5)
    N(1)     26(5)      39(8)      63(6)       3(5)      -1(4)      -5(4)
    C(1)     47(8)      78(11)     74(10)     19(8)     -14(7)       3(7)
    C(2)     18(5)      38(7)      57(6)      -3(8)      -9(4)       7(7)
    C(3)      8(5)      32(7)      71(8)       0(6)      -5(5)      -1(5)
    C(4)     27(5)      59(8)      72(7)      16(11)      0(5)       7(9)
    C(5)      8(5)      68(13)     91(9)      -4(8)       9(5)       8(7)
    C(6)     65(8)      64(13)     84(10)     -8(9)      15(7)      -7(9)
    C(7)     87(10)    120(16)     64(9)      -7(15)      2(7)     -10(17)
    C(8)     49(10)    115(17)    114(15)      8(13)     20(10)      5(10)
    C(9)     69(11)     68(12)    115(15)     22(10)     23(10)    -12(8)
    C(10)    35(8)      85(13)     88(12)     12(9)       3(7)      -6(8)
    C(11)    22(6)      46(11)     53(8)       2(7)      -8(6)       4(7)
    C(12)    60(9)      49(11)     89(11)      1(10)    -32(8)      15(9)
    C(13A)  120(30)     90(30)     70(20)     40(20)    -50(20)    -30(20)
    C(13B)   60(20)     50(20)     60(20)     20(20)    -50(20)     -5(18)
    C(14)   107(13)     94(19)     77(10)      5(10)    -19(9)      45(11)
    C(15)    42(8)      78(15)    165(17)     40(12)     14(9)      19(8)
    _______________________________________________________________________
         Table 5.  Hydrogen coordinates ( x 10^4) and isotropic
         displacement parameters (A^2 x 10^3) for 1037.
         ________________________________________________________________
                         x             y             z           U(eq)
         ________________________________________________________________
          H(2O)        2611          8247            69          66
          H(1N)        4205         10301          2051          52
          H(1A)        3694          6477            79          82
          H(1B)        4293          8028           555          82
          H(2)         3549         11505           676          47
          H(3)         3218          6867          1398          46
          H(4A)        2933         11966          1861          64
          H(4B)        2396          9877          1550          64
          H(6)         3456         12007          3263          85
          H(7)         3459         10531          4565         110
          H(8)         2846          7073          4840         110
          H(9)         2223          4888          3768         100
          H(10)        2226          6201          2479          84
          H(13A)       6122          6084          4188         122
          H(13B)       5494          7730          4297         122
          H(13C)       5957          8613          3683         122
          H(13D)       5869          8603          3843          77
          H(13E)       6069          8149          2989          77
          H(13F)       6335          6289          3704          77
          H(14A)       4706          5187          4065         115
          H(14B)       5289          3176          4196         115
          H(14C)       4685          2766          3502         115
          H(15A)       5994          3002          2923         114
          H(15B)       5743          4971          2233         114
          H(15C)       5282          2687          2414         114
         ________________________________________________________________
         Table 6.  Torsion angles [deg] for 1037.
         ________________________________________________________________
          I(1)-C(1)-C(2)-O(2)                                  65.2(13)
          I(1)-C(1)-C(2)-C(3)                                -171.3(8)
          C(11)-N(1)-C(3)-C(2)                               -119.9(12)
          C(11)-N(1)-C(3)-C(4)                                116.0(12)
          O(2)-C(2)-C(3)-N(1)                                -176.8(11)
          C(1)-C(2)-C(3)-N(1)                                  60.4(13)
          O(2)-C(2)-C(3)-C(4)                                 -54.2(15)
          C(1)-C(2)-C(3)-C(4)                                -177.0(10)
          N(1)-C(3)-C(4)-C(5)                                 -52.7(15)
          C(2)-C(3)-C(4)-C(5)                                -175.5(11)
          C(3)-C(4)-C(5)-C(6)                                  92.7(16)
          C(3)-C(4)-C(5)-C(10)                                -82.3(14)
          C(10)-C(5)-C(6)-C(7)                                 -2(2)
          C(4)-C(5)-C(6)-C(7)                                -177.1(14)
          C(5)-C(6)-C(7)-C(8)                                   0(3)
          C(6)-C(7)-C(8)-C(9)                                   1(3)
          C(7)-C(8)-C(9)-C(10)                                  0(3)
          C(8)-C(9)-C(10)-C(5)                                 -2(2)
          C(6)-C(5)-C(10)-C(9)                                  3(2)
          C(4)-C(5)-C(10)-C(9)                                177.9(13)
          C(12)-O(1)-C(11)-O(3)                                 2(2)
          C(12)-O(1)-C(11)-N(1)                              -178.2(12)
          C(3)-N(1)-C(11)-O(3)                                  8(2)
          C(3)-N(1)-C(11)-O(1)                               -172.5(9)
          C(11)-O(1)-C(12)-C(15)                               61.2(17)
          C(11)-O(1)-C(12)-C(14)                              -64.5(16)
          C(11)-O(1)-C(12)-C(13B)                             162(2)
          C(11)-O(1)-C(12)-C(13A)                            -165(2)
         ________________________________________________________________
         Symmetry transformations used to generate equivalent atoms:
  Table 7.  Hydrogen bonds for 1037 [A and deg.].
 ____________________________________________________________________________
 D-H...A                      d(D-H)      d(H...A)    d(D...A)    <(DHA)
 N(1)-H(1N)...O(3)#1          0.86        2.18        2.965(14)   150.8
 O(2)-H(2O)...O(2)#2          0.82        1.97        2.791(4)    177.3
 ____________________________________________________________________________
 Symmetry transformations used to generate equivalent atoms:
 #1 x,y+1,z    #2 -x+1/2,y-1/2,-z
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